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Abstract  
This study set out to investigate the association between sleep among pregnant women 
with gestational diabetes (GDM) and their glucose control. Functional data analysis 
(FDA) methods were applied to glucose data collected via continuous glucose monitoring 
(CGM) systems.  FDA is an advanced statistical method that respects the complexity of 
the dense auto-correlated data produced from repeated measurement of glucose over 
time. 
192 pregnant women with GDM at their third trimester were recruited. Over a period of 
one week participants wore an actigraph (Actiwatch2 Respironics) which is a watch-like 
device on their non-dominant wrist to objectively measure their sleep, have a 
professional CGM system (iPro2 Medtronic) attached to them to continuously measure 
and record their interstitial glucose every 5 minutes, and complete the Pittsburgh Sleep 
Quality Index (PSQI) questionnaire to self-report their habitual sleep pattern for the 
previous month. Their demographic data and type of treatment they received were also 
collected. 152 participants had sufficient data retrieved from them, i.e. the PSQI 
questionnaire data and at least one night actigraphy-derived sleep data and one 24-hour 
day of CGM data. 
Using FDA methods, sequential glucose values data-points recorded over time with the 
CGM system were converted into a smooth 24-hour glucose curves with a functional 
form (as a function of time). The glucose curve was then used as one value, instead of 
the multiple data-points values it represents. Glucose control was assessed using the 
smooth glucose curves, as well as, a conventional summary metrics. The associations 
between participants’ actigraphy-derived and self-reported sleep characteristics and 
glucose control, were evaluated using standard and multilevel regression modelling for 
the conventional CGM data summary metrics and functional regression modelling for the 
smooth glucose curves.  
The study discovered a positive association between sleep disturbances and glucose 
control. Sleep disturbances were measured as poor sleep quality, short and long sleep 
durations compared to an average 6-8 hours sleep duration and difficulties in initiating 
and maintaining sleep. The timing and the amplitude of these associations were more 
apparent with FDA regression models than regression models with summary metrics. 
This study recommends the use of FDA in research involving the use of CGM systems, 
and encourages the clinician and the policy makers to consider sleep disturbances as a 
risk factor in glycaemic dysregulation in GDM. 
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Chapter 1 Introduction 
This thesis has two main elements: Firstly, a translational element involving the 
evaluation of a clinical question which answer can be translated directly to clinical 
practice; and secondly, a methodological element involving developing the novel 
application of advance statistical methods to analyse continuous glucose monitoring 
(CGM) data. The clinical question under investigation is that are sleep disturbances 
associated with higher and more variable glucose in pregnant women with gestational 
diabetes (GDM)? In order to best evaluate this question I developed the application of 
functional data analysis (FDA) to the CGM data. 
 
The current chapter introduces the background and the rationale of this study. It provides 
a contextual outline on: sleep and sleep during pregnancy; how to measure sleep using 
subjective and objective tools; GDM epidemiology, diagnosis and complications; how to 
measure glycaemic control; CGM technology; traditional methods to analyse CGM data 
and the advantage of applying FDA to CGM data.  
1.1 Sleep and circadian rhythm 
Sleep, though recurring every day and lasting about one third of human beings’ life, is 
still a mystery (Frank Marcos, 2006). A very naive definition of sleep is “a rapidly 
reversible state of immobility and greatly reduced sensory responsiveness” (Siegel, 
2008). Sleep is not just a passive, sedentary, low activity, reduced consciousness body 
state (Kryger, 2005). In fact, while asleep the brain and many organs are highly active 
undergoing a process of whole body restoration. Whilst asleep distinctive brain activity 
can be detected using electroencephalogram (EEG). This shows signals demarcating 
two cyclic recurring sleep modes: 1) rapid eye movement (REM) sleep mode; and 2) 
non-rapid eye movement (NREM) sleep mode.  NREM sleep comprises about 75% of 
total sleep time and has three stages, stage one is the transition time between being 
awake and asleep, stage two is the light sleep, while stage three (slow wave sleep) is the 
deepest and most body restorative sleep stage. On the other hand, REM sleep has only 
one stage and comprises 25% of total sleep time. During REM sleep the brain is highly 
active and voluntary muscles are highly flaccid. A complete cycle of these stages last 90 
to 100 minutes and a round 4-5 cycles are repeated during a night sleep. 
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Sleep is one of the vital items to the survival of human beings and all the living creatures. 
In an animal study, total sleep deprivation led to the death of all rats involved in the study 
after 11-23 days (Everson et al., 1989), while in human a rare inherited fatal familial 
insomnia will eventually lead to death within 18 month of onset (Schenkein and 
Montagna, 2006). Whilst asleep, muscles and damaged body tissues are repaired, the 
memory is consolidated and assorted different hormones are released. In order for these 
restorative activities to be fulfilled and for a person to feel rested and refreshed after 
awakening, human beings need sufficient sleep duration and quality. Disturbed nighttime 
sleep with inadequate sleep duration and quality has been linked to mood swings, lower 
attentiveness and feelings of tiredness and weakness the next day (Rogers et al., 2003). 
Furthermore, chronic sleep disturbances have been linked to the risk of developing 
various diseases and disorders (Depner et al., 2014; Grandner et al., 2012; Shankar et 
al., 2010). The mechanism proposed by Hanlon and Van Cauter (2011)  is that sleep 
curtailment induces cellular immune system activation and inflammation. Such 
inflammatory responses are linked to the risk of developing arthritis, diabetes and 
cardiovascular disorders (Irwin et al., 2006). It is noticeable that there has been an 
increase in the prevalence of diabetes in tandem with an increase in the prevalence of 
chronic sleep curtailment. It has been estimated that average sleep duration has 
dropped by almost 2 hours in the past 50 years (Knutson et al., 2010). In the United 
Kingdom and in the United States, a third of the population reports sleeping less than 7 
hours per night  (National Sleep Foundation, 2005; Barnes et al., 2013). An extended 
literature review on the association of sleep duration and glucose metabolism is 
presented in section 1.2.  
The two states of sleep and wakefulness run in oscillatory cycles of about 24 hours 
known as circadian rhythms. These oscillations are entrained by external cues, most 
importantly the exposure to light and dark, as well as social cues like physical activity 
and feeding. This means that sleep generally takes place during the night when it is dark, 
and wakefulness takes place during the day when it is light. The partitioning of sleep and 
wake is driven by an internal timing system known as the circadian clock. We now know 
that each cell throughout the human body has an endogenous molecular clock that 
oscillates over approximately 24 hours (Mohawk et al., 2012; Bargiello and Young, 
1984). The oscillations of each of these independent cells are synchronised to each 
other and the external light/dark cycle through the suprachiasmatic nucleus (SCN) which 
is located in the brain hypothalamus (Brancaccio et al., 2014). The SCN works like a 
conductor that unifies and sets the coherence of an orchestra. Circadian rhythms 
influence nearly all human body systems and behaviours including not only sleep and 
wakefulness, but also the function of the cardiorespiratory, renal, gastrointestinal, hepatic 
and immune systems, as well as endocrine hormone release, and core 
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temperature(Garcia et al., 2001; Cailotto et al., 2005; Warren et al., 1994). Many 
hormones involved in metabolism, such as insulin, glucagon, corticosterone and leptin, 
have circadian rhythmicity (La Fleur, 2003). Moreover, circadian rhythms influence 
metabolism and energy homeostasis in peripheral tissues (Froy, 2010). In animal studies 
lesions in circadian rhythm regulatory system caused not only sleep/wakefulness 
irregularities but also, hormone imbalance, obesity, glucose intolerance and diabetes 
mellitus (Arble et al., 2010; Turek et al., 2005).  
In humans, circadian rhythm entrainment to the light/dark cycle is manifested differently 
in individuals, a feature known as chronotype (Phillips, 2009). Individuals can be 
characterised into ‘morning larks’ preferring early bed, sleep and wake-up times, or ‘night 
owls’ preferring late bed, sleep and wake-up times (Gale and Martyn, 1998).  If an 
individual’s chronotype clashes (out of phase) with work or social requirements then 
circadian sleep disturbances can occur. For example, if individuals with an early 
chronotype are made to stay awake late at night for social commitments their underlying 
circadian rhythms still make them wake-up early next day this leads to sleep deficit. If 
individuals with a late chronotype who naturally sleep late are made to wake-up early for 
work commitments, this overrides their natural circadian rhythm and they also get a 
sleep deficit.  Both  result in what is referred to as ‘social jet lag’ and both lead to 
curtailment of sleep duration, a perception of poor sleep quality and circadian 
misalignment (Abdullah et al., 2014). However, some studies had found a positive 
relationship between late chronotype, independent of sleep duration, with glucose 
intolerance and with higher Glycosylated haemoglobin (HbA1c) , HbA1c is indicator of 
glycaemic control,  in type 2 diabetes (T2DM) patients (Reutrakul et al., 2013) and in 
participants with prediabetes (Anothaisintawee et al., 2017). Nevertheless, other study 
found that social jet lag and circadian misalignment but not chronotype were associated 
with higher HbA1c in in patients with type 1 diabetes (T1DM) (Larcher et al., 2016) and 
T2DM (Reutrakul et al., 2015) and with  insulin resistance in healthy adults (Wong et al., 
2015).  
1.2 Measuring sleep 
Sleep characteristics such as sleep duration, quality and timing can be evaluated both 
subjectively and objectively. Subjective evaluation consists of tools such as sleep 
logs/diaries and sleep questionnaires. Sleep logs are the simplest method used to 
evaluate sleep, though poor compliance with filling them out can bias their results 
(Herring et al., 2013). An alternative approach involves using questionnaires and there 
are numerous sleep questionnaires that have been designed for and used in sleep 
related studies. Among these questionnaires three are most commonly used: 1) the 
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Pittsburgh Sleep Quality Index (PSQI) questionnaire evaluating reported sleep duration 
and overall sleep quality (Buysse et al., 1989); 2) the Berlin Sleep Questionnaire 
evaluating sleep breathing  disorders (Netzer et al., 1999); and 3) the Epworth 
Sleepiness Scale questionnaire evaluating daytime sleepiness and dysfunction resulting 
from nighttime sleep disturbances (Johns, 1991). However, these are retrospective tools, 
validated only for certain specific sleep characteristics or disorders, and are highly 
subjective (Buysse et al., 1989; Johns, 1992; Douglass et al., 1994; Partinen and 
Gislason, 1995; Netzer et al., 1999).  
Polysomnography (PSG) is considered the “gold standard” for objectively measuring 
sleep (Ancoli-Israel et al., 2003; Kushida et al., 2005). It is usually conducted in a 
suitably-equipped specialist sleep laboratory where patients/study participants have to 
spend the night attached to multiple electrodes and related apparatus. PSG measures 
brain electrical activities, as well as, ocular (eye) muscle and body movement, breathing 
pattern, pulse rate, blood oxygen level and body temperature. It can demarcate the 
frequency and duration of sleep stages and it defines sleep onset and sleep offset using 
multiple inputs including change from waking brain activity to NREM sleep brain activity, 
ocular movement, drop in body temperature and sedentary body situation.  
PSG is widely used for the evaluation of sleep disorders such as sleep disordered 
breathing (SDB), narcolepsy, parasomnia, sleep related seizure disorder and periodic 
limb movement sleep disorder. However, polysomnography is not recommended for the 
diagnosis of circadian rhythm related sleep disorders as it is impractical to apply it 
continuously for prolonged periods (Kushida et al., 2005). Moreover, polysomnography 
can be expensive, inconvenient and impractical in studying certain populations (Kushida 
et al., 2001).  In a study asking pregnant women to have overnight polysomnography 
only 58 agreed out of 430 approached and ten of them withdrew before the start of the 
procedure (Wilson et al., 2011). 
Actigraphy is a rather simpler, non-invasive objective tool to assess sleep characteristics 
(Ancoli-Israel et al., 2003; Sadeh and Acebo, 2002; Morgenthaler et al., 2007b; Hofstra 
and de Weerd, 2008; Sadeh, 2011). Actigraphy uses small wearable and portable 
devices that use accelerometer techniques to estimate sleep/wakefulness by detecting 
body movement. They assume that the person wearing them is asleep when not moving. 
Actigraphy, does not need a specialist laboratory. It provides objective information on 
sleep habits in a patient's/participant’s natural sleep environment, and can conveniently 
estimate sleep/wake patterns continuously for prolonged periods (Kushida et al., 2001). 
Actigraphy has been used for estimating night time sleep parameters across different 
age groups, characterizing circadian patterns and sleep disturbances in individuals with 
insomnia and hypersomnia, and evaluating responses to treatments for circadian rhythm 
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disorders and insomnia (Littner et al., 2003). However, actigraphy is more valid and 
accurate in defining sleep characteristics in healthy individuals with no sleep related 
complaints than in individuals with sleep disturbances (Stone and Ancoli-Israel, 2011).  
Actigraphy has low specificity in detecting wakefulness while the individual is lying still 
and thus it has to be used in adjunct to other sleep assessment methods such as sleep 
logs/diaries (Sadeh, 2011; Tahmasian et al., 2010). Furthermore, the usefulness of 
actigraphy in defining and monitoring circadian rhythm patterns and sleep characteristics 
in some populations such as pregnant women has not been fully assessed (Stone and 
Ancoli-Israel, 2011). More details on the mechanism of action and validation of 
actigraphy are presented in the methods chapter. 
1.3 Role of sleep duration in glucose homeostasis 
Sleep is important for health. This section reviews the current evidence for whether sleep 
is involved in the pathogenesis of type 2 diabetes (T2DM). Evidence for whether sleep in 
individuals suffering from diabetes has a role in their glucose control is likewise 
reviewed. Summary tables of the findings of all the studies included in this section is 
available in Table 1-1 to Table 1-4. 
1.3.1 Association between sleep and insulin resistance and glucose 
intolerance  
Insulin resistance impairs insulin mediated cellular glucose uptake in individuals with 
T2DM. It progresses over many years prior to any clinically manifested glucose 
dysregulation. Observational and interventional studies have explored the relationship 
between sleep duration and insulin resistance.  
An observational study among non-diabetic overweight-obese participants, compared 
self-reported sleep duration in insulin-resistant individuals (n= 35) with that seen in 
insulin-sensitive individuals (n=21). Insulin sensitivity was evaluated using steady-state 
plasma glucose concentrations during the insulin suppression test. Those with insulin 
resistance slept 43 minutes less per night (p-value = 0.018). The study also found that 
60% of insulin-resistant participants slept less than 7 hours in comparison to only 24% 
only of insulin-sensitive participants (p-value 0.013) (Liu et al., 2013). In another cross-
sectional study among adults over 20 years of age (n=301), PSQI questionnaire was 
used to evaluate sleep and the extent of Insulin resistance was assessed using fasting 
insulin concentration and the homeostatic model assessment - insulin resistance 
(HOMA2-IR) value (Lee et al., 2013). Fasting insulin and HOMA-IR were categorised into 
high and low groups using their 75th percentile as the cut-off point. Poor sleep quality 
(PSQI>5) was associated with higher probability of high fasting insulin and high HOMA-
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IR (chi2 p-values <0.05), and both short sleep duration < 5.5 hours) and long sleep 
duration (≥ 8.5 hours) were associated with higher probability of high fasting insulin and 
high HOMA-IR, compared to average (6.5-7.49 hours) sleep duration, (chi2 p-values 
>0.05). In the same study poor sleep quality and short and long sleep durations were 
associated with the metabolic syndrome, (OR 3.83; 95% CI 1.91 to 7.65), (OR 4.89; 95% 
CI 1.90 to 12.58) and (OR 5.98; 95% CI 1.41 to 25.41), respectively. Whilst observational 
studies are of interest, there have been a collection of interventional studies looking at 
the metabolic consequences of both sleep restriction and sleep extension. 
Multiple small-sized lab-based crossover studies on healthy young participants have 
looked at the effect of sleep restriction on glucose tolerance and insulin sensitivity 
(Nedeltcheva et al., 2009a; Wang et al., 2016b) and insulin sensitivity only (Broussard et 
al., 2012; Donga et al., 2010; St-Onge et al., 2012). Sleep restriction caused reduction of 
glucose tolerance in one study (Nedeltcheva et al., 2009a) and a reduction in insulin 
sensitivity in all the aforementioned studies except one (St-Onge et al., 2012).  In this 
latter study restricting sleep duration was accompanied by controlled feeding conditions. 
A restricted diet was provided and the participants lost weight in both the habitual and 
short sleep phases.(St-Onge et al., 2012). It is possible that in the context of negative 
energy balance, acute short sleep duration does not lead to a state of increased insulin 
resistance.  
Another crossover study of 19 healthy young lean men showed that whilst insulin 
sensitivity deteriorates after acute sleep restriction it recovers after two days of catch-up 
sleep (Broussard et al., 2016). Under lab-controlled conditions participants had up to 8.5 
hours of sleep per night for 4 consecutive nights and only up to 4.5 hours of sleep for 
another 4 consecutive nights in a randomised order. After the nights of restricted sleep 
participants had the opportunity of sleeping 10-12 hours for two nights. Participants had 
a 23% decrease in insulin sensitivity after 4 days of sleep curtailment compared to 
normal sleep. However, insulin sensitivity was restored after 2 days of catch-up sleep. 
Although the study showed that catch-up sleep may reverse the negative impact of 
short-term sleep deprivation, the long-term impact of repeated sleep deprivation and 
catch-up sleep cycles on diabetes risk is not known.  
These studies were all performed under controlled laboratory environments and explored 
acute and often severe sleep restriction. In contrast, Robertson et al. (2013) studied 
participants in their home environment to determine if milder and more chronic sleep 
restriction, akin to modern daily life voluntary sleep curtailment, has a role to play. 
Nineteen healthy, young, normal-weight men with habitual sleep durations of 7.0–7.5 
hours and no sleep disturbances were randomised to either study arm (1.5 hours 
reduction in habitual bedtime) or control arm (habitual bedtime) for three weeks. Sleep 
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restriction led to a decrease in insulin sensitivity at the end of first week. It then 
recovered to baseline levels at the end of the study period. Whether sleep restriction 
effects on insulin sensitivity are short lived adaptive responses to an acute stress, or 
whether they persist longer term requires further investigation. 
Given that short sleep duration and sleep restriction are linked to the development of 
insulin resistance it was timely that one study addressed whether sleep extension has 
beneficial effects on insulin sensitivity and glucose tolerance. Sixteen young healthy non-
obese adults, mostly females, with chronic sleep curtailment had two weeks of habitual 
(their usual) time in bed followed by 6 weeks of extension time-in-bed in their home 
environment (Leproult et al., 2015). During the time-in-bed extension phase; participants 
went to bed an hour earlier and had longer sleep duration during weekdays but 
sustained the same sleep duration during weekends. The study reported no statistically 
significant difference between fasting glucose and insulin levels measured at the end of 
the habitual sleep phase and the extended sleep phase, however the authors did not 
present any statistics. They reported a ”linear relationship”, though only showing 
correlation coefficients, between the relative change in sleep duration and the relative 
change in fasting glucose (r = +0.65, p-value = 0.017) and insulin levels (r = −0.57, p-
value = 0.053). More work is clearly needed to support a potential benefit of sleep 
extension on glucose tolerance and insulin sensitivity.  
1.3.2 Association between sleep and T2DM 
Several large cohort studies have investigated the association between sleep duration 
and the risk of subsequently developing T2DM, studied over varying lengths of follow-up 
(Yaggi et al., 2006; Gangwisch et al., 2007; Kowall et al., 2016; Holliday et al., 2013; 
Rafalson et al., 2010; Gutierrez-Repiso et al., 2014; Kita et al., 2012; Tuomilehto et al., 
2009; Ferrie et al., 2015; Cespedes et al., 2016). Several large studies in the USA and 
Germany have shown a U-shaped association between sleep duration and increased 
risk of T2DM (Gangwisch et al., 2007; Kowall et al., 2016; Yaggi et al., 2006). These 
studies relied on self-reported sleep duration at baseline and mainly self-reported 
clinically diagnosed T2DM. Using 7 hours of sleep duration per night as a reference 
category, those with shorter and longer sleep duration were more likely to develop T2DM 
over 5-15 years follow-up period, risk estimates ranging between 1.47 to 1.95 for short 
sleep duration and between 1.40 to 3.12 for long sleep duration. Regression models 
employed in these studies were adjusted for many potential confounders, mainly; age, 
physical activity, BMI, alcohol consumption, ethnicity, education, marital status, 
depression and history of hypertension.  
However, not all studies have shown this U-shaped relationship. A large Australian study 
with more than192,000 adult participants, used information recorded in medical 
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insurance records and reported a positive association between short <6 hours (but not 
long) sleep duration and subsequent incidence of T2DM, with 7 hours sleep duration as 
a reference (Holliday et al., 2013). However, T2DM incidence was determined from 
hospital admission records. Those who developed T2DM but were not admitted to 
hospital during the follow-up period could not be identified which might have led to 
underestimation of the actual diabetes incidence. In addition, the follow-up period was 
relatively short (mean duration 2.3 years). Moreover, another American cohort study 
showed that short (but not long) sleep duration, with 6-8 hour sleep duration as a 
reference, had higher odds of developing impaired fasting glucose (IFG) over six years 
of follow-up,  OR 3.0, 95% CI 1.05-8.59; OR 1.6, 95% CI 0.45-5.42: for short and long 
sleep duration respectively (Rafalson et al., 2010). Whereas a Finnish study in 
overweight individuals with impaired glucose tolerance found an increased risk of T2DM 
only in participants with long sleep duration ≥ 9 hours( HR 2.29, 95% CI 1.38–3.80) 
(Tuomilehto et al., 2009). However, two recent meta-analyses of nine (Shan et al., 2015) 
and fourteen (Anothaisintawee et al., 2015) prospective cohort studies have also 
confirmed the U-shaped relationship (Figure 1-1). 
A couple of other studies have investigated the association between short compared to 
normal sleep duration and the risk of T2DM without examining the U-shaped 
relationship. The first showed that sleeping ≤7 hours per night was associated with a 
higher odds of developing T2DM after 6 years follow-up (OR 1.96, 95% CI 1.10-
3.50)(Gutierrez-Repiso et al., 2014). The study also found that the odds of becoming 
obese were significantly higher in subjects who slept ≤7 hours per night (OR 1.99, 95% 
CI 1.12-3.55). However, the study reported no association between sleep duration and 
TD2M after 11 years follow-up. This could be related to the attrition in the study 
population over time and to the mediation effect exhibited by adjusting for weight gain in 
the regression model. The second study found that sleeping ≤5 hours compared to >7 
hours was associated with a higher odds of T2DM after 2 years follow-up (OR 5.37, 95% 
CI 1.38-20.91)(Kita et al., 2012).  
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Figure 1-1. U-shaped relationship between sleep duration and risk of T2DM (Shan 
et al., 2015) ; reused with permission. 
 
Extending the understanding of the relationship between sleep duration and risk of 
T2DM, the impact of a change in sleep duration over time has also been investigated. In 
the UK Whitehall II study, the change in sleep duration was calculated for participants 
without diabetes at the beginning and end of each of four 5-year cycles , while T2DM 
incidence was observed at the end of the subsequent cycle (Ferrie et al., 2015). Another 
prospective study (the Nurses' Health Study) examined whether historic changes in 
women’s sleep duration over the preceding 14 years were associated with developing 
T2DM over the subsequent 12 year follow up (Cespedes et al., 2016). Both studies 
showed a higher risk of developing T2DM in participants with chronic short sleep 
duration (≤5.5-6 hours) (Whitehall II study: OR 1.35, 95% CI 1.04- 1.76; Nurses' Health 
Study: HR 1.10, 95%CI 1.001, 1.21 )  and in those with an increase of 2 hours or more in 
their sleep duration over time (Whitehall II study: OR 1.65 , 95% CI 1.15- 2.37; Nurses' 
Health Study: HR 1.15, 95% CI 1.01- 1.30) compared to those who maintained a 7-8 
hour sleep duration. These studies suggest that the adverse metabolic influence of short 
sleep duration may not be ameliorated by sleeping longer hours later in life.   
Although they do not carry the same weight as prospective studies, a couple of large 
cross-sectional studies (n=130973 and n= 56507, respectively)  have shown a U-shaped 
association between sleep duration and T2DM (Jackson et al., 2013; Buxton and 
Marcelli, 2010), this association was observed only in White participants but not Black 
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participants (Jackson et al., 2013) . However, a study among middle-aged and old 
Chinese people (n= 25184) showed that longer self-reported sleep duration over a 24-
hour period (≥ 8 hours compared to 7-7.9 hours) was positively associated with having 
T2DM, in women but not men (Wu et al., 2015). While, objectively measured sleep 
duration (using wrist actigraphy) in 2151 multi-ethnic participants showed higher odds of 
IFG in participants with short sleep duration (≤5 hours), but not those with long sleep 
duration ( ≥ 8 hours) compared to participants who slept between 5 and 8 hours.  The 
association was reduced and became non-statistically significant after adjusting for 
apnoea-hypopnoea index (a measure of sleep hypoxia associated with sleep-disordered 
breathing) (Bakker et al., 2015). Taken together, these large studies and meta-analyses 
support that a U-shaped relationship exists between sleep duration and the risk of 
T2DM.  
1.3.3 Association between sleep duration and glycaemic control in 
patients with diabetes  
Given the mounting evidence supporting a relationship between sleep duration and the 
development of insulin resistance and T2DM, it is relevant to consider whether sleep 
duration has an impact on glycaemic control in people with established diabetes. Most 
studies to date are cross-sectional with a sample size ranging from as low as 18 
participants to as high as 8543 participants. Most of these studies evaluated glycaemic 
control using HbA1c except one that used capillary glucose levels (Barone et al., 2015).  
Among 4870 Japanese adults, aged ≥20 years with T2DM, shorter and longer self–
reported sleep durations, including naps, were positively associated with  higher HbA1c 
levels compared to a sleep duration of 6.5–7.4 hours (Figure 1-2) (Ohkuma et al., 2013). 
Likewise, a large Korean study which included participants with both T1DM and T2DM 
reported a U-shaped relationship between self-sleep duration and HbA1c (Kim et al., 
2013a). In this later study, being a female or younger than 65 years with short sleep 
duration was associated with a higher risk of poor glycaemic control. However, only 
longer self-reported sleep duration (> 9 hours) compared to average (6-9 hours) self-
reported sleep duration was associated with poor glycaemic control (higher HbA1c)  in 
T2DM patients in a large Chinese study including 8543 participants aged 40 years or 
more (Zheng et al., 2015). A smaller Taiwanese study including 46 participants aged 43-
83 years with T2DM, found positive association between poor sleep quality (PSQI score 
≥ 8 compared to PSQI score ≤ 5) and self-reported sleep efficiency, but not self-reported 
sleep duration, with poor glycaemic control (higher HbA1c) (Tsai et al., 2012b). While in 
African Americans with T2DM, perceived sleep debt but not sleep duration was positively 
associated with poor glycaemic control (Knutson et al., 2006).  
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Figure 1-2. Higher HbA1c observed in shorter and longer sleep duration in 
Japanese T2DM compared to 6.5–7.4 hour sleep duration (*P < 0.05; **P < 
0.01 ) (Ohkuma et al., 2013) ; reused under the Creative Commons Attribution 
License. 
Using wrist actigraphy to objectively measure sleep parameters in 47 T2DM participants, 
poor sleep quality as estimated by higher moving time during sleep, higher fragmentation 
index and lower sleep efficiency, (but not sleep duration) was found to correlate slightly 
with higher HbA1c (Trento et al., 2008). On the other hand, (Borel et al., 2013) observed 
a higher HbA1c in T1DM participants with actigraphy-measured sleep duration < 6.5 
hours compared to those with actigraphy-measured sleep duration > 6.5 hours, ( mean 
HbA1c 8.5% and 7.7% respectively; p-value = 0.001). After adjusting for confounders, 
they reported a 0.64% increase in mean HbA1c level with shorter sleep duration 
compared to longer sleep duration, however they did not accompany their estimate with 
a 95% CI or a p-value. Lastly Barone et al. (2015) assessed sleep parameters in a group 
of 18 young adults with T1DM using 10 days sleep diaries and one night 
polysomnography. They assessed glycaemic control by measuring HbA1c after the 
polysomnography night and by using the overall mean and SD of multiple daily capillary 
glucose concentrations from a glucometer. Capillary glucose concentrations were 
recorded for 10 days simultaneous with the sleep diaries. The study showed no 
correlation between self-reported sleep duration and subjective sleep quality with either 
mean capillary glucose or SD capillary glucose. However, awakening index and arousal 
index from the polysomnography were positively correlated with HbA1c. Furthermore, 
the study reported a positive correlation between self-reported sleep onset latency and 
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SD glucose. Only correlation coefficients were reported in this study with no adjustment 
for potential confounders. 
In summary, these cross sectional studies propose a potential U-shaped association 
between both short and long sleep durations and a poor glycaemic control. However, a 
reverse causality cannot be excluded in these studies. Among individuals with diabetes 
and hyperglycaemia osmotic symptoms such as nocturia (excessive urination at night), 
polydipsia (excessive thirst) and restlessness are common (Warren et al., 2003) and 
may potentially exert detrimental influence on the individuals’ sleep duration and quality 
(Barone and Menna-Barreto, 2011). In addition most studies to date are limited as they 
have only explored the relationship using subjective self-reported sleep duration. The 
three small studies that have assessed sleep duration objectively, seem to show weaker 
relationships to glucose control. An additional limitation is that HbA1c is often chosen as 
the measure of glucose control, yet it reflects the preceding 3 months of glucose control, 
and is temporally distant to the assessment of sleep duration, which may weaken any 
association. Randomised clinical trials with exposure to sleep duration modification 
(restriction or extending) and/or robust methods of assessing the temporal relation 
between nighttime sleep and the following daytime glucose control are needed to yield 
more definitive answers. 
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Table 1-1 Prospective studies on sleep and the risk of developing T2DM. 
Author (year) Country Participants Study design Exposure Outcome Results Comments 
Gangwisch et 
al. (2007) 
USA 8992 adult aged 32-
68 years  
Prospective 
cohort 
Subjective 
nighttime  sleep 
duration 
T2DM incidence 
over  8-10 year 
follow-up period 
U-shaped 
associations 
from the NHANES cohort 
(Yaggi et al., 
2006) 
USA 1564 men aged 40-
70 years  
Prospective 
cohort study 
Subjective 
nighttime sleep 
duration 
T2DM incidence 
over  15 year 
follow-up period 
U-shaped 
associations 
 from the Massachusetts 
Male Aging Study 
(Kowall et al., 
2016) 
Germany 4814 adults aged 
45-75 years  
Prospective 
cohort study 
Subjective 
nighttime sleep 
duration 
T2DM incidence 
over  5 year 
follow-up period 
U-shaped 
associations 
from the Heinz Nixdorf 
Recall study 
(Holliday et al., 
2013) 
Australia 192728 adults aged 
≥ 45 selected from 
medical insurance 
database 
Prospective 
cohort study 
Subjective 
sleep duration 
T2DM incidence 
over a mean 
follow up period 
of 2.3 years 
Positive 
association, 
only short 
sleep duration 
Diabetes incidents extracted 
from hospital admission or 
mortality electronic records, 
short follow up period 
(Rafalson et 
al., 2010) 
USA 363 participants; 91 
cases, 272 controls, 
aged 35-79 years 
nested case-
control 
Subjective 
sleep duration 
(weekdays 
only) 
Impaired fasting 
glucose  
Positive 
association, 
only short 
sleep duration 
 
(Tuomilehto et 
al., 2009) 
Finland 522 participants 
aged 40–64 years 
without diabetes 
Two 
Prospective 
cohorts based 
Subjective 
sleep duration 
T2DM incidence 
over 7 year 
follow up period 
Positive 
association, 
Only in the control arm 
cohort 
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randomly allocated 
either to a study arm 
or to a control arm. 
on arms of a 
randomised 
controlled trial 
only long 
sleep duration 
(Gutierrez-
Repiso et al., 
2014) 
Spain 1145 randomly 
selected participants 
aged 16-65 years 
from the Pizzara 
study 
Prospective 
cohort 
Subjective 
nighttime sleep 
duration 
T2DM incidence 
at 6 and 11 years 
follow up 
Positive 
association 
only at 6 year 
follow up 
Change in sleep duration 
over the 11 year follow up 
(Kita et al., 
2012) 
Japan 3570 adults aged 
35-55 years  
Prospective 
cohort  
Subjective 
sleep duration 
and sleep 
quality 
T2DM incidence 
after 2 year 
follow up) 
Positive 
spurious 
association 
Statistical issues 
(Ferrie et al., 
2015) 
UK 5613 adults aged 
35-55 years from 
the Whitehall II 
study 
Prospective 
cohort, four 5-
year cycles 
Change in 
nighttime sleep 
duration in the 
following cycle 
T2DM incidence 
at the end of 
subsequent cycle 
Positive 
association, 
increase ≥ 2 
hours 
Association could be 
mediated by weight gain 
(Cespedes et 
al., 2016) 
USA 59031 middle aged 
to old women 
without diabetes 
Prospective 
cohort study 
Change in 
sleep duration 
over 14 years  
T2DM incidence 
over  12 year 
follow up period 
Positive 
association, 
increase ≥ 2 
hours 
Association only with 
increase in sleep duration ≥ 
2 h/day, Change in sleep 
duration from a historic 
baseline to time of enrolment 
NHANES National health and nutrition examination survey  
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Table 1-2 Cross-sectional studies on sleep and the risk of developing T2DM. 
Author, year Country Participant Study 
design 
Exposure Outcome Result Comment 
(Jackson et al., 
2013) 
USA 130943 adults 
aged 18-85 years 
from the NHIS 
(years 2004 to 
2011) 
Cross 
sectional 
Subjective 
sleep duration 
in a 24 hours 
period 
self-reported T2DM 
status  
U-shaped 
associations 
Stronger association in 
white population 
(Buxton and 
Marcelli, 2010) 
USA 56507 adults from 
the NHIS (years 
2004 to 2005) 
Cross 
sectional 
Subjective 
sleep duration 
in a 24 hours 
period 
self-reported chronic 
diseases including 
T2DM 
U-shaped 
associations 
multilevel logistic 
regression 
(Wu et al., 
2015) 
China 25184 adults mean 
age 63 years from 
the Dongfeng-
Tongji Cohort study 
Cross 
sectional 
Subjective 
sleep duration  
Risk of metabolic 
syndrome including 
T2DM 
No association 
with nighttime 
sleep duration 
Positive association 
with daytime napping 
duration 
 
(Bakker et al., 
2015) 
USA 2151 participant 
aged 45-84 years 
from the Multi-
Ethnic Study of 
Atherosclerosis 
Cross 
sectional 
Objective 
sleep duration 
Diabetes  No association Model adjusted for OSA 
 
NHIS National health interview survey  
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Table 1-3 Studies on sleep and development of insulin resistance  
Author (year) Country Participants Study 
design 
Exposure Outcome Results Comments 
Liu et al. (2013) USA 56 non-diabetic 
overweight-obese 
participants 
Cross 
sectional 
Subjective 
sleep duration 
Insulin 
sensitivity 
Positive 
association 
Only P-values 
reported. 
Broussard et 
al. (2012) 
USA 7 young healthy 
participants 
Crossover 
clinical study 
Sleep 
restriction 
Insulin 
sensitivity 
Positive 
association 
Small sample size 
Nedeltcheva et 
al. (2009a) 
USA 11 young-middle 
aged healthy 
participants 
Crossover 
clinical study 
Sleep 
restriction 
Insulin 
sensitivity and 
glucose 
tolerance 
positive association Small sample size 
Wang et al. 
(2016b) 
USA 15 young healthy 
non-obese 
participants 
Crossover 
clinical study 
time-in-bed 
restriction by 1 
to 3 hours for 3 
nights 
Insulin 
sensitivity and 
glucose 
tolerance  
Positive 
association with 
insulin sensitivity 
No association with 
glucose tolerance 
Donga et al. 
(2010) 
The 
Netherlands 
9 healthy 
participants, 
mean age 44.6 
years 
Crossover 
clinical study 
Sleep 
restriction 
Insulin 
sensitivity 
Positive 
association 
Small sample size 
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St-Onge et al. 
(2012) 
USA 27 healthy young 
non-obese adults 
Crossover 
clinical study 
Time in bed 
restricted to 4 
hours 
insulin 
sensitivity 
No association Participants had 
controlled diet and lost 
weight during the study 
Robertson et 
al. (2013) 
UK 19 healthy young 
lean men 
Randomised 
controlled 
trial 
Around 1.5 
hours sleep 
restriction per 
night for 3 
weeks 
insulin 
sensitivity 
Positive 
association only at 
the end of first 
week 
absence of an overall 
effect of sleep 
restriction on insulin 
sensitivity 
Broussard et 
al. (2016) 
USA 19 healthy young 
lean men 
Crossover 
clinical study 
two days of 
catch-up sleep 
Recovery of 
insulin 
sensitivity 
Positive 
association 
 
Leproult et al. 
(2015) 
Belgium 16 healthy young 
non-obese adults 
with chronic sleep 
restriction 
Crossover 
clinical study 
Around one 
hour sleep 
extension per 
night for 6 
weeks 
Fasting glucose 
and insulin 
levels 
No difference in 
pre- and post- 
intervention levels 
Moderate correlation 
between relative 
change in sleep 
duration and relative 
change in fasting 
glucose and insulin 
levels 
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Table 1-4 Studies on sleep and glycaemic control in patients with diabetes  
Author 
(year) 
Country Participants Study 
design 
Exposure Outcome Results Comments 
Ohkuma et 
al. (2013) 
Japan 4870 adults, 
aged ≥20 years 
with T2DM 
Cross-
sectional 
Subjective sleep 
duration including 
naps 
Glycaemic 
control (HbA1c) 
U-shaped 
associations 
 
Kim et al. 
(2013a) 
Korea 2134 adults, 
aged > 20 years 
with T1DM or 
T2DM 
Cross-
sectional  
Subjective daily 
sleep duration 
Glycaemic 
control (HbA1c) 
positive 
associations 
J-shaped trend with HbA1c; stronger 
in females and in the younger age 
group (<65 years). Association 
disappear after adjusting for more 
covariate in the logistic regression 
model. 
Zheng et al. 
(2015) 
China 8543 adults, 
aged ≥40 years 
with T2DM or 
impaired glucose 
tolerance 
Cross-
sectional 
Subjective 
nighttime sleep 
duration  
Glycaemic 
control (HbA1c, 
FPG, PPG) 
Positive 
association 
with long sleep 
duration 
Only adjusted means and p-values 
reported but no estimate of 
association 
(Tsai et al., 
2012b) 
Taiwan 46 adults, aged 
43-83 years with 
T2DM 
Cross-
sectional 
Subjective sleep 
duration and 
quality (PSQI) 
Glycaemic 
control (HbA1c) 
Positive 
association  
Participants with diabetic 
complication or major co-morbidities 
were excluded. association only with 
sleep efficiency and PSQI score of 8 
or more but not sleep duration  
19 
 
(Knutson et 
al., 2006) 
USA 
 
161 African 
Americans, mean 
age 57 years with 
T2DM 
Cross 
sectional 
Subjective sleep 
duration and 
sleep quality, 
modified PSQI, 
and perceived 
sleep debt 
Glycaemic 
control (HbA1c) 
Positive 
association  
Sleep debt association only in 
participants without diabetic 
complication or not using insulin. 
sleep quality only in participants with 
diabetic complication or using insulin 
association  
(Trento et 
al., 2008) 
Italy 47 middle aged 
adults with T2DM 
and 23 healthy 
controls 
Cross 
sectional 
study  
Objective sleep 
parameters; 
duration and 
quality using wrist 
actigraphy 
glycaemic 
control (HbA1c)  
in T2DM group 
Not reported Weak negative correlation with 
sleep efficiency and mild positive 
correlation with moving time while 
asleep. No estimate measures of 
association reported 
(Borel et al., 
2013) 
France 79 adults, median 
age 40 years with 
T1DM 
Cross 
sectional 
study 
Objective sleep 
parameters using 
wrist actigraphy 
glycaemic 
control (HbA1c)   
Positive 
association 
 
(Barone et 
al., 2015) 
Brazil 18 young adult, 
aged 20-38 years 
with T1DM 
Cross 
sectional 
Objective sleep 
measures using 
wrist actigraphy 
Glycaemic 
control (average 
glucose from 
glucometer 
reading) 
No association Methodological issues 
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1.4 Sleep during pregnancy and glucose homeostasis 
During pregnancy, changes in sleep patterns and sleep duration are commonly reported 
and are mainly due to the physiological, biochemical and anatomical changes that 
accompany pregnancy  (Balserak and Lee, 2011). These changes are likely to be 
influenced ,as well , by the concentrations and the circadian rhythms of pregnancy 
hormones such as oestrogen, progesterone, placental corticotrophin and oxytocin (Pien 
and Schwab, 2004; Seron-Ferre et al., 1993). 
Indeed, sleep is disturbed as early as the first trimester of pregnancy (Facco et al., 
2010b; Hedman et al., 2002; Lee et al., 2000), with noticeable sleepiness and a 
correspondent increase in total sleeping time, although the quality of sleep is 
deteriorated (higher number of awakenings and less deep sleep), compared to pre-
pregnancy sleep quality. As the pregnancy progress, the total amount of sleep begins to 
decrease, sleep quality declines and the frequency of sleep disturbances increase, 
reaching a maximum in the third trimester (Hedman et al., 2002; Facco et al., 2010b). 
Using polysomnography to objectively assess sleep, pregnant women in the third 
trimester of pregnancy compared to non-pregnant women, had longer wake after sleep 
onset (WASO) duration, i.e. spent longer awake in the middle of their nighttime sleeping 
interval, more fragmented sleep, poorer sleep efficiency,  more time in light sleep stage, 
less time in deep sleep stage, and less time in REM sleep stage (Wilson et al., 2011). 
When assessed subjectively, sleep quality was likewise poorer in pregnant women than 
non-pregnant women (Ko et al., 2010). The changes in sleep are usually attributed to 
foetal movements, pregnancy related backache, frequent urination, leg cramps and 
anxiety (Balserak and Lee, 2011). Despite documentation of changes to the quality and 
the architecture of sleep during pregnancy, mean sleep duration (both subjective and 
objectively assessed) in the third trimester of pregnancy was similar to the sleep duration 
before pregnancy (Lee et al., 2000; Hedman et al., 2002).  Hedman et al. (2002) 
reported mean (SD) of self-reported sleep duration at night of 7.8 (0.9) hours before the 
pregnancy, 8.2 (0.9) hours in the first trimester, 8.0 (1.0) hours in the second trimester 
and 7.8 (1.2) hours in the third trimester. Lee et al. (2000) reported mean (SD) of 2-
nights polysomnography measured sleep duration of 6.9 (1.0) hours before pregnancy, 
7.4 (1.1) hours in first trimester and 6.9 (1.1) hours in the third trimester. Nevertheless, a 
similar mean does not imply a similar distribution, as pregnant women tend to have 
higher proportions of both short and long sleep duration compared to non-pregnant 
women (Alafif et al., 2016). 
The detrimental effect of sleep disturbances has now been well demonstrated in the 
general population, but pregnant women are different, and may not necessarily have the 
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same responses. There has recently been a surge in literature proposing that sleep 
disturbances during pregnancy are associated with poor pregnancy outcomes for both 
mother and infant (Chang et al., 2010), with a higher likelihood of gestational 
hypertensive disorders, gestational diabetes (GDM), unplanned Caesarean deliveries, 
intra-uterine growth restriction and still birth (Palagini et al., 2014; O'Brien, 2012; 
Bourjeily et al., 2010). Sleep disturbances, particularly short sleep duration and sleep 
disordered breathing, have also been shown to be significantly associated with glucose 
intolerance in pregnancy (Facco et al., 2010a; Reutrakul et al., 2011) with greater risks 
among overweight pregnant women (Qiu et al., 2010).  
In a cohort of multi-ethnic pregnant women (at 26-28 weeks of gestation) from Singapore 
(n=686): 43% reported poor sleep quality (PSQI>5) and 11.2% reported short sleep 
duration (< 6 hours) (Cai et al., 2017). In the same study pregnant women with poor 
sleep quality and short sleep duration were at higher risk of being diagnosed with GDM 
(adjusted OR; 95% CI were 1.75; 1.11 to 2.76, and 1.96; 1.05 to 3.66, respectively). In 
another study from the USA a cohort of pregnant women (n=901) were studied early 
pregnancy (<14 weeks of gestation) and their sleep was objectively assessed using wrist 
actigraphy. Only 87% of the participants submitted what the study considered as ‘valid’ 
actigraphy records.  27.9% of women had a sleep duration of <7 hours and 2.6% had a 
sleep duration of >9 hours. Median WASO duration was 42.2 minutes and median mid-
sleep point was 03:38 am (Reid et al., 2017). In this cohort short sleep duration (<7 
hours) compared to longer sleep duration (≥ 7 hours) and late chronotype (sleep 
midpoint >05:00 am) compared to earlier chronotype (sleep midpoint ≤ 05:00 am were 
associated with an increased odds of developing GDM, (OR 2.24; 95% CI 1.11 to 4.53) 
and (OR 2.58; 95% CI 1.24 to 5.36), respectively. WASO duration was not associated 
with the odds of developing GDM in this study (Facco et al., 2017). 
The association between sleep disturbances and glycaemic control among pregnant 
women with established pre-pregnancy T1DM or T1DM was not explored. There is only 
one published study on the association between sleep disturbances and glycaemic 
control in pregnant women with GDM (Twedt et al., 2015). In this study only 45 pregnant 
women were enrolled to participate immediately after being diagnosed with GDM. The 
study excluded women on glucose lowering medications, namely insulin and glyburide. 
The gestational age of enrolment was very wide ranging between 6 weeks to 33 weeks 
of gestation, median 28 weeks. Sleep in this study was assessed using actigraphy 
(Actiwatch Spectrum Respironics device with medium threshold settings). Whereas 
glycaemic control was assessed using fasting and 1-hour post prandial capillary blood 
concentrations. Only 37 participants out of the 45 enrolled returned at least one day of 
sufficient data (i.e. having both sleep and glucose data). They gave rise to 213 nights of 
actigraphy sleep data with at least one glucose reading the following day. Thus 209 
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fasting glucose readings, 196 breakfast, 188 lunch, and 204 dinner postprandial readings 
were available for analysis. The study reported a sleep duration ranging from 1.1 to 12.3 
hours with a median of 6.8 hours. 
Multiple linear mixed effect regression models, adjusted for maternal age, gestational 
age at enrolment and pre-pregnancy BMI, were applied in the study to assess the 
proposed associations. The study found that each one hour increase in sleep duration 
was associated with lower fasting and 1-hour postprandial capillary blood glucose 
concentrations, as follows; 2.09 mg/dl (0.12 mmol/l) lower fasting blood glucose 
concentration (95% CI -3.98 to -0.20 mg/dl), 3.05 mg/dl (0.17 mmol/l) lower post-
breakfast blood glucose concentration though not statistically significant (95% CI -6.52 to 
0.42 mg/dl), 4.62 mg/dl (0.26 mmol/l) lower post-lunch blood glucose concentration (95% 
CI -8.75 to -0.50 mg/dl), and 6.07 mg/dl (0.34 mmol/dl) lower post-dinner blood glucose 
concentration (95% CI -9.40 to -2.73). After categorising sleep duration into groups to 
assess for a possible U-shaped relation between sleep duration and glucose levels, only 
short sleep duration (<5 hours) but not long sleep duration (≥9hours) was associated 
with higher glucose concentration, compared to ≥7 to <9 hours sleep duration. However, 
the results reported did not show a linear trend of the association especially for post-
breakfast and post-dinner associations. After plotting their results for post-breakfast 
regression model (Figure 1-3), it was very clear that a J-shape/U-shaped association 
might be present. However, the study had a small sample size of nights with sleep 
duration of 9 hours or more (only 10 nights out of the total 213 night), which might 
explain the wide confidence interval and the non-statistically significant results. 
Despite the accumulative number of evidence suggesting a substantial relationship 
between sleep disturbances and; higher risk of developing T2DM and lower glycaemic 
control in non-pregnant population, and the increase risk of GDM in pregnant women, 
there is a paucity of research among pregnant women with GDM. Sleep remains largely 
unrecognised as a potentially modifiable risk factor for diabetes in pregnancy. There is a 
clear gap in the literature in the association between sleep and glycaemic control in GDM 
which the current study is trying to bridge.  
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Figure 1-3 Plot of the regression model results (the β coefficient and the Upper 
and the lower 95% CI limits) of association between sleep duration categories 
and post-breakfast glucose concentration as reported by Twedt et al. (2015) 
 
 
1.5 Gestational diabetes (GDM) 
1.5.1 Pathophysiology and definition  
With the progression of pregnancy and the normal growth of the placenta, a surge in 
placental and other pregnancy related hormones contributes to insulin resistance of the 
mother (Kampmann et al., 2015). This leads to less insulin mediated glucose uptake to 
the mother’s muscle/liver/adipose tissues, and allows a higher level of glucose l to 
circulate in the blood. This allows more glucose to cross the placenta for the ‘benefit’ of 
the growing foetus. However to avoid hyperglycaemia, pregnant women usually 
compensate for the insulin resistance by producing more insulin.  A failure in the 
production of adequate compensatory insulin by the pregnant women will lead to the 
development of GDM.  
GDM was defined previously as any degree of glucose intolerance (hyperglycaemia) with 
its onset or first recognition during pregnancy (The Expert Committee on the Diagnosis 
and Classification of Diabetes Mellitus, 1997). This definition includes pregnancy related 
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hyperglycaemia, as well as, hyperglycaemia caused by pre-gestational diabetes that was 
first detected during pregnancy. However, a more recent definition by the American 
Diabetes Association (ADA) excludes patients with overt diabetes from the GDM 
definition (ADA, 2011; ADA, 2013; ADA, 2014). Likewise, the World Health Organization 
has classified hyperglycaemia first detected in pregnancy to either GDM or diabetes in 
pregnancy based on a diagnostic threshold (more details in GDM diagnosis section 
1.5.5) (WHO, 2013).  
1.5.2 Risk factors  
Pregnant women who develop GDM often have a genetic predisposition. Those women 
with a family history of T2DM are at greater risk, suggesting shared genetic and 
environmental influences. Pregnant women from Asian, Hispanic, African, Middle-
Eastern and Native American ethnic backgrounds have a higher risk of GDM compared 
to pregnant women from White European ethnic backgrounds. Other established risk 
factors include: high pre-pregnancy BMI (obese pregnant women have three times the 
risk of developing GDM compared to lean pregnant women) (Torloni et al., 2009; Chu et 
al., 2007), and increasing maternal age (7-10 times increase risk in pregnant women 
aged 25 years or older compared to less than 25 years). For multigravida (women with a 
previous pregnancy), added risk factors include: GDM in the previous pregnancy, 
previous macrosomia (giving birth to a big baby weighing more than 4500 g) and 
previous unexplained stillbirth (Egan et al., 2017). 
1.5.3 Prevalence   
GDM is highly common worldwide and it is estimated by the International Diabetes 
Federation (2015) that 1 in 7 births are affected by GDM. However, the prevalence 
varies across the world affecting from <1% to 28% of all pregnancies (Jiwani et al., 2012) 
and reaching 39% of pregnancies in obese pregnant women (Egan et al., 2017). This 
variation in the prevalence is due to variation in the nationally implemented methods and 
criteria to screen for GDM in different countries and whether the screening is universal 
for all pregnant women or selective based on high risk criteria. Even in the same country 
prevalence rates will vary from one region to another depending on the distribution of 
these risk factors among its population (Kampmann et al., 2015).  
1.5.4 Complications  
GDM has short and long term sequelae for the pregnant women and their offspring 
(Egan et al., 2017). Short-term sequelae include a higher risk of macrosomia, and large-
for-gestational-age (LGA) infants, polyhydramnios (pathological excessive amniotic fluid 
surrounding the foetus), caesarean section, neonatal hypoglycaemia, neonatal 
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hypocalcaemia, neonatal distress syndrome, neonatal intensive care unit admission, and 
maternal gestational hypertension, (O'Sullivan et al., 2012; Hod et al., 1991; Anand et al., 
2017). GDM, even with slight degree of hyperglycaemia, is associated with a 30% higher 
risk of giving birth to a LGA neonate (O'Sullivan et al., 2012) and around 19.7%- 22.6% 
of neonates born to mothers with GDM are LGA (Luoto et al., 2011). Glucose circulating 
in the mother’s blood, but not the mother’s insulin, can pass the placental barrier freely to 
the foetal circulation. Thus, a high maternal glucose level results in a high glucose 
concentration in the foetal circulation. In attempt to control this high influx of glucose, the 
foetus produces extra insulin. However, insulin is a growth factor and it causes excessive 
foetal growth, with the extra glucose being stored predominantly as abdominal fat, 
leading to macrosomia and a LGA neonate. Large foetuses are at higher risk of being 
delivered by caesarean section and of suffering shoulder dystocia and other birth trauma 
with vaginal delivery (Hod et al., 1991; Reece et al., 2009; Mitanchez, 2010)  
Long-term sequelae for the offspring include: a higher risk of developing obesity, glucose 
intolerance, T2DM and metabolic syndrome later in life (Yogev and Visser, 2009; 
Dabelea et al., 2000; Zhu et al., 2016). Whilst maternal dysglycaemia usually returns to a 
normal level after delivery, the mother is at higher risk of developing GDM in a 
subsequent pregnancy (England et al., 2015) and at higher risk of developing glucose 
intolerance and T2DM in the following years, 6.9% at five years and 21.1% at ten years 
following GDM (Sivaraman et al., 2013). 
1.5.5 Diagnosis 
Diagnosis of GDM is currently based on the results of an oral glucose tolerance test 
(OGTT) mostly performed at 24-28 weeks of gestation. However the diagnostic cut-
points keep changing and updating based on the emergence of new evidence. 
Diagnostic criteria varies widely between different health authorities and diabetes 
associations. The International Association of the Diabetes and Pregnancy Study Groups 
(IADPSG) updated their diagnostic criteria based on the hyperglycaemia and adverse 
pregnancy outcomes (HAPO) study (Hapo Study Cooperative Research Group, 2008; 
Metzger et al., 2010). Later on the World Health Organisation (WHO) updated their 
criteria and followed a similar diagnostic criteria as the IADPSG (WHO, 2013). These 
criteria recommend testing for hyperglycaemic disorders initially at the first antenatal visit 
and later on, at 24-28 weeks’ gestation if the earlier assessment was normal. High 
glucose levels are classified as overt diabetes or diabetes in pregnancy (DIP), while 
lesser values are classified as GDM.  GDM can be diagnosed at any time in pregnancy, 
based on a 75g-load OGTT, if one or more of the following is met: fasting glucose 5.1-
6.9 mmol/l (92 -125 mg/dl), 1-hour glucose ≥ 10.0 mmol/l (180 mg/dl) or 2-hour glucose 
8.5-11.0 mmol/l (153 -199 mg/dl). On the other hand overt diabetes during pregnancy is 
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diagnosed at the initial visit if the glycated haemoglobin (HbA1c) level ≥ 6.5% or if at any 
visit the fasting glucose ≥ 7.0 mmol/l (126 mg/ dl), 2-hour following a 75g-load OGTT 
glucose ≥ 11.1 mmol/l (200 mg/dl) or random glucose ≥ 11.1 mmol/l (200 mg/ dl) (in the 
presence of diabetes symptoms and followed by confirmatory fasting glucose or HbA1c).   
In the United Kingdom the National Institute for Health and Care Excellence (NICE) 
guidelines are generally followed, and they published an update to their GDM diagnostic 
criteria in 2015. They recommend a 75g-load OGTT to test for GDM in women with risk 
factors at 24–28 weeks of gestation. However an earlier test, arranged immediately after 
their first antenatal visit, is recommended for women with history of GDM in their 
previous pregnancy with a repeat test at 24-28 weeks if the earlier was normal (NICE, 
2015). Diagnosis of GDM will be confirmed if the fasting glucose level ≥ 5.6 mmol/l or the 
2‑hour post glucose load ≥ 7.8 mmol/l. Risk factors determined by NICE to qualify for 
testing are: BMI > 30kg/m2, previous macrosomic baby, previous GDM, family history of 
diabetes in a first-degree relative and an ethnic family background with a high 
prevalence of diabetes. 
On the other hand, the American Diabetes Association (ADA) recommend either a one-
step strategy similar to the IADPSG or a two-step strategy screening first by a 50-gram 
oral glucose challenge test and followed by a 3-hour 100 g glucose load OGTT if the 
latter was normal (ADA, 2017a). 
1.5.6 Management  
To avoid complications for both the mother and the offspring an intensive management 
strategy is followed, even for asymptomatic mothers and those with a mild degree of 
hyperglycaemia (Metzger et al., 2007). In order to control pregnant women’s glucose 
level, they are advised on lifestyle modification regarding diet modification via 
individualised advice sessions from dietitians, as well as, performing regular physical 
exercise. Moreover, they are instructed to daily self-monitor their blood glucose (SMBG) 
using glucometer devices to test their blood glucose at least four times a day, fasting and 
one hour after each meal, and to keep their glucose levels within strict defined targets 
(ADA, 2017b). The latest published glucose level targets during pregnancy are as 
follows: fasting glucose ≤ 5.3 mmol/l (95 mg/dl) and either one-hour postprandial glucose 
≤7.8 mmol/l (140 mg/dl) or two-hour postprandial glucose ≤ 6.7 mmol/l (120 mg/dl) (ADA, 
2017b; NICE, 2015). In the case that lifestyle modification was not successful in keeping 
the blood glucose to target after 1-2 weeks of diagnosis, or if the pregnant woman has a 
very high fasting glucose level (≥ 7 mmol/l) from the first assessment visit then blood-
glucose lowering medication such as metformin and insulin are introduced to the 
management plan. 
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1.5.7 Measuring glycaemic control 
Whilst glycated haemoglobin (HbA1c), is widely acceptable as a measure of glycaemic 
control in the non-pregnant population, it is considered less reliable than SMBG as a 
measure of glycaemic control during pregnancy (Yu et al., 2014b). This has been 
attributed to the higher turnover and shorter life span of red blood cells during pregnancy 
and thus less time for the red blood cell haemoglobin molecules to get glycated (Rafat 
and Ahmad, 2012). This results in lower values of HbA1c during pregnancy which 
continue to reduce as pregnancy advances (O'Kane et al., 2001). Whilst it has been 
demonstrated that there is a relationship between average glucose and HbA1c during 
pregnancy in women with diabetes, the relationship is different to that seen in a non-
pregnant population (Law GR et al 2017). Moreover, HbA1c represents the overall mean 
blood glucose concentration for a preceding period of 8-10 weeks but does not give any 
information about the variation of glucose concentrations over that period. In a study by 
Kerssen et al. (2003) pregnant women with T1DM and HbA1c ≤ 7% had around half of 
their daily blood glucose measured values above the recommended threshold (7.8 
mmol/l) . 
Daily fasting and 1-hour postprandial SMBG, as stated in the previous section is 
therefore the recommended tool to clinically evaluate glycaemic control in GDM. 
Nonetheless, the frequency and timing of SMBG also have some limitations. The 
postprandial timing assumes that the time from starting food intake until the peak of 
postprandial glucose concentration is one hour. However, this may not be the case 
during pregnancy due to pregnancy related delayed gastric emptying. A study aiming to 
closely assess glucose levels in non-diabetic pregnancy using continuous glucose 
monitoring found that the time to peak glucose concentration is highly variable with a 
mean (SD) of 71 (±30) minutes in normal weight women and 88 (±31) minutes in obese 
women (Yogev et al., 2004). Time to peak glucose concentration in another study 
involving pregnant women with diabetes (26 GDM on diet, 19 GDM on insulin, and 20 
T1DM on insulin) ranged from 75 (±30) minutes to 102 (±47) minutes (Ben-Haroush et 
al., 2004). Thus it seems likely that the actual postprandial peaks in glucose are being 
missed by current SMBG, limiting our understanding of the true variation in glucose 
occurring. Whilst this could be overcome by more frequent SMBG testing, this would 
necessitate more finger pricks, which are painful, inconvenient and widely disliked. 
SMBG testing also only takes place during the day when the women are awake and able 
to perform it. Whilst asleep they are not able to and so overnight glucose levels are not 
routinely assessed. In a study published by Law et al. (2015) overnight relative 
hyperglycaemia detected by continuous glucose monitoring (CGM) was associated with 
a higher risk of having a LGA infant, which supports the fact that SMBG testing is limited 
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in its usefulness at detecting glucose variations associated with adverse clinical 
outcomes in pregnancy   
 To overcome the limitations of SMBG recent advances in technology, now allow closer 
monitoring of glucose through the use of continuous glucose monitoring systems. Their 
potential utility in both clinical and research settings is huge (Festin, 2008; Chitayat et al., 
2009; Hawkins, 2010; Murphy, 2013).  
1.6 Continuous glucose monitoring (CGM) systems 
CGM systems measure glucose in the subcutaneous interstitial fluid (ISF) via an 
electrochemical amperometric sensor (Rebrin and Steil, 2000). They are usually 
calibrated by SMBG values to predict an estimate of plasma glucose via specific 
mathematical algorithms (Rebrin et al., 1999; Mastrototaro, 2000). A detailed description 
of the mechanism of action of CGM is presented in the methods chapter. In brief, most 
CGM systems record a glucose value every 5 minutes yielding up to 288 of time-ordered 
successive glucose values per day. This dense time-series data can be presented as a 
long data list and plotted as glucose curves over time (Figure 1-4). They provide ample 
information about magnitude, frequency and duration of glucose excursions as well as 
other diurnal glucose behaviour (Klonoff, 2005; Murphy et al., 2007).However such very 
dense data as CGM data can also bring challenges for analysis.  
Conventionally summary metrics evaluating glycaemic control have been proposed to 
extract some of the valuable information CGM data potentially provides (Service, 2013; 
Inchiostro et al., 2013; Rodbard, 2009a; Kovatchev et al., 2006; McDonnell et al., 2005). 
These summary metrics include: mean , median, standard deviation (SD) and 
interquartile range (IQR) of glucose concentrations, total area under glucose curve 
(AUC), AUC above normative range, AUC below normative range, proportion of time 
spent within, below or above normative range, coefficient of variation of glucose 
concentrations, mean amplitude of glycaemic excursions (MAGE), mean of daily 
differences (MODD), J index, M-value, Continuous Overall Net Glycaemic Action 
(CONGA), the Low Blood Glucose Index (LBGI) and the High Blood Glucose Index 
(HBGI), the Average Daily Risk Range (ADRR). The information contained within these 
metrics and the methods for calculating them are described in the following paragraphs 
(sections 1.6.1 to 1.6.8) with the assistance of six simulated glucose curves; curve A, 
curve B, curve C, curve D, curve E and curve F (Figure 1-7 to Figure 1-10). 
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Figure 1-4 CGM system output showing daily glucose curves for one participant 
 
1.6.1 Mean glucose and total AUC  
Mean glucose is calculated by dividing the sum of all glucose values across a time 
period (e.g. 24 hours) by the number of glucose readings obtained during that time 
period (288 reading in a 24 hour period). Mean is a measure describing the central 
location in normally distributed data, where half of the data will be above and the other 
half below the mean (Figure 1-5 Normal distribution curve). However, glucose values 
have a tendency to be skewed to the right as glucose has a limited lower value of zero 
and theoretically no upper limit (Figure 1-6). A child from the USA has been recorded to 
survive a blood glucose level of 147.6 mmol/l (2,656 mg/dl) (GuinnessWorldRecords, 
2008). Therefore, a mean glucose will be potentially biased towards higher values. Mean 
glucose is highly correlated with HbA1c and provides a good estimate of overall 
glycaemic control (Nathan et al., 2008; Zhou et al., 2013; Law et al., 2017).   
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Figure 1-5 Normal distribution curve 
 
It is worth noting that the mean glucose is equivalent to the standardised total AUC. The 
standardised total AUC equals the sum of the all the trapezoids of 5 minutes width and 
bounded by a zero lower limit and glucose curve upper limit and then divided by the total 
duration, e.g. for a 1-hour period there will be twelve 5-minute trapezoids. The height of a 
trapezoid is equal to the averaged glucose concentration measured over a 5-minute 
interval and thus the standardised total AUC is calculated by summing the glucose 
concentrations and dividing them by the number of intervals. This is exactly how a mean 
glucose is calculated. 
However, an overall mean cannot differentiate between glucose curves with different 
postprandial amplitudes of glucose excursion or diverse variability, neither can it infer the 
time of day when troublesome glucose concentrations arise. Glucose curve B and 
glucose curve E for example (Figure 1-7) have the exact same mean glucose ( 
Table 1-6), though glucose curve E is spending more time within the normative range 
and has shallower excursions with less proportion of the excursion spreading outside the 
normative range and thus is more controlled, less variable and more stable than curve B. 
Therefore, a mean glucose alone cannot fully describe glycaemic control and it needs to 
be supplemented by other measures of variability.  
A median is another measure of central location which is not biased by the skewness of 
the data. However, a median glucose is less favourable to use than the mean glucose, 
as it does not estimate the total AUC and there is no study that has examined its 
correlation to HbA1c. 
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Figure 1-6 Histogram of simulated glucose curve B from Figure 1-10. 
 
 
 
Figure 1-7 Simulated glucose curve B and curve E having the same mean but 
different variability measures. 
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1.6.2 Standard deviation (SD) and coefficient of variation (CV) 
The SD of glucose, calculates the dispersion of glucose values around its mean. It is a 
simple method and widely used as a measure of glycaemic variability (DeVries, 2013). 
The main criticism of using SD is that it is a measure of dispersion in normally distributed 
data, where the mean ± 2SD will approximately span the middle 95% of the data (Figure 
1-5 Normal distribution curve), whereas, as explained previously with the mean glucose 
(section 1.6.1), glucose data is potentially skewed. However, the SD of glucose was 
found to be higher in people with diabetes and poor overall glucose control as 
determined by a higher HbA1c compared to those with diabetes and good overall 
glucose control, and higher in people with diabetes and good overall glucose control 
compared to those without diabetes. The SD of mean glucose also correlates highly to 
other more complicated indices of glucose variability like MAGE, MODD and CONGA 
(Rodbard, 2012). The SD of glucose can also be standardised and expressed as a 
percentage of the mean and presented as a coefficient of variation (CV). 
However, the SD of glucose does not reflect the proportion of time spent, or indeed the 
extent of glucose excursion outside a recommended glucose range in an individual 
(Figure 1-8). 
 
 
Figure 1-8 Simulated glucose curves A and D have the same SD glucose but have 
different mean glucose and different proportion of time within the normal 
range 
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1.6.3 Time spent within, below or above normative range and AUC 
above and below normative range 
The aim when controlling glucose in people with diabetes is to keep glucose 
concentration within a tight ‘normal’ range that is bounded by an upper and lower 
thresholds while allowing for mild fluctuation around meal times. Binding to and departing 
across these limits can be quantified by measures like: time spent within, below or above 
the normative range and AUC-above and AUC-below the normative range.  
Time spent within, below or above the normative range can be presented as the actual 
time duration in hours and minutes in a 24-hour period or as proportion of a rather 
variable nyctohemeral (day-and-night) duration. Acknowledging that time spent outside 
the normative range limits differ from the amount of actual glucose concentrations 
outside the same limits. For example glucose curves F and B (Figure 1-9) have the same 
amount of time spent outside the normative range limits but clearly different glucose 
concentrations outside the same limits.  
On the other hand, AUC-above and AUC-below the normative range has an emphasis 
on the amount of glucose concentration outside the normative range without any regards 
to the time. AUC-above normative range is the area spanning above the upper threshold 
and bounded by the glucose curve from the top, whereas AUC-below normative range is 
the area bounded by the lower threshold from the top and glucose curve from the bottom 
and sides, AUC-above and AUC-below are marked on curve A- Figure 1-10. Both AUC-
above and AUC-below normative range are standardised by reporting them as a ratio of 
the total AUC. 
 
Figure 1-9 Simulated glucose curves F and B have the same duration of time spent 
above and below the normative range but show different glucose 
concentrations outside the range 
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Figure 1-10 Two similar simulated glucose curves; curve A and curve B, except for 
a higher last peak in curve B 
 
1.6.4 Mean amplitude of glycaemic excursions (MAGE) 
The mean amplitude of glycaemic excursions (MAGE) was first described in 1970 as a 
measure of intra-day glucose variability and stability. With the surge of CGM systems 
MAGE became widely used in research to describe variability in daily glucose 
concentrations’ (Marling et al., 2011; Inchiostro et al., 2013). The amplitude of glycaemic 
excursions (glucose peaks) was originally estimated manually by measuring the 
difference between consecutive nadirs and peaks (or peaks and nadirs) of glucose 
curves obtained from per hour analysis of venous blood glucose. The mean of all 
differences that exceeded 1 standard deviation were then calculated (Service et al., 
1970). The original manual calculation method is burdensome and as a result many 
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automated calculation algorithms and software applications have been created to 
measure MAGE from CGM data (Baghurst, 2011; Czerwoniuk et al., 2011; Marics et al., 
2015). However, automated MAGE calculations show poor agreement (Sechterberger et 
al., 2014). Moreover, the higher than 1SD criteria of including an excursion is arbitrary 
and may result in a MAGE with a misleading inference. An explanation is offered in the 
following example: glucose curves A and B are quite similar except for a higher last peak 
in curve B (Figure 1-10). Calculated manually, MAGE of curve A is (5+5.5+12.5)/3= 
7.667 mmol/l as only the first 3 amplitudes of glucose excursions were included and the 
last one excluded because it is less than 1SD, whereas MAGE of curve B is 
(5+5.5+12.5+3.5)/4= 6.625 mmol/l as all glucose excursion were higher than 1SD and all 
of them were included to calculate the mean. A lower MAGE of curve B is 
misrepresenting the amount of glucose level variability and instability curve B has in 
compare to curve A.  
Table 1-6 displays more summary metrics of curve A and curve B. Therefore, MAGE 
does not seem to be a good measure of intra-day glucose variability and stability for data 
derived from CGM systems. 
1.6.5 J-index 
The J-index combines information from the mean and the SD glucose. It is calculated by 
squaring the sum of the mean and the SD and then multiplying the result by different 
factors for glucose measured in mmol/l and mg/dl, Equation 1.1 and Equation 1.2 
respectively. In normally distributed data adding 1SD to the mean will encompass around 
34% of the data directly above the mean (Figure 1-5). However, what the value of J-
index encompasses is not clear, it does not have an established ‘normal’ range and it 
has a unit of mmol2/l2 (mg2/dl2) which is not very informative. 
𝐽 − 𝑖𝑛𝑑𝑒𝑥 =  0.324(𝑀𝑒𝑎𝑛 + 𝑆𝐷)2   glucose measured in mmol/l   Equation 1.1 
𝐽 − 𝑖𝑛𝑑𝑒𝑥 =  0.001(𝑀𝑒𝑎𝑛 + 𝑆𝐷)2   glucose measured in mg/dl Equation 1.2 
1.6.6 Mean of daily differences (MODD) 
MODD is another summary metric from before the era of CGM (Molnar et al., 1972). It 
was developed by the same group that developed MAGE to measure day to day (inter-
day) glucose variations. It is calculated by taking the mean and SD of the differences 
between pairs of glucose values measured at the same time points (hourly) on two 
consecutive days. MODD calculation was based on an experiment performed under 
strict conditions, with similar timing and quantity of meals and activities. However these 
conditions are not feasible under usual living conditions and thus MODD values will be 
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distorted by dyssynchrony in the meals and activities timing. An issue that can only be 
resolved by aligning the curves at peaks and troughs. Therefore MODD cannot be a 
reliable indicator of inter-day variability for data derived from CGM under normal living 
conditions.  
1.6.7 M-value 
The M value was first described to quantify the efficacy of glucose lowering treatment 
(Schlichtkrull et al., 1965). The estimation basically depends on calculating the ratio of 
each measured blood glucose to a reference or a preferred blood glucose level of 120 
mg/dl (6.7 mmol/l). These ratios are then logarithmically transformed, their absolute 
value (numeric value without negative/positive sign) cubed and the mean of all the 
values obtained. A correction factor (W/20) is then added to the resulting mean value, 
where W is the difference between the maximum and minimum blood glucose (BG) 
values over a 24-hours period (Equation 1.3). 
𝑀 − 𝑣𝑎𝑙𝑢𝑒 =
∑(|10 ∗ log
𝐵𝐺
120 |)
3
𝑁
+  𝑊/20 Equation 1.3  
The closer the M-value to zero is the closer the measured BG values to the reference 
level, however the M-value puts more weight on hypoglycaemic values as displayed in 
Table 1-5. It was designed in such a way as to provide a treatment safety margin and to 
avoid hypoglycaemia when comparing the efficacy of different insulin regimens. This is a 
feature which is totally justifiable when comparing glucose levels following glucose 
lowering medicines administration. However, it is not a desirable feature when assessing 
overall glycaemic control.  
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BG (mg/dl) M BG (mg/dl) M BG (mg/dl) M BG (mg/dl) M 
5 2629.3 85 3.4 165 2.6 245 29.8 
10 1256.8 90 2.0 170 3.5 250 32.4 
15 736.5 95 1.0 175 4.4 255 35.1 
20 471.2 100 0.5 180 5.5 260 37.9 
25 316.2 105 0.2 185 6.6 265 40.7 
30 218.2 110 0.1 190 7.9 270 43.7 
35 153.2 115 0.0 195 9.4 275 46.7 
40 108.6 120 0.0 200 10.9 280 49.8 
45 77.3 125 0.0 205 12.6 285 53.0 
50 55.0 130 0.0 210 14.4 290 56.3 
55 38.9 135 0.1 215 16.2 295 59.6 
60 27.3 140 0.3 220 18.2 300 63.0 
65 18.9 145 0.6 225 20.3 305 66.5 
70 12.8 150 0.9 230 22.6 310 70.0 
75 8.5 155 1.4 235 24.9 315 73.6 
80 5.5 160 2.0 240 27.3 316 74.4 
Table 1-5 Calculated M for a range of blood glucose values, 𝑴 = (|𝟏𝟎 ∗ 𝐥𝐨𝐠
𝑩𝑮
𝟏𝟐𝟎
|)𝟑 
 
1.6.8 Continuous Overall Net Glycaemic Action (CONGA) 
CONGA was developed specifically to derive variability information from CGM data. It 
represents the standard deviation of the differences between a glucose concentration 
value at one time point (k) and a glucose concentration value at the next time point (k + 
n), for all the glucose concentration data points within a 24-hour period, n could range 
between 1 and 8 hours. CONGA1 for instance is the SD of all the 1-hour apart 
differences of all glucose concentrations values measured over a 24-hour period 
(McDonnell et al., 2005). A closer look at CONGA1 reveals that it represents the SD of 
the hourly rate of change (speed) of the glucose level over a 24-hour period. Assuming 
that the rate-of-change is normally distributed and the up-hill rate-of-change (positive 
speed values) will cancel the down-hill rate-of-change (negative speed values) then the 
mean rate-of-change will be zero and ±1 CONGA will represent the dispersion of rate-of-
change values around the mean and spanning the middle 64% of the rate-of-change 
values (Figure 1-5) , however the frequency distribution of the rate of change does not 
always have a normal distribution (Service, 2013).  
Figure 1-11 shows that glucose curve C has steeper excursions, i.e. faster rate-of-
change, than curve A. Glucose curve C has a higher CONGA1 than glucose curve A 
(Table 1-6). Thus glucose curve C has more variability according to the CONGA result. It 
has also a higher SD and M-value than glucose curve A, however, both glucose curves 
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have the same MAGE value. Further, CONGA has the same trend as SD for all glucose 
curves presented in Table 1-6.   
CONGA could be a good measure of glucose variability. It provides similar information to 
that which the SD of glucose provides. However, it would be more useful if it assessed 
the amplitude of rate-of-change and the dynamics of glucose over the time period 
particularly postprandial (after meals) rather than just assessing the dispersion of the 
rate-of-change of glucose around its mean. 
 
 
Figure 1-11 Two similar simulated glucose curves; curve A and curve C, except for 
steeper peaks in curve C 
 
1.6.9 Comments on summary metrics of CGM data 
Summarising CGM data into a signal value provides an overall crude estimate of a 
wealthy data source. Each summary metric evaluates one aspect only, either amplitude 
or variability, of the whole picture that CGM data provides. Furthermore, summary 
metrics do not address the extensive temporal information available from CGM namely 
the diurnal glucose pattern and rate-of-change of glucose.   
Moreover, the lack of Gaussian (normal) distribution of CGM data affects the validity of 
some of the summary metrics. In addition, CGM glucose values are not independent of 
each other and they constitute a time-series function. Time-series is a collection of 
observations of a quantity, obtained at successive time points, often with equal intervals 
between them (Chatfield, 2004). Many of the summary metrics like mean and SD are 
based on the assumption of independent, identically distributed random variables (IID?) 
which is not the case in correlated glucose data points from CGM time-series function. 
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Each time point value is highly correlated to its preceding and subsequent values, mainly 
within a 60 minute spectrum in CGM data (Rodbard, 2009b). The subsequent 
observation can be partially predicted by the current and preceding observations. Using 
summary statistics to describe a time series can be possible only if supplemented with a 
specific ‘autocorrelation function’ and a consideration of the time order. However, this 
specification is only applicable to a stationary time-series with no major trends or 
cyclic/periodic fluctuations. Calculating usual summary statistics for non-stationary time 
series as in the case of CGM data “can be seriously misleading” (Chatfield, 2004).  
 
Table 1-6 Summary metrics of six simulated glucose curves, curve A, curve B, 
curve C and curve G. 
Summery metric Curve 
A 
Curve 
B 
Curve 
C 
Curve 
D 
Curve 
E 
Curve 
F 
Mean (mmol/l) 5.97 6.01 5.51 9.97 6.01 5.62 
Median (mmol/l) 5.00 5.00 4.00 9.00 5.00 5.00 
SD (mmol/l) 3.17 3.18 3.34 3.17 2.48 2.11 
CV 0.53 0.53 0.61 0.32 0.41 0.38 
AUC (mmol/l/ minute) 5.97 6.01 5.51 9.97 6.01 5.62 
25th percentile (mmol/l) 4.00 4.00 3.50 8.00 4.00 4.00 
75th percentile (mmol/l) 7.00 7.13 7.00 11.00 7.06 7.13 
IQR (mmol/l) 3.00 3.13 3.50 3.00 3.06 3.13 
MAGE (mmol/l) 7.67 6.63 7.67 7.67 5.00 5.00 
J index (mmol2/l2) 27.05 27.36 25.33 55.92 23.37 19.36 
Mean+1SD (mmol/l) 9.14 9.19 8.84 13.14 8.49 7.73 
Mean-1SD (mmol/l) 2.80 2.83 2.17 6.80 3.52 3.51 
Mean+2SD (mmol/l) 12.31 12.37 12.18 16.31 10.98 9.84 
Mean-2SD (mmol/l) -0.37 -0.35 -1.17 3.63 1.04 1.40 
M-value 18.74 18.74 27.77 12.55 7.80 10.64 
CONGA1 (mmol/l/hour) 3.18 3.23 3.49 3.18 2.50 2.20 
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1.7 Functional data analysis 
FDA is an advanced statistical method that can address both the correlation between 
adjacent glucose values across the CGM data record, as well as the time dependency 
the glucose values exhibit (Ramsay and Silverman, 2005). Equally, it has the ability to 
extract some desirable information from the CGM data, including: the glucose amplitude, 
variability, diurnal pattern and rate-of-change (Law et al., 2015). Other statistical 
methods such as missed-effect growth and latent models and other traditional time-
series models were adapted to handle complex-structure data similar to those of CGM 
data. However FDA is considered superior to them as it can manage heterogeneous 
data and can estimate relationships effect sizes and statistical significance over time 
(Dass and Shropshire, 2012). FDA methods with application to CGM data are discussed 
in more details in chapter 2. 
 
1.8 Hypothesis and Aims of this thesis 
In summary, numerous observational and some small interventional studies suggest that 
sleep duration is an important factor in the pathogenesis of insulin resistance and T2DM. 
In people with diabetes sleep duration and sleep quality is associated with poorer 
glycose control, although the methodology used to assess this has considerable 
limitations.  
GDM is an extremely common type of diabetes affecting women of childbearing age and 
has adverse effects in pregnancy and long lasting detrimental effects on the children. 
Achieving tight glucose control is critical in the management of these pregnancies, to 
reduce complications. The role of sleep in achieving glucose control in pregnant women 
with GDM has not been explored.  
There are well recognised limitations in the assessment of glucose control by 
contemporary methods, minimising the accuracy of the information obtained. Continuous 
glucose monitoring and the application of functional data analysis, offers the opportunity 
to address this.  
My underlying hypothesis is: 
Sleep disturbances, such as short or long sleep duration, and lower sleep quality 
increase the amplitude and variability of blood glucose in pregnant women with 
gestational diabetes (GDM). 
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The two aims of my thesis are therefore to: 
 Explore the association between sleep and glucose control in pregnant women 
with gestational diabetes. 
 Develop the application of functional data analysis methods to continuous 
glucose monitoring data to enable a more detailed: 1) evaluation of glucose 
control and diurnal variation; and 2) analysis of the sleep and glucose 
relationship. 
1.9 Objectives  
In order to address these two aims, my thesis has the following key objectives:   
1- Evaluate sleep in pregnant women with gestational diabetes subjectively using 
the PSQI questionnaire and objectively using actigraphy gauging the agreement 
between the two tools derived sleep characteristics. 
2- Assess glycaemic control in pregnant women with gestational diabetes using 
CGM. 
3- Apply FDA methods to daily glucose curves derived from CGM data. 
4- Examine the association of subjective and objective sleep characteristics with 
glucose control using: a) the CGM derived summary indices and b) FDA of daily 
glucose curves. 
5- Explore the causal direction of the relationship between sleep and glucose by 
also examining the association between glucose levels immediately prior to 
sleep, with the characteristics of that subsequent night’s sleep. 
 
 
  
42 
 
 
  
43 
 
Chapter 2 Functional data analysis (FDA) and its application to 
CGM data 
 
The present chapter outlines the functional data definition and FDA methods, the steps 
followed to change CGM data into functional data, and various techniques used to 
extract descriptive and inferential information from functional data. CGM data collected 
as a part of this current study was used to demonstrate some of these FDA techniques. 
However, further specific details on the FDA techniques applied in this study are 
presented in the Methods chapter, Section 3.9.5, and the results are presented in the 
Results chapter, Sections 4.3.5.2, 4.6, 4.7 and 4.8.  
2.1 Functional data and FDA 
FDA is an analytic approach that studies functional data. Functional data are 
observations generated from measuring/recording consecutive discrete values (data-
points) of an underlying smooth process (curve) over a continuous domain such as time, 
often with multiple curves generated from multiple individuals/records (Ramsay and 
Silverman, 2005).  
Functional data are commonly encountered and are becoming more abundant, 
especially with the advance in modern data recording and storing technology. The data 
generated from these technically advanced devices could be of high resolution with 
frequent recording and low noise or of low resolution with infrequent recording and a 
noisy signal. Data such as; CGM data, actigraphy data, electrocardiograph (ECG) data, 
children growth monitoring data, and weather stations’ temperature level data, are 
examples of functional data.  
Data-points of functional data are usually measured with some measurement errors 
(noise) and every data-point is correlated to the data-points surrounding it. These data-
points can be represented by a single mathematical function delineating their underlying 
smooth processes curve and minimising the noise. For example, Figure 2-1 illustrates 
simulated consecutive discrete data-points of a sigmoid mathematical function with some 
added random error. FDA aims to represent such data-points with their functional 
form/object, i.e. the underlying mathematical function. A further descriptive and 
inferential statistical analysis is then performed on these functional objects as a unit of 
observation for each participants rather than the multiple correlated discrete data-points. 
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N.B. the coming paragraphs contain some mathematical notations to enrich the content, 
however skipping them will not affect the context of the text. 
The first step in FDA is a process called smoothing, where these discrete values are 
fitted with a smooth functional object (curve) defining their underlining signal and 
removing the surrounding noise. The function can be expressed as: 
𝑌𝑖𝑗 =  𝑋𝑖(𝑡𝑗) + 𝑒𝑖𝑗 
Equation 2-1 
Where 𝑌𝑖𝑗 are observed discrete values for each participant i at sequence j of time t, and 
𝑋𝑖(𝑡𝑗) are the smoothed values (fitted values on the curve) for each participant i at 
sequence j of time t, and  𝑒𝑖𝑗  are the noise (error) observed for each participant i at 
sequence j of time t.  
With smoothing the aim is to find the mathematical function of time 𝑋𝑖(𝑡) that is best to fit 
the observed values and minimise the sum square of error (the vertical distance between 
observed values and fitted curve). This is usually done by the use of basis expansion 
(details in Section 2.1.1). 
The second step in FDA, is a technique called registration, where all the prominent 
curvatures (peaks and nadirs) of the fitted smooth curves are aligned (rearranged) to 
occur around the same time frame. Registration is explained in more detail in Section 
2.3.      
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Figure 2-1 Discrete values with some random noise (black hollow circles) of a 
smooth process represented by a sigmoid mathematical function (grey 
curve) 
2.1.1 Defining functions by basis expansion 
Basis expansion is a linear combination of known basis functions (in a similar way to the 
linear regression model) and is commonly exploited to find the best fitting curve.  Hence, 
for a sufficiently large number (K) of basis functions (ɸ) (pronounced phi) the estimated 
curve will have the following mathematical notation:  
𝑋𝑖(𝑡) = ∑ 𝑐𝑖𝑘  ɸ𝑘(t)    
𝐾
𝑘=1
 
Equation 2-2 
Basis functions can be considered as building blocks that are weighted using coefficients 
of expansion 𝑐𝑖𝑘 and summed up to construct a smooth curve. 𝐶𝑖𝑘 is data driven using 
ordinary least square (OLS) fitting methods while the type of basis function (ɸ) is 
determined by the researcher according to the behaviour of the data. Basis function 
should have features that match those known to belong to the function being estimated. 
This makes it easier to achieve a satisfactory approximation using a comparatively small 
number of K basis functions. There are many known and established basis functions, 
some of them will be discussed next.  
2.1.1.1 Polynomial basis functions  
The polynomial basis function is one of the oldest, though still widely used, basis. It is a 
collection of monomials (powers of consecutive positive integers) with the following 
functional form 
𝑋𝑖(𝑡) = 𝑃𝑖(𝑡) = 𝑐𝑖0 + 𝑐𝑖1𝑡
1 + 𝑐𝑖2 𝑡
2+ . . . . . . +𝑐𝑖𝑛 𝑡
𝑛 
Equation 2-3 
Where the largest exponent n is the degree of the polynomial function P (t), time t is the 
independent variable and c  is the regression coefficient. A first degree polynomial is just 
a linear regression equation, whilst a second degree polynomial is a parabola (U shaped 
curve) (Figure 2-2). Polynomials are suitable for simple curves. Complex curves with 
many local features need to be fitted with higher degree polynomials but this usually 
leads to overfitting (mixing the underlying signal with the surrounding noise). This is 
mainly due to the high correlation between monomials of high-degree polynomials, 
making polynomials a global basis functions. Local basis functions are more appropriate 
for complex curves. Moreover, polynomials usually fit the centre of the data better than 
the boundaries. 
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Figure 2-2 A parabola , adapted from (Barron and Kastberg)  
 
 
2.1.1.2 Fourier basis  
The Fourier basis is another old and extensively used basis function. It is a simple basis 
comprised of a linear combination of a series of sine and cosine waves (Figure 2-3) 
Fourier basis is best used to delineate periodic signals such as ECG signals and weather 
trend curves with repetition of the signals over a certain period T. It has the following 
mathematical notation: 
𝑋𝑖(𝑡) = 𝑐𝑖0 + 𝑐𝑖1 sin(𝑤𝑡) + 𝑐𝑖2 𝑐𝑜𝑠(𝑤𝑡) + 𝑐𝑖3 sin(2𝑤𝑡)
+ 𝑐𝑖4 𝑐𝑜𝑠(2𝑤𝑡)+ . . . . . . +𝑐𝑖(𝑘−1) sin((𝑘/2)𝑤𝑡) + 𝑐𝑖(𝑘) 𝑐𝑜𝑠((𝑘/2)𝑤𝑡) 
Equation 2-4 
Where 𝑘  is the number of bases excluding the constant term 𝑐𝑖0 , and the parameter 𝑤 =
2𝜋/𝑇. 
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Figure 2-3 Plot of sine wave (blue carve) and cosine wave (red curve) 
 
2.1.1.3 B-spline basis 
The B-spline basis is basically piecewise (subintervals over the time axis) polynomials 
that are linearly summed together to fit a single smooth curve over the whole interval (the 
time period). The places where these subinterval polynomial pieces connect together are 
called break points or knots. By forcing adjacent polynomial pieces to be equal (having 
the same values) at the knots, the resulting curves of spline functions are continuous (i.e. 
connected without gaps at knots) (Figure 2-4).  
There are different types of spline bases (De Boor, 1978), however, only B-spline is 
presented in this thesis. B-spline (short for basis spline) is the most commonly used 
basis within the FDA framework to fit complex and non-periodic signals. De Boor (1972) 
and Paul and Marx (1996) can be consulted for detailed statistical properties of B-spline. 
B-splines are characterised by their order m which is equal to the spline’s polynomial 
degree n+1, number and placement of knots N, and number of bases k. Figure 2-5 is a 
plot of 12 cubic B-spline bases (a piecewise polynomial of degree 3 and order 4) with ten 
knots (eight internal and two external/boundary knots).  The plot shows that the 
polynomial curves overlap and each subinterval (segment between two knots) is covered 
by a number of polynomials equals to the order of the B-spline m, i.e. four in the case of 
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cubic B-spline. Moreover, in a B-spline of order m, number of bases k  is related to the 
number of internal knots N, as follows: k= N+m, i.e. 12 cubic B-spline bases would have 
eight internal knots. Thus, after determining the order of B-spline, either estimating the 
number of bases needed to fit the curve or the minimum number of internal knots 
needed would be sufficient to calculate the other. 
An attractive feature of B-spline is the ease of computing the function derivatives. The 
first derivative is the velocity - the rate of change of outcome value over time, while the 
second derivative is acceleration - the rate of change in velocity over time. Derivatives 
are usually of interest as they can be used to penalise the function roughness (tune 
down the fluctuation within the curve). More detail about penalisation is found in Section 
2.2.  
 
 
Figure 2-4 Schematic presentation of two piecewise splines (the blue and the 
orange curves) connected with one middle knot and two peripheral knots, 
smoothing seven observed discrete data-points (black dots) 
 
Furthermore, derivatives can themselves be explored and examined as data when 
velocity and acceleration of the measured values are of importance. B-spline’s 
derivatives are continuous (connected at knots without gaps) up to m-2 (i.e. up to the 
second derivative of a B-spline of order 4 will be continuous).  
V
al
u
es
Time interval knots
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Figure 2-5 Plot of 12 cubic B-spline bases defined over 24 hours interval, with ten 
equidistance break points and knots (red vertical dashed lines)  
 
Nevertheless, B-splines tend to produce a boundary effect, where the fit of the curve is 
unstable at the boundary of the interval. Furthermore, choosing the appropriate number 
of basis functions can be difficult, as a large number of B-spline bases (collection of 
basis) tend to over-fit the curve to the data-points, while a very low number of bases can 
miss salient features of the curve. However, different methods of determining the number 
of bases have evolved and the introduction of the roughness penalties has dealt with the 
overfitting.    
2.2 Basis functions for CGM data 
The cubic B-spline basis was chosen to fit a mathematical function (presented as smooth 
curve) to daily CGM data. Cubic B-splines, as previously mentioned, are the most used 
bases for non-periodic processes with local features (Ramsay and Silverman, 2005). 
They are very smooth at their knots and continuous at their first and second derivatives. 
The cubic B-spline basis was used since higher order polynomials B-splines are rarely 
needed (Cardot et al., 2003; Prchal and Sarda, 2007). The first step in fitting the cubic B-
spline bases to the CGM data is to determine the number and placement of the knots 
and the number of bases.  
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2.2.1 Number and placement of knots and number of cubic B-spline 
bases 
Knots were placed at the boundaries of the 24-hour time interval, called external knots, 
and at equidistant break points of sub-intervals, called internal knots. The number and 
placement of the internal knots were chosen to best mould the shape of the glucose 
curve. With cubic B-spline, this can be assisted by some rules of thumb: keeping at least 
four to five data-points in a sub-interval and having no more than one inflexion 
(curvature) per sub-interval (Wold, 1974).  Moreover, the more parsimonious basis 
function, i.e. with the smaller number of bases, sufficient enough to represent the 
features of the fitted curve, is preferred. Using the minimally required number of bases 
enhances the degree of freedoms available to test subsequent hypotheses and to 
compute accurate confidence intervals. It also requires less computation and computer 
memory size and is less likely to mix the noise with the underlying process signal 
(Ruppert, 2002; Claeskens et al., 2009).  
In the extreme case of placing a knot at each point of observation, the estimated curve 
will merely interpolate (connect) observed data points together and thus the bias of 
estimate will be zero, however, the variance of estimate will be very high as noise 
would be fitted as well. Where, the bias of estimate equals the mean of the difference 
between observed data points and the mean of estimated data points, and the variance 
of estimate equals the mean of the sum of square differences between the estimated 
points and the mean of estimated points. This conflicts with the reason for why the data 
points were fitted using basis expansion, i.e. estimating the underlying smooth curve and 
minimising noise. Thus, some bias should be tolerated to find the best fitting signal, and 
choosing the number of bases should be based on a trade-off between bias and 
variance.   
This trade-off should minimise the mean sum of squared errors (SSE) and can be 
estimated using generalised cross validation (GCV) Criterion (Craven and Wahba, 1978; 
Ruppert, 2002). Here, SSE is the sum of squared differences between the observed data 
points and the estimated data points (data point on the fitted curve) and GCV is 
calculated for each curve using Equation 2-5. Multiple curves will result in a vector (list) 
of GCV values, one per curve. The overall mean GCV is used as the criterion for the 
trade-off for all the curves.  
𝐺𝐶𝑉 =  
𝑛 ∗ 𝑆𝑆𝐸
(𝑛 − 𝑑𝑓)2
 
Equation 2-5 
Where n is the number of observed data points and df  is the degrees of freedom of the 
fitted curve. The number of bases that substantially decreases the mean GCV criterion is 
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chosen. After this minimal number of knots has been reached, a further increase in the 
number of knots has little effect on the fit (Ruppert, 2002).  
2.2.2 Knots placement and number of bases for CGM data 
CGM data have 288 data points per 24-hour day measured in 5-minute epochs. That is 
12 data-points per hour, six data-points per 30 minutes and only three data-points per 15 
minutes. Knots should be placed at more than 15 minutes break points as the 15 
minutes subinterval has low number of data points, as per the ‘rule of thumb’ explained 
earlier.  
Moreover, to determine the best number of bases, GCV criterion was calculated for a 
wide range of numbers of bases. Figure 2-6 shows a plot of the GCV criterion values 
across a wide range number of bases (R software codes for generating the GCV 
criterion and the plot were adapted from Hooker (2008) and are available in R code 
syntax box 1. The plot demonstrates that there is no substantial decrease in the GCV 
criterion value (there is less than a 0.05 drop in GCV value per five figures increase in 
the number of bases) for the number of bases higher than 25 bases, and there is only a 
trivial decrease in the GCV criterion values for the number of bases higher than 50 
bases. Thus, using the GCV criterion to place a knot at an equidistance sub-interval 
across the 24-hour day indicated the use of 27 to 51 bases. Fitting the CGM data using 
51 bases, 47 internal knots would be placed at thirty-minute equidistant break points, 
while fitting the CGM data using 27 bases, 23 internal knots would be placed at hourly 
equidistant break points.  
To have more insight into the smoothed curve produced by applying these numbers of 
bases and knots, CGM data were fitted using 51, 27, 15 and seven B-spline basis 
functions. Figure 2-7 shows five daily glucose curves fitted using these numbers of 
bases, as follows: plot (A) using 51 cubic B-spline bases with knots every 30 minutes 
displayed prominent fluctuations and diurnal pattern as well as minor oscillations; plot (B) 
using 27 cubic B-spline bases with hourly knots displayed prominent fluctuations and 
diurnal pattern but flattened-out minor oscillations; plot (C) using 15 cubic B-spline bases 
with knots every two hours flattened both prominent and minor features; while plot (D) 
using only 7 cubic B-spline bases with knots every four hours severely flattened out the 
curves.  
Therefore, using all the criteria discussed earlier a 27 cubic B-spline bases with hourly 
knots was chosen to fit the daily glucose curves (from midnight to the following midnight). 
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R code syntax box 1 GCV criterion 
# Import CGM data 
glucose  <- Alldata [c("idseq", "sensorGlucose" , "glu_time" )] 
# Reshape wide 
glucose  <- reshape(glucose, timevar="personDateUI", idvar="timeHourMinuteIn5", 
direction="wide") 
# Glucose matrix 
glucose  <- glucose[c(2:length(glucose))] 
glucose  <- data.matrix(glucose) 
# Define time argument 
xx <- seq(1,288,1)-0.5 
# Create empty matrix to store GCV values for each daily glucose curve and number of 
bases 
bgcvs <- matrix(0,652,285) 
# Create empty list to store mean GCV values for each number of bases 
mean.gcv <- rep(0,285) 
# select penalty 
curv.Lfd = int2Lfd(2) 
# Loop to calculate mean GCV criterion 
for(i in 5:285){ 
# create temporary B-spline basis object 
  tempbasisi = create.bspline.basis(c(0,288),nbasis=i) 
  # Smooth 
  tempglucSmoothi = smooth.basisPar(argvals=xx, y=glucose,fdobj=tempbasisi,curv.Lfd, 
lambda = 1) 
# extract GCV 
  bgcvsi =  tempglucSmoothi$gcv 
  mean.gcv[i] = mean(tempglucSmoothi$gcv) 
} 
# Plot the mean GCV criterions against number of bases  
plot(nbasis[5:100],mean.gcv[5:100],type='b', xlab = "Number of basis", ylab = "Mean GCV", 
xaxp= c(0,100,20),col="blue") 
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Figure 2-6 Generalised cross validation (GCV) criterion values across a wide range 
of cubic B-spline basis functions numbers . Fine vertical and horizontal grid 
lines are only guide lines  
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Figure 2-7 Five daily glucose curves smoothed using (A) 51 cubic B-spline, (B) 27 
cubic B-spline, (C) 15 cubic B-spline and (D) 7 cubic B-spline 
 
  
(A) 51 cubic B-spline, knots 
every 30 minutes 
 
(B) 27 cubic B-spline, knots 
every one hour 
(C) 15 cubic B-spline, knots 
every two hours 
(D) 7 cubic B-spline, knots 
every four hours 
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2.2.3 Fitting the smooth curves to CGM data by basis expansion 
Fitting the smooth curves to the daily CGM data is done by using the penalised OLS 
method to linearly combine the cubic B-spline bases. The best fitting curve is the curve 
that minimised the penalised SSE, whereas the errors are the vertical distance between 
the fitted curve and the observed CGM data points. The penalty is based on the 
roughness of the curve (number and depth of the curvatures) and is estimated using the 
integral of the squared second derivative (acceleration) (Paul and Marx, 1996).  
Furthermore, a ‘smoother parameter’ lambda (λ) that measures the rate of exchange 
between the fit of data, as measured by SSE, and the variability of the data, as 
measured by the roughness penalty, is also implemented to estimate the curve function 
(Ramsay et al., 2009). λ is a positive numerical figure (positive number) and a larger λ 
value will incur more smoothing and less variability to the curve.  It is estimated using the 
GCV criterion in a similar method to estimating the number of bases. λ=4 was estimated 
for CGM data used in this thesis.  
Figure 2-8 shows the smoothed daily glucose curves of all current study participants’ 
available daily CGM data. Each smoothed curve is used thereafter as the unit of 
observation in a further functional descriptive and inferential analysis, including: 
observing the diurnal pattern; calculating the mean curve, the median curve, the 
standard deviation (SD) curve, interquartile range (IQR) curves and correlation matrix; 
and running a functional t-test and functional regression analysis.  
However, before proceeding with all these statistics, a further essential step is needed. 
Revisiting the smooth curves plot in Figure 2-8, it looks more like ‘tangled spaghetti’ with 
no clear pattern because the prominent features of the curves (i.e. the peaks and the 
nadirs) do not occur at the same time every day for all the participants, i.e. the curves 
are not aligned. The timing of the peaks and the nadirs of the glucose curves varies 
between individuals, as well as between days for the same individual. This depends on: 
the individuals’ glucose circadian rhythms, the timing of food intake, and the timing of 
physical activity. This variation in the timing of the occurrence of the peaks and nadirs is 
referred to as ‘phase variability’, while the variation in the height of the peaks and nadirs 
is referred to as ‘amplitude variability’. The removal/separation of phase variability from 
amplitude variability by aligning (rearranging) the curves, a procedure referred to as 
‘registration’ in FDA terminology, is paramount. Failing to register the curves leads to a 
statistically ambiguous results (Marron et al., 2015). This is such that the pointwise mean 
curve in Figure 2-8, which is clearly a flattened-out curve, does not resemble the 
expected pattern of the daily glucose curve. This is more obvious in Figure 2-9 where 
only ten daily curves are displayed with their pointwise mean. Mean glucose curve’s 
peaks are clearly wider and flatter than the plotted glucose curves’ peaks. This 
56 
 
misrepresentation of data summary of the unregistered curves applies to other FDA 
statistical tests as well, and distorts any interpretation extracted from them (Wang et al., 
2016a). The registration methods presented in section 2.3. 
 
 
Figure 2-8 Smoothed daily glucose curves, using 27 cubic B-splines, of all 
available participant data with a superimposed overall pointwise mean curve 
(bold black curve) 
 
 
Figure 2-9 Ten daily glucose curves smoothed using 27 cubic B-splines and their 
pointwise mean curve (bold black curve)  
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2.3 Registration 
Registration is done by rearranging the glucose curves’ main features, such as peaks 
and nadirs, to change them from occurring at variable physical/clock times to occurring 
at about the same system/argument time using different time-warping statistical-function 
methods (Ramsay and Li, 1998). These methods depend on either using landmarks or 
using a continuous criterion. 
2.3.1 Registration using landmarks  
The landmark registration is the traditional method for time-warping, where the timing of 
specific features in the curves are aligned to a predefined landmarks or average 
locations in the time argument (Zhong, 2008; Ramsay and Silverman, 2005). Landmarks 
have to be clearly identifiable and they usually require manual care in defining and 
finding them. Moreover, landmarks should be present in all the curves. In glucose 
curves, these features are usually the peaks associated with a meal intake schedule, i.e. 
breakfast, lunchtime and dinnertime meals. However, these meals are not universal in all 
the curves, as some individuals might either miss certain meals or have more frequent 
meals. Moreover, landmark registration is only aligning features at the predefined 
landmarks and overlooks aligning other curves’ features (Marron et al., 2015). As a 
result, landmark registration was considered as not suitable for registering glucose 
curves. 
2.3.2 Registration using continuous criterions 
The continuous criterion registration method uses the entire curve rather than specified 
features on the curve and can provide a more widespread curve alignment than the 
landmark registration method (Zhong, 2008; Ramsay and Silverman, 2005). Continuous 
registration aligns curves to a reference/target curve (usually the mean of unregistered 
curves) by transforming or warping the time argument domain of each curve using 
special methods. The preferred continuous registration method is to use the minimum 
eigenvalue of cross-product matrix criterion defined by principal components analysis. 
The minimum eigenvalue method usually works well if the target curve is chosen 
carefully. Other methods, such as the least squares fitting criterion, are also available, 
however, it is fundamentally intended to evaluate amplitude rather than phase variability. 
The least squares criterion uses the time-warping function to minimise not only phase 
variation, but also amplitude variation, causing a distortion to the shape of the peaks. In 
contrast to the landmark registration method, the continuous criterions registration 
method is relatively easier to perform and is fully automated using special commands in 
the R software ‘fda’ statistical package. 
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2.3.3 Registering smoothed daily glucose curves 
The continuous criterions registration method was used to register the smoothed daily 
glucose curves with the mean curve of the unregistered curves as the target curve. 
Figure 2-10 shows the same ten daily glucose curves in Figure 2-9 after registration, with 
both the registered and the unregistered mean curves.  It is apparent that the registered 
mean curve has more prominent features and more resemblance to the daily curves. 
However, although registration brought the curves’ prominent features nearer to each 
other, it did not align them perfectly and further alignments would be favoured. 
Registration can be improved by iterations, i.e. repeating the registration process several 
times. At each iteration, the registered curves are re-registered using the mean curve of 
the previous iteration registered curves. The number of iterations needed depends on 
the number of curves and the phase variations between them. Figure 2-11 displays 100 
glucose daily curves: unregistered curves in the upper panel, registered curves after five 
iterations in the middle panel, and the unregistered mean curve together with the 
improved registered mean curves in the lower panel.  
 
Figure 2-10 Ten registered daily glucose curves smoothed using 27 cubic B-
splines with registered mean curve (bold red curve) and unregistered mean 
curve (bold black curve) superimposed  
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Figure 2-11 Upper panel: unregistered daily glucose curve, middle panel: fifth 
iteration registered glucose curve, lower panel: mean unregistered curve 
(black line) and fifth iteration registered mean curves (blue line) 
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2.4 Functional descriptive statistics 
Describing the functions recognises the shape and heterogeneity within the curves, the 
average behaviour and the variation between curves. This entails calculating; mean, SD, 
median, IQR curves and covariance and correlation structure. Functional mean and SD 
curves are the pointwise cross-sectional mean and SD, i.e. they are calculated from all 
the data-points across all fitted curves at each time point. On the other hand, the 
functional median and IQR curves, which are less affected by possible outlier curves, are 
calculated in case the data-points across all the fitted curves are not normally distributed. 
Median and IQR curves are calculated using the concept of depth (López-Pintado and 
Romo, 2009), where the curves are ordered from the most centred curve outward 
prompted by the band depth for functional data, then median (the most cantered curve) 
and the 25th and the 75th percentiles curves are identified. Further, a functional box plot 
was also computed using the same band depth method (Sun and Genton, 2011). All 
descriptive statistics are interpreted in analogy to the standard way in non-functional 
data. 
Moreover, the rate of change of glucose is estimated by calculating the smoothed 
glucose curve’s first derivative, i.e. the curve’s velocity. As the rate of change in glucose 
is not constant, rather it varies across the time of the day, the resulted glucose curve’s 
velocity also varies across time. Thus, a glucose velocity curve (and not just a single 
numeric figure) is estimated for each glucose curve. The estimated glucose velocity 
curve is utilised to understand the dynamic characteristics of glucose curves. They also 
have a mathematical functional form, as do original glucose curves, and thus they can be 
further incorporated in interstitial analysis, that is they can be compared between groups 
and the association between them and other variables can be evaluated.  
2.5 Functional inferential statistics 
2.5.1 Functional t-test 
The functional version of the t-test is utilised to test if the difference in daily glucose 
curves amplitude between two groups is statistically significant, e.g. daily glucose curves 
of a group of participants with short sleep duration compared to daily glucose curves of a 
group of participants with average sleep duration. Ramsay et al. suggested a 
permuatation method for functional t-test (Ramsay et al., 2009; Ramsay and Silverman, 
2005). The method entails calculating a point-wise t-statistics score, i.e. using the 
standard t-statistic formula to calculate the t-statistics value at each time-point of all data-
points across all glucose curves in the two groups, and then plotting it in a graph (red 
solid line in Figure 2-12). A permutation test is then performed to estimate the point-wise 
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and the maximum 0.05 critical values for the maximum of the t-statistic (dotted and 
dashed blue lines in Figure 2-12, respectively). A positive test at certain time-points is 
indicated when the t-statistics line passes over the maximum critical value line. 
 
 
Figure 2-12 Functional permutation t-test graph  
2.5.2 Functional regression 
The standard regression analysis model allows the evaluation of the relationship 
between continuous/categorical scaler exposure and outcome variables, where scalar 
denotes a quantity with magnitude but no direction. These variables, including age, 
weight, glucose concentrations, sex or a specific diagnosis status, are assessed once at 
one point in time. On the other hand, the functional regression analysis model allows for 
the evaluation of the relationship between exposure and outcome variables in the 
functional space (Ferraty et al., 2012; Dass and Shropshire, 2012; Reiss et al., 2010; 
Ramsay and Silverman, 2005). Functional regression can be one of the following: 1) 
scaler-on-function regression modelling scalar outcome and functional exposure; 2) 
function-on-scalar regression modelling functional outcome and scalar exposure; and 3) 
function-on-function regression modelling functional outcome and functional exposure. 
The functional regression coefficient estimate is a function (smooth curve) for scaler-on-
function regression and for function-on-scalar regression, and a three-dimensional 
functional space for function-on-function regression (Figure 2-13). That said, function-on-
function regression modelling methodology is still under development (Meyer et al., 
2015; Ferraty et al., 2012). Furthermore, a 95% confidence band can also be estimated 
for the functional coefficient (R code syntax box 2). If the confidence band does not cross 
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the zero line at certain time-points, then the regression coefficients at these time-points 
are considered statistically significant (Figure 2-14). 
 
Figure 2-13 Schematic illustration of a three-dimensional functional space 
coefficients estimate of a function-on-function regression model(image 
reused from Wikimedia Commons)  
 
 
Figure 2-14 Function-on-scalar regression model’s coefficient curve (black line) 
with 95% confidence band (grey-shaded area), showing a time period with 
statistically significant coefficient (surrounded by a red frame) 
R code syntax box 2 Function-on-scalar regression model and 95% confidence 
band syntax 
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The function-on-scalar regression modelling strategy was used in this study to evaluate 
the association between sleep and glycaemic control. In the generated models, the 
outcome variables were either the daily glucose curves or the daily glucose velocity 
curves, and the scaler exposures were one sleep characteristic at a time together with 
several potential confounders. Scalar-on-function regression models were applied to 
evaluate the association between glucose curves and the following night’s sleep 
variables. As mentioned in the previous paragraph, the resulting functional regression 
coefficients are in a functional form (smooth curves). Each value on the coefficient curve 
at each time point across the argument time (the 24-hour day) is interpreted similarly to 
the standard regression coefficient. Therefore, for a model studying the association 
between sleep duration (exposure) and daily glucose curves (outcome), if the value on 
the regression coefficient curve is 0.5 at 2.00pm then the interpretation will be that each 
hourly increase in sleep duration is associated with a 0.5 mmol/l increase in glucose 
# Run functional regression model 
psqi.model <-  fRegress(Reg.glucose ~ psqitot  + age + bmi + ethnicity + parity + 
treatment + center+ gest_wk , Data_file) 
# Calculate Standard Errors (SE) 
# 1) Calculate error matrix 
# xx= time argument 
errmat.psqi.model <- eval.fd(xx,Reg.glucose) -eval.fd(xx,psqi.model$yhatfdobj$fd) 
# 2) Calculate of transposed error matrix 
SigmaE.psqiSUNe.model  <- var(t(errmat.psqiSUNe.model))  
# 3) Calculate SE  
stderr.psqiSUNe.model <- fRegress.stderr (psqi.model,glucose.smooth$y2cMap, 
SigmaE.psqiSUNe.model) 
# Plot regression coefficient and 95% confidence band 
plotbetaChanged (betaestlist= psqi.model$betaestlist$psqitot$fd ,betastderrlist= 
stderr.psqiSUNe.model$betastderrlist[[2]]) 
# Plot regression intercept and 95% confidence band 
plotbetaChangedintercept (betaestlist= psqi.model$betaestlist$const ,betastderrlist= 
stderr.psqiSUNe.model$betastderrlist[[1]]) 
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concentration at 2.00pm. Thus, the coefficient is time dependent. Moreover, to study a 
possible U-shaped relation between the scalar exposure and the functional outcome, the 
exposure can be categorised into groups or a quadratic term of the exposure could be 
included as a covariate in the regression model in a similar manner to standard 
regression modelling.   
2.5.2.1 Assessing regression models’ goodness of fit 
For assessing the models’ fit, the squared multiple correlation function 𝑅2  and the 
adjusted 𝑅2 are calculated. 𝑅2 assesses the variation in the outcome that could be 
explained by the model 
 
𝑅2 =
𝑆𝑆𝑡𝑜𝑡𝑎𝑙 − 𝑆𝑆𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙𝑠
𝑆𝑆𝑡𝑜𝑡𝑎𝑙
 
Equation 2-6 
Where 𝑆𝑆𝑡𝑜𝑡𝑎𝑙 is the sum of the square difference between the observed outcome 
variable data-points and their overall mean and it represents the total variation in the 
model  
𝑆𝑆𝑡𝑜𝑡𝑎𝑙 = ∑(𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 𝑣𝑎𝑙𝑢𝑒𝑠(𝑡) − 𝑚𝑒𝑎𝑛 𝑔𝑙𝑢𝑐𝑜𝑠𝑒(𝑡))2 
Equation 2-7 
Whereas 𝑆𝑆𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙𝑠 is the sum of the square difference between the observed 
outcome variable data-points and the model’s fitted data-points and it represents the 
unexplained variation 
𝑆𝑆𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙𝑠 = ∑(𝑜𝑏𝑠𝑒𝑟𝑣𝑒𝑑 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 𝑣𝑎𝑙𝑢𝑒𝑠(𝑡) − 𝑓𝑖𝑡𝑡𝑒𝑑 𝑔𝑙𝑢𝑐𝑜𝑠𝑒 𝑣𝑎𝑙𝑢𝑒𝑠(𝑡))2 
Equation 2-8 
However, the 𝑅2 value can be inflated by adding more covariates to the regression 
model and thus cannot be used to compare models with different numbers of covariates. 
On the contrary, adjusted 𝑅2 only increases if the added covariate improves the model 
more than what would be expected by chance. The adjustment is based on the number 
of covariates (𝑝), the sample size (𝑛), and the unexplained part of variation in the 
model (1 − 𝑅2). 
𝑅𝑎𝑑𝑗
2 = 𝑅2 − (
𝑝
𝑛 − 𝑝 − 1
) (1 − 𝑅2) 
Equation 2-9 
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2.6 Approaching multiple days of CGM recording 
CGM data are usually collected from the participants/patients for multiple days ranging 
from one to six 24-hour days (mid-night to the following midnight).  Smoothing these 
daily CGM data will result in one to six daily smooth glucose curves per 
participant/patient.  A participant’s daily glucose curves are correlated and are not 
independent of each other. Using these daily glucose curves would make it necessary to 
consider their correlations by applying a multilevel mixed-effect functional methods 
(Scheipl et al., 2014; Spitzner et al., 2003; Morris et al., 2006; Crainiceanu et al., 2009). 
However, these methods are computationally complicated (Crainiceanu et al., 2009). 
The approach that I developed in this thesis was to calculate the registered mean 
glucose curves for all the participants, using the following steps: 1) each participant’s 
daily glucose curves were aligned separately with two registration iterations, each 
participant needed to have at least two 24-hour glucose curves; 2) the pointwise mean 
curve was calculated for each participant’s registered glucose curves; 3) all participants’ 
specific mean glucose curves were aggregated and registered, five registration iteration 
was needed at this step; 4) lastly, the registered mean glucose curves were used for 
descriptive and inferential functional analyses and they will be referred to in the rest of 
this thesis as the ‘average-glucose curves’. These steps were programmed to operate 
using a ‘registration loop’. The registration loop is an R software syntax for repeating 
function commands codes written by me (details of which are in R code syntax box 3).   
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R code syntax box 3 Registration loop 
# Import CGM data 
glucoseAllid <- Alldata [c("idseq", "days","sensorGlucose" , "glu_time" )] 
# Create empty matrix to store the mean glucose curves of the participants’ 
unregistered mean glucose curves, with number of rows equal to number of 
daily CGM readings (288 readings) per day, and number of columns equal to the 
number of participants 
emptymatrix <- matrix( nrow = 288, ncol = 146)  # matrix for 146 participants 
# Create 2 empty matrices to store the mean glucose curves of the participants’ 
mean glucose curves after first and second registrations’ iterations, with 
number of rows equal to number of daily CGM readings (288 readings) per day, 
and number of columns equal to the number of participants 
Registeredmatrix1 <- matrix( nrow = 288, ncol = 146) 
Registeredmatrix2 <- matrix( nrow = 288, ncol = 146) 
# Define the time argument, that is 288 time-points across the 24-hour day  
xx2= seq(100/12,2400,100/12)-(100/24)   
length(xx2)  # 288 time-points 
# Create the B-spline basis function 
basisobj27 = create.bspline.basis(c(0,2400),nbasis=27)    # B-spline 
fdParobj = fdPar(fdobj=basisobj27, Lfdobj=2, lambda=4)   # applying penalties 
# The registration loop 
for (i in 1:146) { 
#read data      
 glucosei <-  glucoseAllid[which(glucoseAllid$idseq==i),c( 
"days","sensorGlucose" , "glu_time" )] 
# reshape 
wide_glucosei <- reshape(glucosei,timevar ="days" , idvar = "glu_time", 
direction = "wide") 
glucoseDailyi <- wide_glucosei[c(2:length(wide_glucosei))] 
glucoseDailymatrixi <- data.matrix(glucoseDailyi) 
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#smooth       
glucose.smoothi   <- smooth.basis(argvals=xx2, y=glucoseDailymatrixi, 
fdParobj) 
glucose.fdi <- glucose.smoothi$fd 
# calculate the mean 
mean.fdi <- mean.fd(glucose.fdi) 
emptymatrix[,i]= eval.fd(xx2, mean.fdi) 
# register first iteration  
reg.fdi <- register.fd( mean.fdi,glucose.fdi) 
registeredi <- fd(coef= reg.fdi$regfd$coefs, basisobj = reg.fdi$regfd$basis, 
fdnames = reg.fdi$regfd$fdnames) 
# calculate first iteration’s mean glucose curves and store them 
mean.regi <- mean.fd(registeredi) 
Registeredmatrix[,i]= eval.fd(xx2, mean.regi) 
# register second iteration 
reg2.fdi <- register.fd( mean.regi,glucose.fdi) 
registered2i <- fd(coef= reg2.fdi$regfd$coefs, basisobj = reg2.fdi$regfd$basis, 
fdnames = reg2.fdi$regfd$fdnames) 
# calculate second iteration’s mean glucose curves and store them 
mean.reg2i <- mean.fd(registered2i) 
Registeredmatrix2[,i]= eval.fd(xx2, mean.reg2i) 
} 
# Register all the second iteration’s mean glucose curves 
registeredmatrix.fd <- smooth.basis(argvals=xx2, y=Registeredmatrix2, fdParobj) 
reg.mean.curves <- register.fd(mean.fd(registeredmatrix.fd$fd),registeredmatrix.fd$fd ) 
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2.7  Summary 
Glucose values measured continuously using CGM systems have an underlying smooth 
process with a highly correlated adjacent discrete data point’s measure over time. FDA 
deals with the complexity of CGM data by transforming its data-points to a mathematical 
function of time presented as a smooth curve over a time argument axis of a 24-hour 
duration. The transformation can be performed using a penalised B-spline basis function 
expansion, with 27 basis functions and knots placed hourly. Daily glucose curves’ 
prominent features, i.e. peaks and nadirs, vary by amplitude and phase. Amplitude 
variation is an indicator of glucose concentration and glycaemic control, while phase 
variation is an indicator of glucose circadian rhythm and timing of meals and physical 
activities. Daily glucose curves are aligned so their prominent features occur at around 
the same time using a continuous registration method. Registration preserves the 
amplitude variation and removes the phase variation. This is indispensable to identify 
glycaemic control differences between individuals. 
The shape and the dynamic behaviour (rate of change) of the daily glucose curves can 
be explored by calculating: the mean curve, the SD curve, the median curve, the IQR 
curves, the correlation structure, and the glucose velocity curves. Furthermore, functional 
regression models enable the study of the associations, together with the time-
dependency of these associations, between different variables (sleep variables in this 
study) and the daily glucose curves and the daily glucose velocity curves, while adjusting 
for potential confounders.  
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Chapter 3 Methods 
This chapter explains the methods employed in the current study including: study design 
and sample size calculation. Further, it includes a detailed description of the tools and 
devices used for measuring sleep and glycaemic control, with their mechanism of action, 
validity and practical consideration while applying them. Moreover, it explicitly presents 
the recruitment protocol and the statistical analysis methods applied to find the best 
answers for the study objectives. 
3.1 Study design, setting and study participants 
This was a cross sectional study that was part of larger longitudinal cohort project (Leeds 
and York GDM cohort) studying sleep, glucose variability and pregnancy outcomes in 
pregnant women with gestational diabetes. 
Participants were pregnant women diagnosed with gestational diabetes (GDM) during 
their current pregnancy according to NICE guidelines. They were mainly recruited from 
the Diabetes in Pregnancy (DIP) clinics at Leeds Teaching Hospitals NHS Trust. The 
DIP clinic at York Teaching Hospitals NHS Trust joined and served as a second 
recruitment centre for a few months only. According to Leeds clinics’ unpublished audit 
figures, they manage an average of 500 pregnant women with GDM every year.  
3.1.1 Inclusion and exclusion criteria 
All pregnant women aged 18-45 years attending the recruitment centres with a current 
diagnosis of gestational diabetes, at approximately 32 weeks of gestation were eligible to 
be included in the study.  Exclusion criteria included those with multiple pregnancy, 
severe co-existent medical or psychiatric conditions and non-English speaking. 
3.2 Sample size estimation 
A total of 148 participants were needed to be recruited for this study to answer the 
objective ‘evaluating the association between sleep duration and glucose control’. The 
sample size estimation was based on 80% power and a 0.05 significance level, to detect 
a clinically relevant difference in mean glucose level of up to 0.6 mmol/l, with a SD of 1.1, 
and accommodated for 20% missing data. This estimated sample size also provided 
80% power to detect a 0.25 correlation coefficient away from the null. Details of the 
methods used for the sample size estimation are as follows: 
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3.2.1 Sample size estimation for two independent groups t-test 
In order to estimate the sample size for a two independent sample means hypothesis 
test, the following assumptions were made: 1) the ratio of the exposure (short sleep 
duration) in a pregnant population. A ratio of exposed: non-exposed of 1:2 was specified 
as around a third of pregnant women are known to have short sleep duration (Signal et 
al., 2014; Facco et al., 2010b); 2) The CGM-derived mean and SD glucose level in 
pregnant women with gestational diabetes (with and without short sleep duration). At the 
time of estimating the sample size there were no published studies on sleep duration and 
CGM derived glucose levels in pregnant women with GDM. However, studies using 
CGM in GDM pregnancies had reported a mean (SD) glucose level of  5.4 mmol/l (1.1) 
(Dalfrà et al., 2011) , with a mean glucose of 5.5 moll/l (0.6) for participants on diet 
treatment only and 6.6 moll/l (0.7 ) for participants on diet and insulin treatment (Chen et 
al., 2003). Thus the reported maximum SD of 1.1 was used to estimate this study sample 
size. 3) The clinically worthwhile difference (effect size) in mean glucose level. A 0.5% 
difference in HbA1c was associated with a higher risk of complications in gestational 
diabetes (Evers et al., 2002). This is equivalent to an estimated average glucose 
difference of 0.8 mmol/l, using ADA published equation for estimating average glucose 
(eAG) from HbA1c values* ( eAG mg/dl = 28.7 X HbA1c – 46.7 ; eAG mmol/l= eAG mg/dl /18 ) 
(Nathan et al., 2008). This estimation equation was generated from non-pregnant 
population. However, association between eAG and HbA1c during pregnancy has been 
shown to be different (Law et al., 2017). Thus to be conservative a smaller effect size 
value of 0.6 mmol/l was selected.  
The Stata statistical package was used to estimate the sample size needed to detect a 
range of effect sizes in mean glucose level between pregnant women with GDM and 
either short or normal sleep duration, with assumed equal variance of (1.1 mmol/l) , with 
80% and 90% power and 0.05 significant level (Table 3-1). 
 
  
                                               
* available from: http://professional.diabetes.org/diapro/glucose_calc  
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Table 3-1 Estimated required sample size for two independent groups t-test with 
2:1 ratio of exposure, SD(1.1), a range of effect size, with 80% and 90% power 
and 0.05 significant level 
Effect size 
(mmol/l) 
Estimated sample 
size with 80% power 
Estimated sample 
size with 90% power 
0.1 4278 5724 
0.2 1071 1434 
0.3 477 639 
0.4 270 360 
0.5 174 231 
0.6 123 162 
0.7 90 120 
0.8 69 93 
 
3.2.2 Sample size estimation for multiple linear regression and for 
functional regression 
VanVoorhis and Morgan (2007) presented in their article various sample size 
calculation’s ‘rules of thumb’ for multiple linear regression analysis such as: 1- minimal 
size of 50 and add 8 more participants for each covariate, 2- minimal sample size of 104 
plus number of covariates, and 3- a sample size of 10-30 participants for each covariate. 
Using these ‘rules of thumb’ for a regression model with 6 covariates, estimated required 
sample sizes were: 90= (50+8*6), 110= (104+6), and 60 to180= (6*10 to 6*30) 
participants, respectively. A more sophisticated method involving the use of coefficient of 
determination (R2) or correlation coefficient (r) were suggested by Algina and Olejnik 
(2003). Figure 3-1 shows a graph produced by Stata statistical package of the sample 
size estimation for 80% and 90% power with 0.05 significant level for a range of 
correlation coefficients. As there is no a priori information on the correlation between 
sleep duration (or other sleep parameters) and glycaemic indices,  I chose to power the 
study to be able to detect 0.25 correlation coefficient away from the null. Further, no 
published sample size estimation methods for FDA hypothesis testing was found. 
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Figure 3-1 Graph showing estimated sample size for different correlation 
coefficient 
 
3.3 Measuring sleep  
Sleep was evaluated subjectively using The Pittsburgh Sleep Quality Index (PSQI) 
questionnaire and measured objectively using wrist actigraph. Details of these methods 
are presented in the following sections. 
3.3.1 The Pittsburgh Sleep Quality Index (PSQI) 
3.3.1.1 The PSQI instrument 
The PSQI is a score derived from a self-administered questionnaire measuring sleep 
quality over the previous month (Buysse et al., 1989). The questionnaire consists of 
nineteen items that yield scores on seven components, and an extra five items not 
included in the scoring, to be filled only if a bed partner is present. The seven component 
scores are: 1) habitual sleep duration score (actual time spent asleep at night); 2) sleep 
latency score (frequency and duration in minutes between bedtime and sleep onset 
time); 3) subjective sleep quality score (a subjective feeling of sleep satisfaction); 4) 
habitual sleep efficiency score (proportion of duration slept at night to total duration of 
time-in-bed); 5) sleep disturbance score (causes and frequency of sleep disturbances); 
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6) daytime dysfunction score (trouble staying awake during the day and while engaging 
in social activity; and 7) use of sleep medication score.  The other non-scored items are 
related to snoring and breathing-related sleep disorders. Each component is scored with 
a Likert scale from 0 to 3, a score of ‘‘0’’ indicates no difficulty, while a score of “3” 
indicates severe difficulty. All component scores are summed to yield a global/total score 
ranging from 0 to 21. Higher total scores indicate a poorer sleep quality, with participants 
scoring 5 or less considered to have a good sleep quality. A copy of PSQI questionnaire 
and PSQI administration instructions and scoring in Appendix A and Appendix B, 
respectively. 
Whilst a subjective tool, the PSQI potentially offers a more holistic approach to assessing 
the complex architecture of sleep than objective measures like polysomnography and 
actigraphy. It addresses both the quantitative and the qualitative aspects of an 
individual’s personal sleep experience while acknowledging the relative importance that 
different parts of these aspects vary between individuals.  
3.3.1.2 PSQI reliability and validity 
The PSQI instrument has been found to have good internal consistency (good 
correlation between its components) as measured by Cronbach’s α ≥ 0.70  (Cronbach, 
1951) and it has been found to have between a fair to good test-retest reliability (results 
are consistent over time) in multiple populations, including pregnant women in the first 
trimester (Carpenter and Andrykowski, 1998; Backhaus et al., 2002; Beck et al., 2004; 
Jomeen and Martin, 2007; Skouteris et al., 2009; Mollayeva et al., 2016; Qiu et al., 
2016). Moreover, it is a highly valid instrument, a total PSQI score >5 has a sensitivity of 
89-98.7 and specificity of 84.4-86.5 relative to clinical and polysomnography evaluation 
(Buysse et al., 1989; Backhaus et al., 2002). However, different populations may require 
higher cut-off scores (Mollayeva et al., 2016; Dietch et al., 2016). Although there have 
been no validation studies using a score of 5 as a cut-off score during pregnancy, it is 
still widely used in research (Okun et al., 2011).  
3.3.1.3 PSQI extent of use 
The PSQI is widely used in medical literature with 7227 medical documents citing the 
original article as of 22/05/2017 (Scopus). The original questionnaire is written in English 
and it has been translated into 56 additional languages. The questionnaire is available 
free of charge from Department of Psychiatry, University of Pittsburgh web page 
(http://www.psychiatry.pitt.edu/node/8240). The web page also provides a Microsoft 
Access database file for free download and automatically scoring and generating all 
components and total scores. 
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3.3.1.4 Practical procedure 
The PSQI questionnaires were administered on paper-form to the participants at 
recruitment for them to complete. The data was uploaded from the retrieved 
questionnaire to the Microsoft Access database file and all the component scores and 
the PSQI total score were automatically generated. All participants’ data were then 
exported from the database file and saved as a comma separated values (CSV) files.  
PSQI-derived sleep variables (characteristics) that were exploited in further analyses in 
this research were: 1) the PSQI total score, 2) reported sleep duration, 3) sleep onset 
latency (SOL) duration, 4) sleep efficiency (SE), 5) subjective rating of sleep quality, and 
6) mid-sleep time. Mid-sleep time was calculated as the mid time between reported 
bedtime and getting-up time. 
3.3.2 Wrist actigraphs 
Wrist actigraphs were first introduced to measure sleep and circadian rhythms in the 
seventies, evolved quickly and became widely used in clinical settings and in research 
(Morgenthaler et al., 2007a). They are light weight, comfortable to wear, non-invasive, 
wrist-worn watch/bracelet like devices that can be used to measure sleep for multiple 
nights in the individuals’ residence and under usual living conditions. This is in contrast 
to polysomnography which is usually laboratory based and involves attaching many 
leads and wires to individuals doing the sleep study (Ancoli-Israel et al., 2003). 
Actigraphs are basically motion sensors that detect activity by means of a build-in 
accelerometers. They provide continuous data of mobility/immobility periods which are 
used as an objective estimator of wake/sleep periods as absence of movement is a sign 
of being asleep (Martin and Hakim, 2011).  
3.3.2.1 Mechanism of actigraphs 
Wrist actigraphs use either solid-state piezoelectric or micro electrochemical system 
(MEMS) accelerometers (Patrick et al., 1996; Andrejašic, 2008) to measure acceleration 
forces caused by movement, of various intensities and at several axis and directions. 
This is done by transferring mechanical energy from acceleration into electrical current. 
The amplitude and the frequency of the electrical current’s waves is proportional to that 
of acceleration force. MEMS accelerometers factor in acceleration forces exhibited on 
the body by gravity while piezoelectric accelerometers do not.  
The measurements occur almost continuously, around 10 times per second or more 
depending on the resolution of the device. Electrical current from very low acceleration 
(like those related to breathing or to vibrations transferred through the mattress from the 
movement of a bed partner) and from very high acceleration (beyond the physiological 
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abilities of human motion, like those related to being in a transportation vehicle) are 
filtered out. The bandpass filter width varies between different actigraphs brands and 
depends on the accelerometer technology used (Ancoli-Israel et al., 2003). Electrical 
current in ‘Hz’ unit is then converted to acceleration in ‘g’ unit. Gravity unit ‘g’ is equal to 
the rate of acceleration of a free falling body to Earth caused by gravity, and that is 
9.80616 meter/second2 at sea level at 45o latitude and mean sea level. Acceleration 
forces are digitalised into activity counts and averaged over a predefined epoch (time-
slot) of 1,2,5,15,30,60 seconds or even 5 and 10 minutes and stored in the device 
memory. The methods used to transfer electrical current to acceleration, then into activity 
counts are not standardised between different accelerometers types and vendors (Tryon, 
2011). This should be taken in consideration before trying to compare readings from 
different actigraphs. 
3.3.2.2 Placement of actigraphs 
Another factor that influences the activity count is the site of placement of the actigraphy 
device. Where all body parts move during walking or running this is not the case during 
sitting or lying down sleeping, reading a book or streaming the net with a smart phone. 
Placing the actigraph on the wrist rather than other sites like the trunk or the ankle is  
preferred to measure motion delineating wake/sleep phases (Ancoli-Israel et al., 2015). 
Wearing the actigraph on the wrist of the non-dominant hand is the most common 
practice and is reported in the majority of validation studies. However, Sadeh et al. 
(1994) reported similar validation results from actigraphs placed simultaneously on the 
wrists of both dominant and non-dominant hands. 
3.3.2.3 From activity counts to sleep/wake 
Epoch-by-epoch activities’ count data stored in the actigraphs is uploaded to compatible 
computer software where it is processed using a sleep-scoring algorithm (Ancoli-Israel et 
al., 2003). Several automated scoring algorithms are available. One of the oldest 
algorithms, though still used, is the Cole et al. (1992) algorithm. It is basically a logistic 
regression prediction model. The algorithm coefficients were derived from a model using 
polysomnography sleep/wake scores as the outcome and activity counts of a specific 
epoch together with four adjacent epochs before and 2 epochs after it as the exposure. 
Whilst, the Sadeh et al. (1994) scoring algorithm is based on a probability-of-sleep (PS) 
formula derived from discriminant data analysis. A specific epoch is scored sleep 
(immobile) if PS ≥ zero, and wake (mobile) otherwise. Other algorithms were much 
simpler, each epoch is scored sleep/wake depending on a designated weighted activity 
count threshold; low threshold (20 counts per epoch), medium threshold (40 counts per 
epoch) and high threshold (80 counts per epoch).  
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Some actigraphy software has several built-in algorithms and allows researchers to 
select the most appropriate one for their research (Ancoli-Israel et al., 2015). 
Nevertheless, most of these algorithms were developed and validated using various 
actigraphy devices from different manufacturers and there is no consensus nor 
recommendation on which is the best algorithm (Sadeh and Acebo, 2002). New 
algorithms are also being continuously developed (Tilmanne et al., 2009; Nakazaki et al., 
2014). They are still using modalities of multiple linear and logistic regression modelling 
with adjacent epochs as the exposure variables, however they are not considering the 
autocorrelation structure between adjacent epochs’ activity counts and how the resulting 
multicollinearity can bias  the multiple regression model coefficients (Gilthorpe, 2011a). 
Our research team is developing a new algorithm utilising the advance in statistical 
methods and a better understanding of autocorrelation of activity behaviour over time (on 
going-work). Methods of functional data analysis have been applied to raw actigraphy 
data, to model and characterise physical activity, but not yet to identify sleep and wake 
phases (Morris et al., 2006).   
After scoring each epoch throughout the recording period as ‘sleep’ or ‘wake’ the 
software package algorithm marks the time-in-bed Interval for each night-day. The time-
in-bed interval, also referred to as ‘rest Interval’, is defined as the time window between 
bedtime and getting-up from bed time. The major/main sleep interval is located within the 
major rest interval and the algorithm delineates it by marking; sleep onset time, sleep 
end time and any awakening intervals between sleep-onset and sleep-end. Most 
software packages’ accuracy in automatically marking major rest Intervals is poor. Thus, 
major rest intervals need to be manually adjusted for each night-day of every actigraphy 
recording. Failing to do so results in distorted and untrue actigraphy derived sleep 
variables (Chow et al., 2016; Ancoli-Israel et al., 2015). Manual adjustment is done by 
the help of: 1) sleep diaries, 2) markers from event marker button, if integrated within the 
actigraphs and activated, 3) sharp changes in light level, if a light sensor is integrated 
within the actigraph, indicating light turned on/off at the time of waking-up/getting to 
sleep, as well as, 4) sharp changes in activity count from/to sedentary level that usually 
accompanies sleep/wake activity pattern. 
3.3.2.4 Accuracy of Actigraphy 
Actigraphs have been extensively validated against polysomnography. However, as 
stated before, different actigraphs have different technical specifications and use 
different algorithms. Nevertheless, many researchers have meticulously reviewed 
published articles on the accuracy and validation of actigraphs (Van de Water et al., 
2011; Stone and Ancoli-Israel, 2011; Sadeh, 2011; Martin and Hakim, 2011; Acebo and 
LeBourgeois, 2006; Ancoli-Israel et al., 2003; Sadeh and Acebo, 2002). Epoch-by-epoch 
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comparison against polysomnography, showed that actigraphs have high sensitivity with 
~85%-90% ability to correctly score an epoch as ‘sleep’, and poor specificity with only 
~30%-60% ability to correctly score an epoch as ‘wake’.  Overall concordance accuracy 
(actigraph ability to correctly score an epoch as either ‘sleep’ or ‘wake’) was high (~80%) 
for healthy individuals with normal sleep but low in individuals with disturbed sleep 
especially in individuals with insomnia (difficulty initiating or maintaining sleep).  Insomnia 
patients can lie in bed ‘motionless’ while awake.  Actigraphs are just a motion sensors 
and cannot differentiate between motionless wake status versus sleep status. 
Further, actigraphs tend to underestimate sleep onset latency (SOL) duration and wake 
after sleep onset (WASO) duration, and overestimate actual sleep duration and sleep 
efficiency (SE). However, adjunct use of a sleep diary log can significantly improve these 
estimates (Kushida et al., 2001). 
3.3.2.5 Actigraphy practical procedure followed in this research 
3.3.2.5.1 Actigraphy device used 
Actiwatch 2 actigraphs from Philips© Respironics were used (Figure 3-2). They have tri-
axis solid state piezoelectric accelerometers, with high resolution at a sampling rate of 32 
Hz (~ 30 measurements per second), bandwidth filter of 0.35-7.5 Hz, with detected 
acceleration range of 0.5-2 g peak value and they can store results in up to a minimum 
of 15 seconds epochs.  Further, they are lightweight (16 grams with band), have a sleek 
design and small size (measurement of 43mm x 23mm x 10 mm) with a lithium 
rechargeable battery, making them more comfortable to wear and least disturbing. They 
are waterproof at a depth of one metre for 30 minutes, so participants do not have to 
take them off during water related activity. They incorporate a one Mbit non-volatile 
memory that can store activity and light data up to 7.5 days for 15 seconds epochs and 
up to 30 days for 1-minute epochs. Integrated within the Actiwatch 2 actigraphs are 
photopic illuminance light sensors and event marker buttons, but not a heat sensor to 
detect off wrist status (Philips). Data records from the actigraphs were downloaded to 
Actiware® computer software (version 6.02), via a docking station and a USB cable, 
where they were stored and scored. 
3.3.2.5.2 Configuring the Actiwatches 
Actiwatch 2 actigraphs need to be configured before handing them in to participants for 
recording. Configuration involves connecting the Actiwatch to Actiware software where: 
previous data is retrieved and Actiwatch memory is cleaned. This is followed by 
programming the Actiwatch to record a new participant’s activity with: an anonymous 
unique identification number and non-traceable information, a pre-set epoch length (15 
seconds epoch length was chosen to get the highest resolution possible), and a pre-
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programmed recording start date and time. This is done in advance to recruitment and 
the Actiwatch is placed in ‘rest mode’ until the pre-programmed date/time. The only 
method to check if the Actiwatches are configured is to connect them to Actiware and 
check their configuration status. Thus each Actiwatch was labelled with their 
configuration status using a small sticky note wrapped around its band. Further, the 
device serial number was also documented in a data collection sheet together with the 
participant’s identification number and date of recording to avoid mixing-up records. 
 
 
 
Figure 3-2 Actiwatch 2 actigraph (Source: 
http://www.actigraphy.respironics.com) 
 
 
 
 
 
3.3.2.5.3 Cleaning the Actiwatches 
In between use, Actiwatches were washed and meticulously cleaned according to the 
manufacturer’s instructions using a wet cloth and a non-alcoholic detergent or if heavily 
soiled under running water then dried with a soft tissue and left to completely air-dry.   
3.3.2.5.4 Placement of the Actiwatches and duration of recording 
They were attached securely by a member of research team to the participants’ non-
dominant wrist. They were not fitted to be so tight as to be uncomfortable to wear, nor so 
loosely as to move freely around the wrist. Activity was recorded for seven days from the 
date of recruitment, coinciding with CGM recording. 
3.3.2.5.5 Safety consideration and adverse events  
Actiwatches are non-invasive and considered to be low risk medical devices. 
Furthermore, they are unlikely to cause any allergic reaction at the site of skin contact as 
Actiwatches’ cases and bands are made of a high grade polymers and the buckles are 
made of titanium. However, participants were instructed to contact the research team if 
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they experienced any adverse reaction and to immediately remove the Actiwatch if the 
reaction was intense.  
3.3.2.5.6 Participants instructions 
Participants were instructed to keep wearing the actigraph for the whole duration of data 
collection without removing it. In case they developed any adverse events (as stated 
previously) or if they decided to stop participating in the study then they were asked to 
remove it, keep it in a safe place and hand it in on their next appointment. However if 
they just wanted to take it off temporarily they were asked to record the time period it 
was not worn in the sleep diary log sheet (Appendix C). They also needed to record in 
their sleep logs: bed-time (the time they tuck-in and settled in bed ready to sleep), sleep-
onset time (the time they thought they fell asleep), sleep-end time (the time they woke-up 
from sleep) and the get-up from bed time (the time they finally got-up from their bed). 
At the start of the study, a few participants were also instructed to press the event 
marker button at the side of Actiwatch to mark their bed-time and get-up time. This 
instruction was not emphasised later on as participants found it confusing especially as 
there was no indication, like a clicking- sound or light-flash, if it did work or not. 
Participants kept repeatedly pressing it on some occasions and totally forgetting about it 
on others.  
3.3.2.5.7 Actigraphy data records; retrieving, editing and cleaning 
Activity data records from the Actiwatches were retrieved using the Actiware software. 
For each record, the Actiware: 1) automatically scores the activity epochs using a 
specific algorithm, 2) generates rest and sleep Intervals, 3) instantly calculates various 
sleep variables, and 4) produces an actogram (visual display of daily plotted activity 
data) (Figure 3-3). The actogram illustrates, in addition to activity data, light data from the 
light sensor, markers from events marker button in case it was pressed and the rest and 
the sleep intervals. 
To improve the accuracy of the actigraphy-derived sleep variables (as previously 
explained in section 3.3.2.4), the demarcation of the major rest intervals, i.e. bed times 
and getting-up from bed times, were manually edited. Using the intervals manipulation 
facility in the Actiware and with the help of the actogram (Figure 3-4), major rest intervals 
were edited in according to the methods mentioned in section 3.3.2.3 except for event 
marker method. The editing was made by the consensus of two researchers; Alia Alnaji 
(AA) and Eleanor Scott (ES) for the first 20 participants and by AA only for the remaining.  
Moreover, each record’s actogram was manually inspected and ‘cleaned’ to exclude 
partial night’s sleep intervals (caused by interrupted activity recoding due to participant 
taking-off the Actiwatch in the mid of sleep interval or due to device-related issues), as 
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well as, excluding periods of activity recorded before the participant started wearing the 
device, after finally taking it off, and during temporary off-wrist periods. Furthermore, 
records with noisy readings, manifest as continuous nights-days vibration-like activity 
(apparent during rest intervals and off-wrist intervals) are mostly a result from faulty 
devices and thus were also excluded (Figure 3-5). After all editing, Actiware re-
calculated sleep variables for each night-day of the record and produced an aggregate of 
all nights-days. These results together with the actogram were printed out in a clinician’s 
report and given to the participants (an example of the clinician’s report is available in the 
Appendix D).  
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Figure 3-3 An actogram 
 
                Activity Scale: 500/0, White Light Scale: 105545.1/0.1  
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Figure 3-4 Actiware software interface showing a participant’s actogram before 
editing (upper panel) and after editing (lower panel)  
Automatically demarcated bedtime 
Automatically demarcated getting-up from bed time 
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Figure 3-5 Actiware software interface showing a participant’s actogram with a 
vibration-like activities 
 
3.3.2.5.8 Actiware algorithms and settings 
Epochs scoring method 
Actiware scores all epochs in each recoding as either ‘sleep’ or ‘wake’ based on their 
weighted activity counts. The weighted activity count in a 15-second epoch is calculated 
based on activity counts of the epoch in question and those immediately surrounding it, 
as follows: weighted activity count = epoch activity count + 0.2 (sum of activity counts of  
adjacent epochs, 4 epochs each side) + 0.04 (sum of activity counts of  next adjacent 
epochs, 4 epochs each side). If the weighted activity exceeds the pre-defined threshold 
the epoch is scored as ‘wake’, otherwise it is scored as ‘sleep’. 
Sleep interval detection methods 
After the rest interval is demarcated, sleep interval is automatically defined using either 
the immobile minutes method or the sleep epochs method, as follows: 
1- Using the immobile minutes method:  
Detecting sleep onset: Beginning with the first epoch of the rest interval, the algorithm 
identifies the first group of epochs of a selected duration for which all epochs but one are 
Vibration-like 
activities 
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scored as immobile (i.e. having zero activity count). Sleep onset is then set to the first 
epoch of the period satisfying these requirements. 
Detecting sleep end: Beginning with the last epoch of the rest interval, the algorithm 
identifies the last group of epochs of a selected length for which all epochs but one are 
scored as immobile. Sleep end is then set to the last epoch of the period satisfying these 
requirements. 
2- Using sleep epochs method:  
Detecting sleep onset: Beginning with the first epoch of a rest interval, the algorithm 
identifies the first group of epochs scored as sleep that is at least of a pre-specified 
number of epochs in length. Sleep onset is then set to the first epoch of the period 
satisfying these requirements. 
Detecting sleep end: Beginning with the last epoch of a rest interval, the algorithm 
identifies the last group of epochs scored as sleep that is at least of a pre-specified 
number of epochs in length. Sleep end is then set to the last epoch of the period 
satisfying these requirements. 
Planned Actiware algorithm setting 
Medium activity threshold (40 counts per epoch) was chosen to score epochs as ‘sleep’ 
or ‘wake’. This threshold setting have been found to balance between sensitivity and 
specificity (Meltzer et al., 2012; Paquet et al., 2007) and to estimate sleep variables, 
when used in adjunct with sleep diary log, that do not significantly differ from those 
obtained using polysomnography (Kushida et al., 2001). In addition, 10 minute immobility 
method was chosen for detecting sleep onset and sleep end, as it is recommended by 
the manufacturer. Moreover, these settings was commonly used in research during 
pregnancy (Coo Calcagni et al., 2012; Bei et al., 2012; Tsai et al., 2013; Herring et al., 
2014; Twedt et al., 2015; Tsai et al., 2016b; Reid et al., 2017; Facco et al., 2017) and 
thus using it helps to compare this study results to others.  
3.3.2.5.9 Actigraphy-derived sleep variables  
Actiware produces many actigraphy-derived sleep variable summaries (See appendix E 
for the whole list). The following (daily and overall averaged aggregates) were used: 1) 
sleep duration; this is actual time spent asleep, during rest interval, between falling 
asleep (sleep onset) and final awakening (sleep end). 2) Sleep onset latency (SOL) 
duration; this is the length of time from bedtime to sleep onset, SOL is an indicator of 
initial sleep insomnia (i.e. difficulty in falling asleep at the beginning of night). 3) Wake 
after sleep onset (WASO); this is the duration of time spent awake after falling asleep, 
measured in minute, WASO is an indicator of maintaining sleep insomnia (i.e. difficulty in 
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maintaining sleep). 4) Sleep efficiency (SE); this is the proportion of sleep duration out 
of time-in-bed duration, SE is an indicator of sleep quality and disturbance. As well as, 5) 
Mid-sleep time; this is the midpoint between bedtime and getting-up time was 
calculated, Mid-sleep is an indicator of chronotype.  
3.4 Measuring glucose control 
Participants’ glucose control was assessed using a CGM system for 6 days. In contrary 
to SMBG meters, CGM systems offer close monitoring of glucose concentrations and 
allow exploration of the glucose pattern and rate of change during the day and overnight. 
3.4.1 Mechanism of CGM systems 
CGM systems are minimally invasive amperometric biosensors. Glucose concentrations 
are measured through electrochemical detection. A glucose oxidase enzyme-coated 
electrode sensor placed subcutaneously reacts with glucose titration in the interstitial 
fluid of subcutaneous tissue and produces electrical signals proportional to the glucose 
titration (Ocvirk et al., 2017). CGM systems measure an interstitial glucose concentration 
between 2.2 and 22.2 mmol/l (40 and 400 mg/dl) (Kiechle, 2001). Measurements are 
almost continuous and an average value of these electrical signals are received and 
stored in a recorder connected to the sensor. However, sensors measure interstitial 
glucose concentrations which are different from blood glucose concentrations, thus the 
CGM systems use built-in algorithms to estimate blood glucose concentrations from the 
interstitial glucose concentrations, in a process called calibration (Rossetti et al., 2010). 
Capillary blood glucose levels estimated by SMBG glucometer are usually used for 
calibration. The number of calibrating SMBG readings needed for calibration depends on 
the type and the specification of the CGM system. Most available CGM systems need 1-
3 in-vivo SMBG readings for calibration except for a new generation FreeStyle Libre 
Abbott CGM system which is in-vitro factory pre-calibrated (Abbott).  
CGM systems can be either: 1) real-time CGM systems where calibration is performed in 
real-time and glucose concentration results are displayed on a monitor directly available 
for the patients/participants and/or practitioners/researchers; or 2) professional/masked 
CGM systems where calibration is performed retrospectively after removing the sensor 
and uploading the recorder information to a computer software interface. As calibration 
occurs retrospectively in the masked CGM systems, the results are masked from both 
the patients and the practitioners till then. Nevertheless, the retrospective calibration 
enables the CGM system’s algorithm to utilise the SMBG values that both precede and 
follow in time a certain sensor interstitial glucose value. This optimises the algorithm’s 
function and allows masked CGM to be more accurate than real-time CGM, which can 
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only use the preceding SMBG calibration values. More details about accuracy of CGM 
systems in the next section.  
3.4.2 Accuracy of CGM systems 
The accuracy of a CGM system depends on the sensor used, the precision of SMBG 
glucometer measurements used for calibration and the algorithm incorporated to predict 
blood glucose concentrations from the sensor’s interstitial glucose readings. 
Furthermore, medications like paracetamol and vitamin C supplements, as well as tissue 
oedema may affect CGM system accuracy (Signal et al., 2013; Kiechle, 2001). Multiple 
methods have been used to evaluate the accuracy of CGM systems (Bailey et al., 2016). 
The following three methods are commonly reported. 
3.4.2.1 Mean absolute relative difference (MARD) 
CGM accuracy is usually measured using MARD. This is the mean of all the absolute 
relative difference (ARD) between calibrated CGM values and reference glucose values, 
estimated at the same time points (Equation 3-1 and Equation 3-2). The reference 
glucose values are usually plasma glucose concentrations or capillary glucose 
concentrations (other than those used in calibration) (Kirchsteiger et al., 2015). The 
MARD is an error metric and a lower value is favoured. A CGM glucose value of 7.2 
mmol/l and a reference glucose value of 6 mmol/l represents an absolute relative 
difference (ARD) of 20% (Equation 3-1). As the equation uses the absolute value of the 
difference (i.e. the difference is never negative) ARD cannot represent the direction of 
the bias. Thus a sensor value of 4.8 mmol/l and a reference reading of 6 mmol/l 
represents an ARD of 20% as well. Moreover, it is a relative value, i.e. the difference is 
weighted to the reference glucose concentration, therefore it is biased to the smaller 
hypoglycaemic values. For example, a difference of 0.5 mmol/l from a reference glucose 
of low value such as 3.5 mmol/l will yield an ARD of 14.3%, whereas a 0.5 mmol/l 
difference from a reference glucose of high value such as 10.5 mmol/l will yield an ARD 
of 4.8%. This has a clinical use as the amount of error around hypoglycaemia is usually 
more critical. The median absolute relative difference (MedARD) is also commonly used.  
 
𝐴𝑅𝐷 (𝑡 𝑘  ) =  
| 𝐶𝐺𝑀 (𝑡 𝑘  ) − 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 (𝑡 𝑘  ) |
𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 (𝑡 𝑘  )
∗ 100   
Equation 3-1 
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𝑀𝐴𝑅𝐷 =  
1
𝑁
∑ 𝐴𝑅𝐷 (𝑡 𝑘 )
𝑁
𝑘=1
  
Equation 3-2 
Whereas (t k ) is time point t for glucose reading event k , k = 1, 2, 3,….N  
 
3.4.2.2 Bland-Altman difference plot 
Accuracy can also be evaluated using a Bland-Altman difference plot. The mean of all 
the CGM and the reference glucose values estimated at the same time points are plotted 
against their differences (Figure 3-6). A mean of all the differences away from zero 
suggests a systematic bias (error). The closer the difference to the zero and the less 
dispersion of the data points the better the agreement between the CGM and the 
reference glucose values. Upper and lower limits of agreement are calculated then by 
adding and subtracting 1.96 SD of the differences between the sensor and the reference 
glucose values and represent dispersion of variations around the mean. If there is a 
Gaussian distribution, 95% of data points are located between these limits. Moreover, 
the Bland-Altman plot can also scrutinise for proportional bias, i.e. if the disagreement 
(error) increases or decreases with higher values of glucose.  
 
Figure 3-6 Bland-Altman plot of simulated CGM and reference glucose values 
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3.4.2.3 Error grid analysis (EGA) 
Error grid analysis (EGA) for assessing the clinical accuracy of CGM was developed to 
assess the effect of CGM results on treatment decisions. It was adapted from the original 
Clarke Error Grid Analysis which was used to evaluate clinical safety and accuracy of 
SMBG from glucometers (Clarke, 2005; Clarke et al., 1987). It compares self-measured 
glucose values, e.g. on CGM, to laboratory measured glucose values. The grid is divided 
into zones A to E with severity of error increasing as the data points lie away from zone 
A (Figure 3-7). Parkes modified Clarke’s zones slightly and constructed different error 
grids for T1DM and T2DM patients (Parkes et al., 2000). A surveillence error grid was 
recently added to the list with colour-coded risk level zones (Figure 3-8) (Klonoff et al., 
2014; Kovatchev et al., 2014b).    
 
 
Figure 3-7 Original Clarke Error Grid Analysis (Beardsall et al., 2013), reused with 
permission.  
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Figure 3-8 Surveillance error grid with superimposed (a) Clarke’s error grid and (b) 
Parkes’s error grid(Klonoff et al., 2014) ; reused under the Creative Commons 
Attribution License. 
3.4.2.4 Evaluation of CGM systems accuracy 
The American Association of Clinical Endocrinologists Consensus Panel on Continuous 
Glucose Monitoring stated in 2010 that most available CGM systems have a MARD of 
10% to 20% and only 60% to 80% of glucose readings fall into zone A of the Clarke error 
grid (Blevins et al., 2010). In addition there is usually a time lag of 5-10 minutes between 
SMBG and sensor glucose especially during a period of rapid glucose rate change. In 
contrary to SMBG glucometers, there is no established consensus or criteria on what is 
the minimum acceptable limit for CGM system inaccuracy. Furthermore, they are only 
approved for supplementary use with SMBG (Bailey et al., 2016). In a simulation study 
an estimate of  at least 10% MARD was needed for non-adjunct (standalone) use of 
CGM for safe insulin dosing and avoiding hypoglycaemic episodes (Kovatchev et al., 
2014a).  
In the last 16 years there has been a huge development and improvement of CGM 
sensors and algorithms (Facchinetti, 2016). In a study published in 2008; three 
commonly available CGM systems were tested simultaneously on 14 adults with T1DM. 
These were; Guardian (Medtronic), FreeStyle Navigator (Abbott) and Dexcom STS (a 
first-generation device). They were all real-time CGM systems and their results were 
compared to venous blood glucose. Respectively, they had a MARD of 15.2%, 15.3% 
and 21% during euglycaemia and a MARD of 16.2%,10.3% and 21.5% during 
hypoglycaemia (Kovatchev et al., 2008). In the same study Clarke error grid analysis 
showed that 98.9%,98.6%, 98.3% of data points were in zones A+B during euglycaemia, 
respectively, while during hypoglycaemia 84% and 97% of the points were in zones A+B 
for Guardian and Navigator, whilst no sufficient data for Dexcom. In a more recent study 
(Damiano et al., 2013) the previous 3 CGM systems were tested again for accuracy.  Six 
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adults with T1DM and no endogenous insulin secretion participated and the sensors 
were tested simultaneously. The 48-h MARD for the Guardian, the Navigator and the 
Dexcom Seven Plus were 20.2 ± 6.8%, 11.8 ± 3.8%, 16.5 ± 6.7%, respectively. Clarke 
error grid analyses results were as follows: the Guardian achieved 63.7% of points in 
zone A, 33.2% in zone B, 0.3% in zone C, and 2.1% in zone D; the Navigator achieved 
80.6% of points in zone A, 18.3% in zone B, 0% in zone C, and 1.0% in zone D; and the 
Dexcom achieved 76.2% of points  in zone A, 22.7% in zone B, 0.9% in zone C, and 
0.1% in zone D.  
3.4.3 CGM system used in this study 
Medtronic professional iPro2 CGM system was used in this study. IPro2 system is  
approved by the FDA (United State Food and Drug Administration) (FDA, 2016). It 
consists of a disposable sensor, the Enlite© sensor, and a reusable attachable recorder 
device. IPro2 is a "masked" CGM system where neither the participants nor the 
researcher team can see the CGM results until it is downloaded into a computer software 
interface. A masked CGM was preferred in the current study to avoid any potential 
change in behaviour produced by real-time awareness of glucose concentration (Feig et 
al., 2017 ).  
3.4.4 Accuracy of Medtronic CGM systems 
The Medtronic MiniMed (2006) published accuracy performance results for its Guardian 
RT system were a MARD of 19.7 ±18.4% , 62% of the readings were within 20% of 
reference plasma blood glucose and 61.7% of points in zone A, 34.4% in zone B, 0.2% 
in zone C, 3.5 % in zone D and 0.2% in E zone in Clarke error grid analyses. However 
these results were for Guardian CGM with the Sof-Sensor® which was in use before the  
Enlite® sensor. Using the new Enlite sensor and an improved algorithm (Paradigm® 
Veo™) a Medtronic sponsored clinical study published a much improved accuracy with a 
MARD of 13.6%, a bias of 2.1 mg/dl, and 72.7% and 83.7% of the readings were within 
15% and 20% of the reference venous blood glucose (Bailey et al., 2014; Keenan et al., 
2012). Lower accuracy performance for Enlite sensors than those published by the 
manufacturer were reported by Freckmann et al. (2013)  and Matuleviciene et al. (2014) 
with a MARD of 16.4% and 17.9%, respectively. However, Freckmann et al. did not use 
the Paradigm algorithm and they used cappilary blood glucose values as a reference. 
Whereas Matuleviciene et al. used a self-monitoring glucometer device and not a 
standard laboratory test to measure venous blood glucose level. This could have 
affected the validity of the reference glucose as the most accurate SMBG devices have a 
MARD of 5% (Freckmann et al., 2015a; Freckmann et al., 2015b). Calhoun et al. (2013) 
reviewed the accuracy of the Medtronic’s Enlite sensors using MiniMed Paradigm® Veo 
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calibration algorithm and the Sof-Sensors using Guardian® REAL-Time CGM calibration 
algorithm. The review evaluated nocturnal CGM data (10 PM- 6 AM) from 8 different 
studies. These studies used different blood glucose references varying from laboratory 
standard venous blood to capillary blood by glucometers, involved participants in 
paediatrics and/or adult age ranges, and some of these studies were not published. The 
review found that Enlite sensors tend to underestimate blood glucose over the entire 
reference glucose range (-15 mg/dl median bias), while Sof-sensors overestimate in the 
lower range and underestimate in the upper range of the reference glucose (-1 mg/dl 
median bias), with more variability (represented by wider interquartile range (IQR)) in the 
bias proportional to higher glucose level for both sensors (Figure 3-9). Enlite and Sof-
sensor had MedARD of 15% and 12%, respectively. 66% of Enlite and 73% of Sof-
sensor glucose values were within 15 mg/dl difference from the reference glucose values 
for reference glucose values ≤75 mg/dl, and within 20% difference from the reference 
glucose values for reference glucose values >75 mg/dl. Furthermore, Taleb et al. (2016) 
using Enlite sensors with the new algorithm and laboratory standard plasma glucose 
level as a reference, have reported a similar accuracy performance as Medtronic’s 
published results with a mean bias of -0.18 mmol/l and a MARD of 12.38% during rest. 
However, they reported a mean bias of -0.15 mmol/l and a higher MARD of 19.90% 
during exercise. 
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Figure 3-9 Box plot of Sof-Sensor and Enlite sensor bias over ranges of reference 
glucose level (Calhoun et al., 2013)  Black dots denote the mean bias, and 
boxes denote the median (IQR). Reused with permission. 
3.4.5 Accuracy of Medtronic professional iPro CGM system 
A high accuracy performance was published by Medtronic’s website and Medtronic’s 
sponsored clinical studies for professional iPro2 CGM with Sof-sensors and capillary 
blood readings as the reference (Medtronic Diabetes, 2012; Welsh et al., 2012). They 
reported a MARD of 9.9% in adults and 10.1% in children, and 99.0% of adult and 98.4% 
of paediatric values were within zones A and B of the Clarke error grid. However, the 
IPro2 user guide manual published slightly different results (Medtronic MiniMed, 2016b). 
It presented the result of a study in which Enlite sensors were inserted to the abdomen 
and the buttocks of 64 adult participants with T1DM. IPro2 retrospective algorithm was 
used to calibrate the sensors’ values incorporating a minimum of 4 SMBG values. To 
assess the accuracy of the IPro2 results, the CGM derived glucose values were 
compared to, apparently, the same SMBG values that were used for calibration. 11.6% 
and 10.4% MARDs were reported for abdominal insertion site and buttock insertion site, 
retrospectively. With an overall 97.7% of the readings were in Clarke Error grid zones A 
and B, and 87.1% of the CGM readings were within 20% of the reference readings. 
Another accuracy result from a clinical study performed by Medtronic was published 
online on the ClinicalTrials.gov website under ClinicalTrials.gov Identifier NCT01112696, 
last verified in July 2012. Accuracy was defined as proportion of sensor derived glucose 
within 20% agreement with paired laboratory standard venous blood glucose (YSI) and 
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within 20 mg/dl if YSI <80 mg/dl, with higher proportion suggests better accuracy. In this 
study 98 T1DM and T2DM patients participated and completed 6 days of CGM recording 
giving a total of 5857 paired sensor and YSI readings.  79.45 % of the CGM readings 
met the accuracy criteria. However it was not specified at the clinical trials website which 
algorithm was used to calibrate the CGM readings. 
To gain a better insight on accuracy of professional iPro2 CGM with Enlite sensor, I 
performed a systematic review of studies looking at the accuracy of iPro2 including only 
those performed by independent researchers (not employed by or under influence of 
Medtronic). 
 
3.4.6 Systematic review of studies on accuracy of iPro2 
3.4.6.1 Search strategy  
Embase and Ovid MEDLINE(R) databases; (year 2000 to date; search last updated on 
24/4/2017) were explored using explicit search terms. Full details presented in Table 3-2. 
The search returned 29 journal articles after excluding reviews and conference abstracts.  
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Table 3-2 Search terms   
# Search terms results 
1 CGM  4008 
2 CGMS  1716 
3 continuous glucose monitor* 7511 
4 1 or 2 or 3 8673 
5 Medtronic  28732 
6 4 and 5 1134 
7 ipro2 125 
8 Ipro 188 
9 professional  422853 
10 retrospective  1379156 
11 7 or 8 or 9 or 10  1792636 
12 6 and 11 257 
13 accur*  1305189 
14 valid* 1178583 
15 performance  1538002 
16 MARD  419 
17 ARD  2078 
18 13 or 14 or 15 or 16 or 17  3509970 
19 12 and 18 80 
20 remove duplicates from 19  60 
21 
Limit 20 to journal articles (exclude 
reviews and conference abstract) 
29 
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3.4.6.2 Search results  
All the articles were fully scrutinised and only 6 were included (Thomas et al., 2017; 
Munekage et al., 2016; Schaupp et al., 2015; Akintola et al., 2015; Signal et al., 2013; 
Dungan et al., 2013).  Other articles were excluded for multiple reasons: not presenting 
accuracy results for iPro2 (Fokkert et al., 2017; Thomas et al., 2016),  using 
subcutaneous Medtronic Sentrino® CGM system which is designed to display real-time 
glucose levels ICU patients (Wollersheim et al., 2016; Punke et al., 2015), did not 
evaluate device accuracy  (Crenier, 2014; Chen et al., 2015; Del Rio et al., 2014), review 
and not primary article (Zisser et al., 2015), used Dexcom CGM system (Argento et al., 
2014), special case of one 5 years old child with acute lymphoblastic leukaemia with 
9.4% MARD reported between CGM values and SMBG calibration values 
(Visavachaipan et al., 2013), investigating real-time prediction model of serum glucose 
concentration (Pappada et al., 2013), examining accuracy of the Combo-Set sensor 
prototype (insulin pump and sof-sensor combination) using real-time algorithm (O'Neal et 
al., 2013),  used a prototype of iPro CGM to test accuracy of CGM during Hypo- and 
Hyperbaric Conditions  and sponsored by Medtronic (Adolfsson et al., 2012), sensors 
were attached to vinous blood circuit (tubes) of an extracorporeal (outside the body) life 
support system and not inserted to subcutaneous tissue (Steil et al., 2011), testing  
Paradigm Veo algorithm (Keenan et al., 2010), used a microdialysis type of CGM 
systems (Nielsen et al., 2009), or used Medtronic real-time CGM (Mastrototaro et al., 
2008; Maia and Araujo, 2006; Maia and Araujo, 2005c; Maia and Araújo, 2007; Maia and 
Araujo, 2005b; Araujo and Maia, 2005; Maia and Araujo, 2005a). 
3.4.6.3 Review results 
Only two articles studied participants with T2DM while the four others studied either 
healthy participants or severely ill hospitalised participants with no diabetes. None 
studied pregnant women with diabetes. Although not funded by or working for Medtronic, 
some of the authors disclosed some connection to Medtronic. 
Munekage et al. (2016) reported a poor accuracy performance of iPro in critically ill 
patients with a very high MARD of 44%, wide Bland-Altman plot limits of agreement and 
high bias between CGM and blood glucose. However, they inserted iPro CGM in the 
upper arm and used arterial blood glucose for calibration. Akintola et al. (2015) using 
venous blood glucose for calibration reported a MARD of 17.6% in healthy adults for only 
a 24-hour period of CGM recording. The four other studies used cabillary SMBG as a 
reference and reported a very good accuracy performance similar to those published by 
Medtronic. Thomas et al. (2017) reported MedARD ranging between 11.2% -13.2% in 10 
healthy athletes using the abdominal insertion site. Evaluating iPro accuracy in 84 non-
critically ill hospitalised adults with T2DM, Schaupp et al. (2015) reported 9.6% MARD, 
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6.5% MedARD, zero mmol/l median bias, and 98.7% of the values within A+B error grid 
zones. Though they used the same 4 capillary blood glucose for calibration and for 
accuracy assessment. Another study involving hospitalised patients with T2DM with and 
without congestive heart failure (CHF), reported MARD of 11% in CHF and 8% in non-
CHF,  and 98.5% of CHF and 98.7% of non-CHF CGM glucose values were within A+B 
error grid zones (Dungan et al., 2013). Lastly, Signal et al. (2013) evaluated the accuracy 
of iPro devices inserted on the abdomen and on the thigh. They recruited 10 critically ill 
adults in the ICU and inserted two iPro devices concurrently, one device at each 
insertion site. They reported a MARD of 11.8% for the abdomen and 12.4% for the thigh. 
A summary of the included articles’ results are presented in Table 3-3. 
3.4.6.4 Review conclusion  
The iPro professional CGM system with Enlite sensors, has a good accuracy 
performance. More accuracy studies are needed specifically in individuals with diabetes 
and in pregnant women with DIP. 
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Table 3-3 Summary of studies on accuracy of professional Medtronic CGM system 
 Author (year) population Duration Insertion 
site 
Calibration Reference blood 
glucose 
Accuracy results 
1) Thomas et al. 
(2017) 
10 adult athletes, none with 
diabetes 
4-6 days Abdomen  3-4 Capillary 
blood by 
glucometer 
Capillary blood by 
glucometer 
 MedARD 11.2% -
13.2% 
2 Munekage et al. 
(2016) 
15 critically ill surgical 
patients intensive care unit 
(ICU) , none with diabetes 
3592 comparative 
samples (starting at 
operation theatre till 
discharge from ICU) 
Upper arm arterial blood 
glucose 
Venous blood by 
intravenous 
continuous 
glucose monitor 
MARD 44 % 
Bland-Altman plot 
9 5% agreement 
limit -67 to + 57 
mg/dl  
Mean bias -5.2 
mg/dl 
3) Akintola et al. 
(2015) 
34 healthy adults 24-hour Abdomen  4 Capillary 
blood glucose 
by glucometer 
Venous blood by 
laboratory method 
MARD 17.6%  
-2.21 to + 2.41 
mmol/l 95% 
agreement limits 
Mean bias 0.1 
mmol/l 
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4) Schaupp et al. 
(2015) 
84 hospitalised adults with 
T2DM 
501 patient-days Not specified 4 Capillary 
blood glucose 
by glucometer 
The same 4 
Capillary blood by 
glucometer used 
for calibration 
MARD 9.6%, 
MedARD  6.5% 
98.7% in A+B 
zones of error grid 
Median bias 0 
mmol/l 
5) Signal et al. 
(2013) (letter with 
primary research 
results) 
10 critically ill adults in the 
ICU 
Not specified Two devices; 
abdomen 
and thigh) 
 4 capillary 
blood glucose 
by glucometer 
Frequent capillary 
blood glucose by 
glucometer 
MARD; abdomen 
site 11.8% and 
thigh site 12.4% 
 
6 Dungan et al. 
(2013) 
T2DM hospitalised adults; 
43 with congestive heart 
failure (CHF) and 32 with 
no CHF 
Patients were either having 
uncontrolled 
hyperglycaemia  or  using 
significant amount of insulin 
43 hours in CHF and 
32 hours in non-CHF 
abdomen 4 capillary 
blood glucose 
by glucometer 
Hourly capillary 
blood glucose by 
glucometer 
(11%) in CHF and 
(8%) in non-CHF 
98.5% of CHF and 
98.7% of non-CHF  
in A+B zones of 
error grid 
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3.4.7 The iPro2 CGM system practical procedures followed in this 
research 
The sensor was inserted transcutaneously using an automated insertion device (serter) 
and an introducer hollow-needle incorporated with the sensor (Figure 3-10). The needle 
is automatically retracted after the insertion while the sensor electrode remains in the 
subcutaneous tissue (Figure 3-11). The recorder (memory device) is then attached and 
the whole CGM system secured in place with medical adhesive films or over-tapes. 
Practical steps as recommended in the Medtronic’s user guide were strictly followed 
(Medtronic MiniMed, 2016b). All clinical research staff received training on the use of 
iPro2 professional CGM system from the Medtronic company representatives and the 
online step-by-step training manual and videos (Medtronic MiniMed, 2016a) . The iPro2 
devices’ serial numbers were recorded in the participants’ data collection sheets together 
with participants’ identification numbers and dates of recording before connecting them 
to the sensors in order to avoid mixing-up participants records. 
3.4.7.1 Insertion sites 
The best location for sensor insertion are areas with sufficient subcutaneous fat 
including: abdominal area including the front, sides, and back of the body, and upper 
buttock area. Areas to avoid include areas with tight fitting clothes, areas with hard skin 
or scars, body areas which move a lot during physical activity, areas around the waist or 
two inches around the belly button. In the current study either left or right upper buttock 
areas were used as they were considered more convenient for pregnant women (Figure 
3-12). Accuracy of Enlite® glucose sensor’s buttock area insertion site was not found to 
be significantly different compared to an abdominal insertion site (Bailey et al., 2014).  
 
 
Figure 3-10 iPro2 professional CGM system and serter (Source: 
https://www.medtronic-diabetes.co.uk) 
 
Electrode 
Sensor 
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Figure 3-11 Diagrammatic picture of iPro2 professional CGM system in situ 
(Source: https://www.medtronic-diabetes.co.uk) 
 
 
 
 
Figure 3-12 iPro2 CGM insertion sites  (Source: https://www.medtronic-diabetes.co.uk) 
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iPro recorder 
Glucose molecule 
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Interstitial fluid 
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3.4.7.2 Infection control procedures 
The skin at the site of insertion was inspected for any signs of infection and then 
prepared by alcohol swab and left to air-dry before insertion. Universal infection control 
precautions procedure were used during handling the sensor to avoid potential blood 
and body fluid contact. This included washing hands with water and detergents or using 
alcohol rub, wearing gloves and preparing sterile gauze to use in case of bleeding from 
the insertion site. Used sensors were disposed in sharps containers, memory parts were 
cleaned from tape adhesive residues using a medical adhesive remover (Zoff © 
Adhesive Remover Wipes1 was used) and thoroughly cleaned and disinfected according 
to the manufacturer instructions before being reused. 
3.4.7.3 Safety and adverse events following CGM 
CGM systems are usually well tolerated (Jadviscokova et al., 2007; Yu et al., 2014a; 
Kosiborod et al., 2014). In the current study there were no reports of insertion site 
infection or major adverse events. Only 3 participants removed the CGM system after 
experiencing itching related to the adhesive tape. 
3.4.7.4 Duration of recording 
Patients wore the CGM system for one week from recruitment day. They returned on day 
seven for device removal. The iPro2 CGM system is waterproof and no limitations were 
required for water related activities. They were instructed to continue wearing the device 
for the whole period unless they experienced any adverse events or they decided that 
they no longer wished to participate in the study. In this case or in case the CGM system 
fell out, they were advised to keep it in a plastic bag and return it to the clinic.    
3.4.7.5 Calibration 
In the iPro2 CGM system an average interstitial glucose value is stored every five 
minutes, providing up to 288 interstitial glucose measurements per day. It is not pre-
calibrated and thus it needs an in-vivo calibration using glucose values from SMBG 
glucometers. In this study participants used various types of glucometers as provided by 
the DIP clinic. Participants were instructed to record at least 4 SMBG reading per day as 
per standard DIP clinical care. They were provided by a log sheet to record the values 
and the timings of their SMBG readings (Appendix F). 
                                               
1 Available from smith&nephew  http://www.smith-
nephew.com/uk/products/wound_management/product-search/zoff/ 
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3.4.8 CGM data 
Data from the CGM system’s recorders were downloaded to the computer using the 
Carelink interface which is the manufacturer’s online software (Medtronic CareLink). 
SMBG readings were input manually to Carelink.  The software built-in algorithm used 
the SMBG readings to calibrate the interstitial glucose values and produced estimated 
blood glucose values. The algorithm needed at least one SMBG reading every 12 hours 
to operate. Calibration readings further apart and missing calibration readings resulted in 
a failure of the algorithm and no estimation of blood glucose level generated. Missing 
calibration readings was caused when participants either did not record their SMBG 
values on the log sheet or they forgot to document the timing of the recorded SMBG 
measurements. 
Carelink produces different summary reports (example available in Appendix G) and 
stores all the downloaded sensors values, time-points of recording (in 5-minute epochs) 
and the calibrated glucose values in a dense long CSV table format. 288 estimated blood 
glucose values are expected in a 24 hours period. Each participant's raw glucose data 
were exported as CSV files from Carelink and read into Stata statistical package where 
all participants’ data were merged and then were saved as Stata file.  
3.4.8.1 CGM data cleaning 
Data from day zero (day of recruitment/sensor insertion) were excluded from any 
analysis as this data is considered less accurate. This is due to a temporary shift in the 
subcutaneous interstitial fluid equilibrium caused by insertion wound and associated 
trauma (Heller and Feldman, 2008). Summary report metrics from Carelink were not 
used in the analysis, instead daily and overall CGM summary metrics for each participant 
were computed in Stata. Daily metrics were calculated either for a 24-hour day (from 
midnight to next midnight) or for a variable-length day (from wakeup time to next wakeup 
time) depending on the specific objective being addressed by the study and analysis 
techniques employed. Partial 24-hour or variable-length days with missing data caused 
by either device failure or missing calibration readings, were excluded. Missing glucose 
data especially around glycaemic excursions (peaks and nadir) may bias the summary 
metrics by either overestimating or underestimating their values (Fonda et al., 2013). 
Further, FDA of CGM data requires a complete dataset of equal time periods without 
missing values. Imputation of missing CGM data was not used in this study as it needed 
information that was not collected, namely: 1) caloric, carbohydrate and other nutrient 
intake, and 2) energy expenditure (Hernandez and Barbour, 2013).  
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3.4.9 Planned CGM data summary metrics 
Acknowledging their limitations, some of the CGM summary metrics were calculated and 
used to compare the current research results to other researchers’ results. These 
summary metrics were: mean glucose; SD glucose; proportion of time within, above and 
below target; and ratio of AUC-above and AUC-below targets. The normative target 
range was set to be between 3.5 mmol/l lower threshold and 7.8 mmol/l upper threshold. 
NICE recommends a blood sugar below 5.3 mmol/l fasting and 7.8 mmol/l one hour after 
meal for pregnant women with diabetes (NICE, 2015). Though, they do not recommend 
a lower limit except for those on glucose lowering medications (namely insulin and  
glibinclamide) to maintain their capillary blood glucose level above 4 mmol/l in order to 
lower the risk of iatrogenic (clinically induced) severe hypoglycaemia. The American 
Diabetes Association Workgroup on Hypoglycaemia (2005) defined hypoglycaemia as all 
episodes of an abnormally low plasma glucose concentration that expose the individuals 
to potential harm, whereas severe hypoglycaemia is hypoglycaemia that requires the 
assistance of another person and impedes self-management. However, the 
hypoglycaemic threshold is debated and in-general a glucose level ≤ 3.9 mmol/l (70 
mg/dl) is set as a conservative lower limit to alert individuals with diabetes for a higher 
probability of severe hypoglycaemia (Seaquist et al., 2013; Cryer, 2009). In contrary to 
hyperglycaemia, hypoglycaemia during pregnancy in humans does not appear to have 
detrimental effects on the offspring, albeit it is still detrimental for the mothers’ wellbeing 
(Ringholm et al., 2012; Rosenn et al., 1995; Frier and Fisher, 2007). A lower limit of 3.5 
mmol/l was set as a hypoglycaemic threshold in this study to allow comparisons with 
others (Stewart et al., 2016; Feig et al., 2016).  
3.5 Study protocol 
The current section set out the original study protocol, the reasons it was modified, the 
methods used to improve recruitment into the study and the final study protocol. 
3.5.1 Original study protocol 
Women diagnosed with GDM, at 26-28 weeks of gestation, were referred to attend the 
DIP clinic within a week, and followed-up every 1-2 weeks thereafter. At their first DIP 
visit, they were approached by the research team and given general information about 
the study. Those who showed interest were provided with detailed written information 
about the study and offered the opportunity to ask questions and find out more about the 
research study. If they were still keen to participate, they were asked to sign a written 
consent and were given a unique identifier code. They were asked to complete the PSQI 
sleep questionnaire and wear the actigraph and a member of the research team set the 
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CGM system for them. Baseline characteristics including: age, measured weight and 
height at first antenatal visit, measured weight at recruitment visit, gestation in weeks at 
recruitment visit, medications including glucose lowering medications, comorbidities, 
reported ethnic backgrounds and OGTT results were collected from participants’ files 
using a data collection sheet (Appendix H). Participants were asked to complete a sleep 
diary and a glucometer readings log sheet (Appendix C and Appendix F). They were also 
provided with an iPro2 user instructions sheet and research team contact information. 
They were asked to return to clinic after 1 week for all paperwork and devices to be 
retrieved. They were instructed to remove the devices and put them in a plastic bag and 
return them during their next visit if they experienced any complications or if they decided 
to withdraw from the study for any reason.  
They were followed up during their regular DIP clinic visit at 32-34 gestation weeks and 
asked to repeat the same procedure again. All participants continued to receive GDM 
standard management by the DIP clinic’s multidisciplinary clinical team as recommended 
by NICE (NICE, 2008; NICE, 2015). A flow chart of this study protocol summary 
presented in Figure 3-13. 
 
  
Figure 3-13 Flow chart of the original study protocol 
 
First 
contact
•First DIP clinic visit. At 26-28 weeks of gestation.
•Study information, recruitment and informed consent.
•PSQI sleep questionnaire
•CGM and glucometer log
•Actigraphy and sleep log
Second 
contact
•Follow up after 1 week
•Retreiving devices and questionnaire
Third 
contact
•DIP clinic visit at 32-34 weeks of gestation
•PSQI sleep questionnaire
•CGM and glucometer log
•Actigraphy and sleep log
Fourth 
contact
•Follow up after 1 week
•Retreiving devices and questionnaire
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3.5.2 The need to change the original study protocol and how this 
decision was reached  
Four months into the study cohort recruitment (October 2013-January 2014) only one 
participant had been recruited in the study. This was a very poor uptake considering the 
abundance of study-eligible pregnant women with gestational diabetes attending the DIP 
clinic every month (30 potential participants on average every month). Studies that 
looked into reasons for declining participation in clinical studies found that it was mostly 
related to issues with study protocol (Brintnall-Karabelas et al., 2011; Williams et al., 
2007; Thoma et al., 2010). Thus a decision was made to revisit the study protocol and 
find out how to improve the recruitment rate. Several steps were taken as follows: 
3.5.2.1 Appreciating the research environment  
The DIP clinic is very busy and the first DIP clinic visit is particularly stressful and 
relatively long. It is the visit the pregnant women make directly after being diagnosed 
with gestational diabetes. It was observed how this diagnosis came as a shock for many 
of the pregnant ladies who blamed themselves for not being careful enough to avoid 
having such a condition. Others were afraid of having to take injections as they had 
heard from friends or read on the internet, and they were also concerned about possible 
complications to themselves and their babies. The consultation visit is a lengthy one as 
the pregnant women have to see all the multidisciplinary clinical team: midwife and 
obstetrician to check on mother’s and foetus’s general health, diabetologist for diabetes 
and glycaemic control information and plan, dietitian for diet consultation including 
instructions on recording dietary intake for the coming week, and nurse assistant for 
instructions on the use of capillary blood glucose meter (glucometer). Adding information 
about research and recruitment to the study at this same visit was overwhelming and 
unpractical.  
3.5.2.2 Taking feedback from potential participants 
During attempts to recruit potential participants, most of the reasons for declining were 
mainly something like: “Do I have to do this as well? If not I’m not bothered!” or “Sorry I 
can’t I’m too busy”. Others however were afraid of potential complications of using the 
CGM system and a few could not wear the Actiwatch due to some restrictions at their 
work place.  
3.5.2.3 Involving DIP clinic’s clinical staff 
The principle investigator (PI) and AA had a group discussion with the DIP medical team 
as involving people with direct contact with the study population would potentially 
improve the understanding of the research environment. The DIP medical team had 
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raised their concerns about the practicality and the timing of recruitment and how it may 
interfere with the patients’ care. Harm could be introduced by adding emotional or 
psychological distress or interfering with their comprehension of important information 
and instructions they are receiving from the medical team for managing their GDM 
complicated pregnancy (Babbie, 2014).  
Involving medical staff led to being awarded a highly commended certificate from the 
BMJ awards for Diabetes team of the year to Leeds Diabetes in Pregnancy team for 
EMBARC (EMBedding an Active Research Culture) in the Diabetes in Pregnancy clinic 
project. An award that recognised an innovative project that has measurably improved 
care in diabetes (Appendix I). 
3.5.2.4 Incentives for participating 
Small to moderately sized monetary incentives of  $1-$15 have been found to 
significantly increase recruitment rate in trials and response rate in surveys compared to 
no incentives (Ulrich et al., 2005; Edwards et al., 2005; Martinson et al., 2000). The 
original study protocol did not include any incentives. 
3.5.3 Restructured final study protocol 
The following steps were taken based on the reassessment of the original study protocol, 
discussions with clinical staff and patients, and recommendations to improve recruitment 
rate found in the literature (Bower et al., 2014; Thoma et al., 2010): 
- Change recruitment time to around 32 weeks of gestation, giving patients time to 
understand their GDM condition and be more experienced with using the 
glucometer and food choices. 
- Simplify study protocol with collecting data only once. 
- Distributing research culture among staff and patients. Study flyers (Appendix J) 
were given to the clinical staff and distributed in the waiting area.  
- Adding incentives: £10 pound voucher and full CGM and Actigraphy reports.  
A flow chart of the final study protocol is presented in Figure 3-14. 
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Figure 3-14 Flow chart of the final recruitment protocol 
3.6 Ethical considerations  
The research was performed under the NHS and Leeds Teaching Hospitals Trust 
(LTHT) research governance standards and GMC codes of conduct for research. NHS 
Local Research Ethics Committee approval was obtained prior to the start of the 
research for the original protocol and then for the amendment; REC reference 13/H/0268 
on 19/09/2013 and 17/11/2014 respectively. NHS site specific approval at Leeds 
Teaching Hospitals Trust was granted on 14/11/ 2013, LTHT R&D number; ED13/10839 
(122874/WY). All research team members had completed an introduction to good clinical 
practice (GCP) online e-learning course and had research passports with letter of access 
to conduct research from Leeds Teaching Hospitals NHS Trust. Ethics documents are 
available in Appendix K to Appendix Q. 
Participants were provided with full written study information sheets and the study was 
explained by the research team prior to their enrolment. Written informed consent was 
obtained from all the participants before commencing the study. Participants had the 
right to withdraw from the study at any time-point thereafter. Participation did not affect 
the standard clinical care provided by clinical staff.  
  
First 
contact
•First DIP clinic visit at 26-28 weeks of gestation.
•Familiarising potential participants with DIP clinic's research policy, study flyer 
distributed.
Second 
contact
•DIP clinic visit at 28-30 weeks of gestation.
•Study information given for potential recriuts.
Third 
contact
•DIP clinic visit at  30-34 weeks of gestation.
•Recruitment and informed consent.
•PSQI sleep questionnaire.
•CGM and glucometer log.
•Actigraphy and sleep log.
Fourth 
contact
•After 1 week for retreiving devices and questionnaire.
•Handing in £10 voucher.
Fifth
contact
•next appointment handing in the CGM and Actigraphy reports.
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3.7 Database management 
The study database was built using data collected from different tools. Demographic, 
anthropometrics and other participant’s characteristics were collected via data collection 
sheets, entered into Microsoft Excel spreadsheet then exported to Stata software and 
stored as Stata data file. Raw CGM data were exported as separate long CSV files for 
each participant, then they were all appended using Stata software and stored in a very 
long Stata data file. PSQI scoring and reported sleep variables datasheets were 
exported from the PSQI Microsoft Access database file to Stata software and stored as 
Stata data file. Actigraphy-derived daily sleep characteristics for all the participants were 
exported from the Actiware software as one large Microsoft Excel spreadsheet to Stata 
software and stored as Stata data file.  
All these Stata data files were merged to form one large database linked using the 
following two identifiers: 1) the participants’ unique study number and 2) the date of 
recorded data. The date of getting-up from sleep as recorded by actigraphy was linked to 
the date of CGM recording, as such the night sleep (the exposure variable) will 
chronologically precede the CGM recording day (the outcome variable), and thus 
allowing temporality in the relation between sleep and glucose control. This arrangement 
of data was used throughout the analysis except for when examining the impact of 
glucose level around bed time on the immediately following night sleep. In that latter 
situation CGM data were arranged to chronologically precede the immediately following 
night sleep. 
Multiple sub-databases were created to ease manipulation and analysis of variables 
when exploring a specific study objective.  
3.8 Data security  
All the study’s sheets, forms, configured devices and electronic databases 
including/relating to: data collection sheets, PSQI questionnaires, glucometer logs, sleep 
diaries, CGM systems and records, actigraphy configuration and records and the merged 
databases were totally anonymised using unique allocated study identifier number (ID) 
with no link to participants’ confidential information. They were all stored in University of 
Leeds secure offices and servers except for CGM data which was uploaded and stored 
via Medtronic CareLink online secure software data management webpage. Databases 
were regularly updated and backed up. A linkage list of the participants study ID with 
their confidential information including: name, NHS number and date of birth were 
retained with the research nurse. A paper-form of the list was kept in a locked drawer 
inside a secure office within LTHT and YTHT premises and an electronic Excel-
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spreadsheet list was encrypted and saved in a secure LTHT and YTHT servers. The 
linkage list was needed in order to follow the participants’ pregnancy outcome. 
3.9 Statistical methods 
3.9.1 Descriptive analysis 
A detailed description of the full dataset and the complete dataset (participants’ records 
with no missing variables) is presented in the results chapter. Continuous variables such 
as; age, BMI, gestational age at recruitment, OGTT results (fasting and 2-hours post 
prandial), PSQI total score, sleep duration, sleep efficiency, SOL duration, WASO, 
bedtime, getting-up time, glucose readings from CGM, proportion of time 
within/above/below glucose target, ratio of glucose AUC below/ above threshold to the 
total glucose AUC were presented as mean and SD if normally distributed or as median 
and Interquartile range (IQR) if not normally distributed.  
Categorical variables or grouped continuous variables were summarised as frequencies 
and proportions. These data such as: PSQI total score where a score of 5 or less is 
considered to be good sleep quality and a score of more than 5 is considered to be poor 
sleep quality; Parity status (number of living children) was grouped into nulliparous (0 
living children) and parous (one or more living children); type of medication used to 
manage GDM (no medication diet only, Metformin 500 mg twice daily, Metformin 1g 
twice daily, Insulin with/without Metformin), and ethnicity. 
Ethnicity was self-reported by participants and obtained from their health file. Ethnicity 
data was comprised of a long list of multiple ethnicity groups, as per the health files 
information form. In order to use this data in the analysis, the ethnicity groups were 
recoded initially into four broad categories; White, Black, Asian and Others, as shown in 
Table 3-4. However, in further analyses, Asian, Black and Others ethnicity groups were 
recoded into one broader category of Non-white ethnicity.  
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Table 3-4 Original health file self-reported ethnicity groups and the recoded broad 
ethnicity categories 
Original health file ethnicity 
category 
Recoded broad 
ethnicity category 
 White British 
 White Irish 
 White others 
White 
 Indian 
 Pakistani 
 Bangladeshi 
 Other Asian backgrounds 
 Mixed White and Asian 
Asian 
 Black African 
 Black Caribbean 
 Other Black backgrounds 
 Mixed White and Black 
Black 
 Chinese 
 Arab 
 Any other ethnic group 
 Not stated 
Others 
  
3.9.2 Agreement between reported and actigraphy measured sleep 
characteristics 
The Bland-Altman difference plot method was used to evaluate the agreement between 
reported and actigraphy sleep characteristics (Bland and Altman, 1986; Giavarina, 
2015). These were: sleep duration, sleep efficiency, SOL duration, bedtime, and getting-
up from bed time. The method involves, separately per sleep variable, calculating the 
differences and the averages of each participants sleep variable’s values reported by 
PSQI and measured by actigraphy, calculating the mean and SD of the differences, 
followed by drawing a scatter plot of the differences (y- axis) against the averages (x-
axis), drawing horizontal line crossing the y-axis at the mean of the differences, and 2 
more horizontal lines crossing the y-axis at the mean±1.96 SD of the differences. The 
mean±1.96 SD lines demarcate the upper and lower limits of agreement where 95% of 
the data points lie in between. The narrower the distance between the upper and lower 
limits of agreement and the less dispersion of the data points the better the agreement 
between the reported and actigraphy measured sleep variable. A mean of the difference 
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of actigraphy minus reported sleep variable larger or smaller than zero is suggestive of a 
systematic bias (error) where actigraphy, respectively, overestimate or underestimate 
reported sleep variable. In addition the Bland-Altman plot can detect trends in the 
relationship, i.e. proportional bias, between the differences and the averages, like in 
instance if large differences were observed with smaller values of the sleep variable and 
only slight differences observed with large values of the sleep variable, or vice versa. 
Proportional bias can be checked by a linear regression model of the differences on the 
averages. A statistically significant slope (β coefficient) of  the model best fitted line is 
indicative of proportional bias (Ludbrook, 2010).  
3.9.3 Standard regression analysis 
The associations between different reported and overall actigraphy-measured sleep 
characteristics (the exposures) with overall CGM derived glycaemic characteristics (the 
outcomes) were tested using standard multivariable regression analysis models. 
Regression analysis estimates the associations between exposures and outcomes by 
identifying a ‘best fitting’ line connecting their data points. The ‘best fitting’ line is 
identified using ordinary least square (OLS) method. Regression line of a simple model, 
having only one exposure (𝑥), has the equation in the form: 
𝑌𝑖 = 𝛼 + 𝛽 𝑥𝑖 +  𝑒𝑖    ,    𝑒𝑖 ~ 𝑁(0, 𝜎
2) 
Equation 3-3 
Where 𝑌𝑖 is the fitted outcome for the 𝑖th participant. 𝛼 is the line intercept and represent 
the expected outcome if the 𝑥𝑖 = 0 . 𝛽 is the slope of regression line, or the regression 
coefficient, of exposure 𝑥𝑖 . The regression coefficient represents the expected amount of 
change in the outcome for each unit increase in the exposure. 𝑒𝑖 is the residual error, 
residuals are assumed to be normally distributed, with zero mean and variance 𝜎2 and 
homogeneously distributed across values of exposure.  
Each standard regression model is one from a series of models having one sleep 
characteristic as the exposure and one glycaemic characteristics as the outcome, at a 
time. All models were adjusted for potential confounders, details of the confounders and 
the methods used to identify them are given in section 3.9.6.  
Reported sleep characteristics were variables obtained from PSQI questionnaire, i.e. 
PSQI total score, reported sleep duration, reported sleep efficiency, reported SOL 
duration, mid-sleep time, subjective rating of sleep quality. Overall actigraphy-measured 
sleep characteristics were the calculated mean of all available night’s actigraphy sleep 
data. Overall actigraphy-measured sleep characteristics used were:  sleep duration, 
sleep efficiency, SOL duration, mid-sleep time and WASO. Overall CGM derived 
glycaemic characteristics were the calculated mean of all daily valid CGM data record’s 
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summary measures. The valid CGM data record was the CGM record with no-missing 
data over a 24-hour day that is 288 CGM glucose readings from midnight to next 
midnight. Overall summary measures used were: average glucose, SD glucose, 
proportion of time within/above/below glucose target and ratio of glucose AUC below/ 
above threshold to the total glucose AUC. Figure 3-15 displays a schematic mapping of 
exposures and outcomes variables and their potential relationship. 
 
 
Figure 3-15 Schematic mapping of exposures and outcomes variables and 
potential relationship 
 
Linear regression modelling was applied for continuous variables outcomes. However 
variables such as; proportion of time within/above/below glucose target and ratio of 
glucose AUC below/ above threshold to the total glucose AUC, although numeric they 
are proportions and ratios and thus limited by a lower value of zero (0%) and upper value 
of 1 (100%). Furthermore, these variables were strongly skewed as their values were 
aggregated either at 100% or just below it for some of the variables, or at 0% and just 
above it for the other variables. This resulted in some issues when applying the linear 
regression modelling strategy. That is the models’ post-estimation diagnostic showed 
models’ residuals which were non-normally distributed and non- homoscedastic (non-
constant variance across the values of the exposure). These issues affect the validity of 
the regression models.  A possible solution to deal with these issues was to apply 
logarithmic transformation to the skewed data, however, it was not effective. Another 
solution was to calculate robust standard errors (SE) , however it is very conservative 
and leads to a very wide 95% CI which would lead to a higher probability of type II error 
(i.e. incorrectly accepting a null hypothesis of no association) and would also result in a 
prediction of outcome values outside their (0% to 100%) natural range.  A third solution 
was to cut these proportion and ratio variables into binary outcome (two groups): 0; lower 
and 1; higher, based on their median values and then apply logistic regression modelling 
methods (Scott Long, 1997). A more statistically advanced solution was to apply a 
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fractional heteroskedastic probit regression model with zero/one inflated beta with robust 
standard errors (Bayes and Valdivieso, 2016). Fractional outcome regression models 
could be fitted in Stata software version14, however, model specifications and 
interpretation of model’s coefficients are not straightforward. Therefore the third solution, 
categorising these outcomes into binary variables, was chosen and applied. 
Nevertheless, this option had its caveats as categorising variables could introduce 
measurement errors.  
The grouping of data was as follows: proportion of duration within recommended range 
groups; lower ≤ 93% and higher > 93%, proportion of duration above recommended 
range groups; lower ≤ 4.4% and higher >4.4%, proportion of duration below 
recommended range groups; lower =0.0% and higher > 0.0%, ratio of AUC above 
recommended range; lower ≤ 0.43% and higher > 0.43%, ratio of AUC above 
recommended range; lower = 0.0% and higher > 0.0%. Logistic regression models odds 
ratios (OR) and 95% CI are presented in the result chapter, 
To examine potential U/J shaped relationships between sleep duration and glycaemic 
characteristics two methods were used. The first method was by applying polynomial 
regression: simply adding a quadratic term (squared sleep duration) in addition to the 
linear term (sleep duration) in the regression model. The second method was by 
categorising sleep duration into 3 categories: average, short and long. The literature 
categorising a 'normal/average' sleep duration is extremely varied, with ranges between 
‘7-8’, ‘7-9’, ‘6-8’ and ‘6-9’ were all proposed. Thus the decision was made to use data 
driven cut points using the interquartile range where 50% of participants’ sleep duration 
data lie. Thus 6-8 hours was defined as the average sleep duration, less than 6 hours 
was defined as short sleep duration and more than 8 hours as long sleep duration. 
To determine the best fitting model, the likelihood ratio test was implied if the models 
were nested (large model has all the terms (variables) a smaller model has plus some 
extra terms) as in the case when comparing the fit of linear term only sleep duration 
regression model and linear and quadratic term sleep duration regression model. Akaike 
information criteria (AIC) and Bayesian information criteria (BIC) were used to determine 
best fitting model in case of non-nested models like in the case when comparing linear 
tem sleep duration model and sleep categories regression model. The best fitting models 
are presented in the results chapter. 
SOL duration was categorised according to the established cut point of initial insomnia 
(difficulty in falling asleep at the start of sleep period) as: normal; SOL duration <30 
minute, and High; SOL duration ≥ 30 minutes (Lichstein et al., 2011). 
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3.9.4 Multilevel mixed effect regression analysis 
Multilevel data analysis involves analysing data with a hierarchical structure, for example 
like in the case where individuals are nested within a clinic, clinics nested within a city, 
cities nested within a health authority and so forth. Each level in this hierarchy is 
influenced by the level they are nested in, i.e. individuals are influenced by the clinic they 
receive medical advice from, moreover, clinics in the same city are influenced by 
common practices, and cities follow strategies imposed by their local authority. Likewise, 
clinic performance is influenced by the characteristics of individuals seeking help there 
and cities strategies might change based on performance of the clinics operating within 
its jurisdiction.  
In the current research, although it was not sampled in a clustered hierarchical manner 
but rather a longitudinal fashion, the multiple days of measurements of CGM glucose 
and actigraphy are considered to be nested within participants. Sleep and CGM glucose 
might differ between days within the same participant, however they are potentially more 
correlated to each other than to sleep and CGM glucose from days belonging to other 
participants. This correlation violates the assumption of independent variables necessary 
for the validity of a standard regression model. Moreover, modelling the association 
between daily sleep and CGM data and ignoring their dependence and clustering within 
participants would lead to spurious association and type I error in statistical hypothesis 
testing as it would potentially result in narrower 95% CI and a smaller p-value. One 
method to overcome this dilemma is to summarise the multiple days’ data into one 
overall measurement per participant, usually by calculating their mean, and then 
applying standard regression models as in the previous section 3.9.3. This method can 
answer the question of how the overall sleep characteristic is related to an overall 
glycaemic characteristic, however it cannot give an answer of how night sleep is directly 
related to the following day/night's glycaemic characteristics. Moreover, this method 
cannot identify the variability in the relationship between days within the same participant 
and the variability in the relationship between various participants. On the other hand, 
another, more appropriate method is multilevel modelling as it can answer the direct 
relationship question and avoid the cumbersome clustering issue by incorporating the 
hierarchal structure in the model.  Moreover, it can identify between days within 
participant variability and between various participants variability. Multilevel modelling is 
also referred to as mixed effect regression as it consists of two parts: a fixed part similar 
to the standard regression and a random part where the between and within participants 
variation is specified (Snijders and Bosker, 2012; Hox, 2010).  
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Random intercept multilevel models were applied. It allows for variation in the model’s 
intercept between participants, i.e. random effect, however all participants would have 
the same regression line slope, i.e. fixed effect.   
The multilevel model specification for outcome 𝑌𝑖𝑗 on 𝑖th day of 𝑗th participant is as 
follows:  
𝑌𝑖𝑗 = 𝛼 + 𝛽 𝑥𝑖𝑗 +  𝜁𝑗 +  𝑒𝑖𝑗     ,   𝜁𝑗 ~ 𝑁(0, 𝜓)  𝑒𝑖 ~ 𝑁(0, 𝜃) 
Equation 3-4 
Where 𝛼 is the overall model intercept and represent the expected outcome if the 𝑥𝑖𝑗 =
0 . In a random intercept model the intercept is allowed to vary a cross participants, the 
amount of variation, random effect, is specified by the error term 𝜁𝑗  (pronounced 
zeta). 𝜁𝑗  is specific for each participant and assumed to have a normal distribution with 0 
mean and variance 𝜓 (pronounced psi), 𝜓 represents the between participant variability. 
𝛽 is the slope of all participants’ regression lines. It is interpreted in a similar way to the 
standard regression model coefficient, also referred to as the fixed effect of the multilevel 
model. 𝑒𝑖𝑗 is the residual error for the 𝑖th day of the 𝑗th participant, residuals are 
assumed to be normally distributed, with zero mean and variance 𝜃 (pronounced theta),  
represents the within participants variability. The sum of the two error terms 𝜁𝑗 and 𝑒𝑖𝑗 
represent model’s total residual error (Rabe-Hesketh and Skrondal, 2012).  
Further, correlation between days within participants, also referred to as intra-class 
correlation (ICC), was calculated from the model as follow: 
 
𝑰𝑪𝑪 =  
𝜓 (𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑝𝑎𝑟𝑡𝑖𝑐𝑖𝑝𝑎𝑛𝑡 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒)
𝜓(𝑏𝑒𝑡𝑤𝑒𝑒𝑛 𝑝𝑎𝑟𝑡𝑖𝑐𝑖𝑝𝑎𝑛𝑡𝑠 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒) + 𝜃(𝑤𝑖𝑡ℎ𝑖𝑛 𝑝𝑎𝑟𝑡𝑖𝑐𝑖𝑝𝑎𝑛𝑡𝑠 𝑣𝑎𝑟𝑖𝑎𝑛𝑐𝑒)
 
Equation 3-5 
 
Reported sleep characteristics were only evaluated once for each participants, however, 
actigraphy measured sleep characteristics and CGM glucose were evaluated for multiple 
days (Figure 3-15). Valid CGM day definition used for multilevel models differs from the 
definition in section 3.9.3. It was defined as the day/night period, with no missing CGM 
glucose data, that directly followed a night sleep. Day/night period is the day period 
following a night sleep, starting from the time participant getting-up from bed, plus the 
following night sleep period up to the time of next getting-up from bed (see Figure 3-16 
for schematic illustration). Daily getting-up from bed time was extracted from actigraphy 
data. Available actigraphy night sleep daily data were used. 
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Proportion and ratio variables outcomes were grouped in a similar categories as 
explained in section 3.9.3 and multilevel logistic regression models were applied. 
For each multilevel model the model fit was compared to model fit of standard regression 
analysis of daily data without acknowledging the hierarchy, using likelihood ratio test.   
 
 
Figure 3-16 Schematic illustration of the relationship between actigraphy 
measured night sleep and demarcation of the following day/night period CGM 
glucose 
 
3.9.5 Functional data analysis and functional regression models 
All participants’ 24-hour daily CGM data records were fitted with smooth curves using a 
27 penalised cubic B-spline basis expansion with knots placed at 1-hour equidistance 
intervals as explained previously in Chapter 2. The resulting smooth daily glucose curves 
were registered using the registration loop and all participants average-glucose curves 
were estimated and registered. 
The following descriptive statistics for all participants’ average-glucose curves were 
calculated: the point-wise mean and SD curves, median and IQR curves using functional 
boxplot, correlation matrix, and glucose velocity curves. 
Several function-on-scalar regression models were produced to examine the 
associations between reported sleep characteristics from PSQI questionnaire and the 
overall actigraphy-measured sleep characteristics (the exposures) and the average-
glucose curves (the outcome). In addition, another set of function-on-scalar regression 
models were produced to examine the association between reported sleep 
characteristics from PSQI questionnaire and the overall actigraphy-measured sleep 
characteristics (the exposures) and the glucose velocity curves, in order to examine how 
much variation in rate-of-change of glucose concentration can be explained by sleep 
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characteristics. 95% confidence bands were calculated for all the coefficient curves from 
all the aforementioned regression models. 
Further, to examine the reverse association, that is the association of glucose 
concentrations around bedtime with the daily actigraphy-derived sleep characteristics of 
the directly following sleep, the following steps were followed: 1) All available CGM data 
records were rearranged differently. Instead of a 24-hour day duration, they were 
rearranged into a16-hour interval duration spanning from 14 hours before bedtime to 2 
hours after bedtime. The daily bedtimes were extracted from the actigraphy records. This 
rearrangement of CGM data was performed using time-series syntax commands in Stata 
software. Figure 3-17 presents a schematic display of this CGM data rearrangement; 2) 
These 16-hour CGM data intervals were fitted into smoothed curves using the same 27 
penalised cubic B-splines basis expansions.  
Scalar-on-function regression models were produced to examine the associations 
between the 16-hour interval glucose curves (the exposures) and the following sleep 
actigraphy-measures: sleep efficiency, WASO and SOL durations. To examine the 
association between the 16-hour interval glucose curves and the actigraphy-measured 
sleep duration, the curves were categorised into three groups: curves that were followed 
by short sleep duration (< 6 hours), curves that were followed by long sleep duration (>8 
hours) and curves that were followed by average sleep duration (6-8 hours). Mean 
glucose curves were estimated and compared for all the three groups. Permutation 
functional t-tests were calculated to evaluate the presence of a statistically significant 
differences in glucose concentration between the groups. That is the difference between 
the mean glucose curves of the glucose curves that were followed by short and average 
actigraphy-measured sleep durations, and is the difference between mean glucose 
curves of the glucose curves that were followed by long and average actigraphy-
measured sleep durations.  
All the functional regression models were adjusted for the same set of confounders used 
in the standard regression models. These confounders are identified in section 3.9.6 . 
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Figure 3-17 Schematic demonstration of the rearrangement of CGM records (A, B, 
C and D) to study the association between glucose concentration around 
bedtime and the characteristics of the following sleep (N.B lengths of the 
horizontal bars are not proportionate to scale) 
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3.9.6 Adjusting regression models for potential confounders 
The Directed Acyclic Graph (DAG) causal diagram method (Greenland et al., 1999; 
Gilthorpe, 2011b; Pearl, 2016) was used to identify the minimal adjustment set, i.e. the 
minimum set of confounders, for estimating the adjusted total effect of sleep variables on 
glycaemic variables. DAGs are basically visualising, through diagrams, unidirectional 
assumed causal relationships between a set of variables. A variable that is causally 
associated with the outcome and the exposure but not on the causal pathway from the 
exposure to the outcome is identified as a ‘confounder’ (Greenland et al., 1999). On the 
other hand, a variable that lies on the pathway between the exposure and the outcome is 
identified as a ‘mediator’. Moreover, a variable that is hypothesised to be causally linked 
to the outcome but not the exposure is identified as a ‘competing exposure’. A regression 
analysis model should be adjusted for confounders, to avoid confounders’ bias. The 
model can include competing exposures, to narrow the confidence limit of the model 
estimates, but should avoid including mediators in the model, to avoid introducing extra 
bias (Gilthorpe, 2011b). 
The DAG presented in Figure 3-18 was plotted using Dagitty program tool (available 
from http://www.dagitty.net/development/dags.html#). In this DAG the green shaded oval 
shape with black arrow head is the ‘exposure’, the blue shaded oval shape with black bar 
is the ‘main outcome’, other blue shaded oval shapes are ‘mediator’ variables that are 
lying in the middle of the causal path, red shaded oval shapes are the ‘confounder’ 
variables. The identified confounders are: age, booking BMI, ethnicity, type of treatment 
and parity status. In a multilevel model where weekend and weekdays can be identified 
from the daily data, weekend/weekday status was also added to the confounder set 
(Figure 3-19). 
3.10 Statistical software 
The software Stata (StataCorp, 2014) was used to merge and store data files into a large 
database. It was also used for data manipulation, producing CGM summary metrics, 
descriptive analysis, multivariable regression and multilevel regression analyses. The 
software R (2010) with package ‘fda’ was used for functional data analysis. 
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Figure 3-18 DAG of causal relationship between sleep variables (main exposure) 
and glycaemic control variables (main outcome) and other covariates 
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Figure 3-19 DAG of causal relationship between sleep variables (main exposure) 
and glycaemic control variables (main outcome) and other covariates 
including weekend/weekday variable 
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Chapter 4 Results 
4.1 Participants recruited 
4.1.1 Original recruitment policy; recruitment around 28 weeks of 
gestation 
The recruitment of participants was started in LTHT-DIP clinic by Dr Eberta Tan (ET) in 
the period from November 2013 to January 2014 inclusive. Although there were 
approximately 35 eligible pregnant women with GDM per month, only one consented and 
participated in the study. This participant had 6 days of CGM recording, completed the 
PSQI questionnaire, but returned no actigraphy recording as she decided not to wear the 
Actiwatch.  
Recruitment attempts were started by myself (AA) in the period from September- 
November 2014 inclusive. AA was able to recruit seven participants. All of them 
completed the PSQI questionnaire, two participants took-off the Actiwatches at home, 
and only three consented for CGM to be inserted.  
4.1.2 Final recruitment policy; recruitment around 32 weeks of 
gestation 
Recruitment at 32weeks of gestation started on the last week of November 2014 and 
continued until the end of April 2017. Recruitment was carried out by AA, DE and LA. In 
Leeds, clinics were held on Wednesday and Thursday afternoons. Usually only one 
member of the research team was able to recruit during the clinic. Due to limited 
equipment, the maximum number of subjects that could be recruited per month was 
between 14-16 participants. Each participant required 30-40 minutes for consenting, 
setup and instructions. Out of 910 eligible potential recruits, 170 participants were 
recruited over 26 calendar months from LTHT-DIP.    
York (YTHT-DIP) joined the research from October 2015 to June 2016. Fourteen 
participants were recruited from this centre during this period. Recruitment was carried 
out by HO. 
  
124 
 
4.2 Final dataset 
In total 192 participants were recruited into the study (8 participants from LTHT-DIP with 
original recruitment policy, 170 participants from LTHT-DIP with final recruitment policy, 
and 14 participants from YTHT-DIP with final recruitment policy). However only 152 
participants had full data records available from PSQI questionnaire, actigraphy and 
CGM (Figure 4-1). Ten participants did not fill their PSQI questionnaire at all, and one 
filled it partially. 26 participants had no actigraphy data due to: taking the Actiwatch off at 
home (n=5); a fault in the Actiwatch (n=16); and the Actiwatch was not configured 
correctly to start recording at time of recruitment (n= 5). 169 participants had at least one 
full day of CGM data. Missing CGM data was mainly due to participants not recording 
their glucometer reading at all, or not recording the time of the glucometer reading 
(n=14). The glucometer reading together with the time it was measured are necessary 
for calibrating the CGM interstitial glucose values. Other causes included: the 
participants did not consent to have CGM iPro (n=4); the participants removed the CGM 
at home (n=3); the CGM fell off from one participant; and no data were retrieved from 
one participant’s CGM. 
4.3 Description of participants 
4.3.1 Demographic and basic characteristics 
The mean (SD) age of participants was 32.8 (5.3) years. They were predominantly from 
white ethnicity background (60.9%) and obese with a BMI mean (SD) of 30.1 (6.5) 
Kg/m2. 34.9% of the participants were nulliparous (had no children previously). Mean 
(SD) gestational age at the time of recruitment was 31.5 (1.1) weeks. Around half of the 
participants were on diet management only for their GDM at the time of recruitment. 
Participant OGTT results were: fasting glucose mean (SD) 4.8 (0.8) mmol/l and 2-hour 
glucose mean (SD) 8.9 (1.2) mmol/l. Those participants with no missing data records 
(n=152) had similar demographics and basic characteristics to those for all participants 
(Table 4-1). 
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Figure 4-1 Flowchart of participants recruitment and attrition with number of 
participants with available data from PSQI questionnaire, Actigraphy and 
CGM  
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Table 4-1 Demographic and basic characteristics of all recruited participants and 
participants with complete records 
Participants; n All participants; 192 Complete records;152 
Age (years); mean (SD) 32.8 (5.3) 32.7 (5.1) 
BMI (kg/m2); mean (SD) 30.1 (6.5) 30.6 (6.4) 
OGTT results; mean (SD)   
Fasting glucose (mmol/l) 4.8 (0.8) 4.9 (0.8) 
2 hours glucose (mmol/l) 8.9 (1.2) 8.8 (1.2) 
Week of gestation; mean (SD) 31.5 (1.1) 31.3 (1.2) 
Treatment; n (%)   
Diet 95 (49.5 %) 71 (46.7%) 
Diet with metformin 500 mg 44 (22.9 %) 35 (23.0%) 
Diet with metformin 1 g 31 (16.1 %) 26 (17.1%) 
Diet with metformin and insulin  22 (11.5 %) 20 (13.2%) 
Parity    
Nulliparous; n (%) 67 (34.9%) 52 (34.2%) 
Parous; n (%) 125 (65.0%) 100 (65.8%) 
Ethnicity; n (%)   
White  117 (60.9 %) 95 (62.5%) 
Asian 41 (21.4 %) 30 (19.7%) 
Black 21 (10.9 %) 19 (12.5%) 
Others 13 (6.8 %) 8 (5.3%) 
Recruitment centre   
Leeds 178 (92.7 %) 140 (92.1%) 
York 14 (7.3 %) 12 (7.9%) 
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4.3.2 Self-reported sleep characteristics 
The participants sleep characteristics, recorded using PSQI questionnaire are presented 
in Table 4-2. 67.4% of the participants self-reported  poor sleep quality with a mean 
PSQI score >5, a median PSQI score of 7, and the middle 50% of participants’ PSQI 
score ranging between 5 and 10. Self-reported sleep duration was slightly skewed to the 
shorter sleep duration with median (IQR) 7(6, 8) hours. Self-reported sleep efficiency 
was also skewed to the left (skewed to the smaller value) with median (IQR) 81.4% (71.0 
%, 91.1%). Sleep onset latency of 30 minutes or more was self-reported by 46% of the 
participants, with SOL median (IQR) 25 (15, 40) minutes. Participants reported, on 
average, going to bed to sleep at 10:35 PM and getting up from bed at 07:30 AM. 47% of 
the participants reported a fairly bad or very bad subjective sleep quality, only 12.7% 
reported sleepiness and trouble staying awake during daytime once or more a week, and 
12.7% stated that keeping up enthusiasm to get things done was a very big problem. 
The most common cause for disturbed sleep (reported to occur three or more times a 
week) were: bathroom visits (80.7%) and wake up in the middle of night or early morning 
(71.9%), followed by having pain (31.0%), cannot get sleep within 30 minutes (27.1%) 
and feeling too hot (23.2%) (Table 4-3). 
4.3.3 Actigraphy measured sleep characteristics 
Actigraphy data was available for 166 participants. Each participant had 1-6 nights of 
actigraphy data and actigraphy-derived sleep characteristics. These sleep characteristics 
are as follows: sleep duration; sleep efficiency; sleep onset latency (SOL) duration; wake 
after sleep onset (WASO) duration; bedtime; get-up from bed time; sleep onset time and 
wake-up time. Overall actigraphy-derived sleep characteristics per participant were 
estimated by calculating the mean of the daily sleep characteristics.  
Table 4-4 displays a summary of all participants overall actigraphy-derived sleep 
characteristics. Median (IQR) of the overall sleep duration was 7.4 (6.7 to 8.0) hours. 
Overall sleep efficiency had a median of 83.7% and IQR from 76.1% to 87.4%. Median 
(IQR) of the overall SOL was 20.4 (12.2, 35.0) minutes with 31% of the participants 
having SOL duration of 30 minutes or more. The mean actigraphy detected bedtime was 
at 11:11 PM and the mean getting-up from bed time was at 08:10 AM. 
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Table 4-2 Self-reported sleep characteristics 
Total responses; n 181 
PSQI total score; median(IQR) 7 (5,10) 
Poor sleep (PSQI score > 5); n (%) 122 (67.4 %) 
Self-reported  sleep duration (hours)  
Mean (SD) 6.9 (1.5 ) 
Median (IQR) 7 (6,8) 
Sleep efficiency (%); median (IQR)  81.4 (71.0, 91.1) 
SOL duration (minutes); median(IQR) 25 (25) 
Bedtime (HH:MM); mean (SD) 22:35 (01:19) 
Get-up time (HH:MM); mean (SD) 07:30 (01:25) 
Subjective sleep quality; n (%)  
Very good 14(7.7%) 
Fairly good 89 (49.1%) 
Fairly bad 62 (34.3%) 
Very bad 16 (8.8%) 
Trouble staying awake during daytime; n (%)  
Not during the past month 125 (69.1 %) 
Less than once a week 33 (18.2 %) 
Once or twice a week 14 (7.7 %) 
Three or more times a week 9 (5.0 %) 
Keep up enthusiasm to get things done; n (%)  
No problem at all 36 (19.9 %) 
Only a very slight problem 78 (43.1 %) 
Somewhat of a problem 44 (24.3 %) 
A very big problem 23 (12.7 %) 
N.B. (HH:MM) is a 24-hour clock format  
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Table 4-3 Self-reported causes of trouble sleeping among 181 participants as 
stated in the PSQI questionnaire 
Cause 
0 1 2 3 
Cannot get to sleep within 30 minutes 27.6 % 21.0 % 24.3 % 27.1 % 
Wake up in the middle of night or early 
morning 
6.6 % 5.0 % 16.6 % 71.9 % 
Bathroom visits 6.1 % 2.2 % 11.1 % 80.7 % 
Cannot breath comfortably 58.5 % 15.5 % 14.4 % 11.6 % 
Cough or snore loudly 58.6 % 19.3 % 8.3 % 13.8 % 
Feel too cold 74.0 % 13.8 % 11.1 % 1.1 % 
Feel too hot 28.2 % 23.8 % 24.8% 23.2% 
Had bad dreams 54.1 % 27.6 % 13.3 % 5.0% 
Have pain 28.1 % 18.8 % 22.1 % 31.0 % 
(0; not during the past month, 1; less than once a week, 2; once or twice a week, 3; three 
or more times a week)  
 
Table 4-4 Overall actigraphy-measured sleep characteristics 
Available data; n 166 
Sleep duration (hours);  
Mean (SD) 7.3 (1.2) 
Median (IQR) 7.4 (6.7, 8.0) 
Sleep efficiency (%); median (IQR)  83.7 (76.1, 87.4) 
SOL duration (minutes); median(IQR) 20.4 (12.2, 35.0) 
WASO (minutes); median(IQR) 46.1 (31.5) 
Bedtime (HH:MM); mean (SD) 23:11 (01:27) 
Get-up time (HH:MM); mean (SD) 08:10 (01:19) 
Sleep-onset time (HH:MM); mean (SD) 23:39 (01:34) 
Wake-up time (HH:MM); mean (SD) 07:50 (01:20) 
Snooze duration (minutes); median (IQR) 17.3 (15.9) 
N.B. (HH:MM) is a 24-hour clock format 
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4.3.4 Agreement between self-reported and actigraphy-measured 
sleep characteristics 
160 participants had self-reported and actigraphy-measured sleep characteristics data 
available. Agreements between the self-reported and the overall actigraphy-measured 
sleep duration, sleep efficiency, SOL duration, bedtime and getting-up time were tested 
using the Bland-Altman method. Table 4-5 summarises the results and is detailed in the 
sections below (0 and 4.3.4.2). Whilst actigraphy is compared to self-reported sleep 
characteristics throughout, this does not imply that either is considered the ‘gold 
standard’ reference. 
 
Table 4-5 Bland-Altman method agreement result between actigraphy and PSQI 
sleep parameters (n=160) 
Sleep characteristic  
Mean difference 
( Actigraphy- PSQI) 
Limits of 
agreement 
Evaluation 
of 
agreement 
Sleep duration 
(hours; minutes) 
00;27 -02;50 to 03;41 Poor 
Sleep efficiency (%) 2.9 -30.0 to 35.9 Poor 
SOL (minutes) - 3.4 -67.2 to 60.4 Poor 
Bedtime  
(hours; minutes) 
00;38 -01;10 to 02;26 Poor 
Getting-up time 
(hours; minutes) 
00;42 -01;30 to 02;54 Poor 
 
4.3.4.1 Agreement between self-reported and overall actigraphy-measured 
sleep duration 
A systematic bias was detected between actigraphy-derived sleep duration and self-
reported sleep duration with a mean difference of 27 minutes. Poor agreement was 
observed with limit of agreements ranging from -02;50 hours; minutes to 03;41 hours; 
minutes (Figure 4-2). Moreover, a proportional bias was also observed between the two 
tools as the differences in sleep durations assessed by them tended to increase for 
shorter sleep durations and increase for longer sleep durations. Akin actigraphy 
overestimated sleep duration compared to self-reported at lower values of sleep 
duration, where self-reported overestimated sleep duration at higher values of sleep 
duration. Figure 4-3. depicts the linear association between the average self-reported 
and actigraphy-measured sleep durations and their differences. The regression 
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coefficient of this line is -0.45 hour (95% CI -0.68 to -0.22, p-value <0.001) indicate that 
for each 1 hour increase in the average sleep duration there is a statistically significant 
27 minutes less difference between actigraphy and self-reported sleep durations. For 
example, a participant with actigraphy-measured sleep duration of 7.00 hours would 
report 6.55 hours sleep duration, whilst a participant with actigraphy-measured sleep 
duration of 6.00 hours would report 5.10 hours of sleep, and a participant with 
actigraphy-measured sleep duration of 9.00 hours would report 8.55 hours of sleep. 
 
 
Figure 4-2 Bland-Altman plot of agreement between self-reported and actigraphy-
measured sleep durations 
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Figure 4-3 Sleep duration bland-Altman plot with best fitted regression line 
between the average self-reported and actigraphy-measured sleep durations 
and their differences  
 
4.3.4.2 Agreement between self-reported and actigraphy measured-sleep 
efficiency 
Actigraphy estimated a higher sleep efficiency compared to self-reported sleep efficiency 
by 2.9% on average. Poor agreement was observed with a limit of agreement ranging 
from as low as -30.0% to +35.9%. Proportional bias between the average sleep 
efficiencies and their differences was also observed with actigraphy overestimating sleep 
efficiency at lower values of sleep efficiency and underestimating sleep efficiency at 
higher values (Figure 4-4). Simple linear regression modelling between the averages and 
the differences of actigraphy-measured and self-reported  sleep efficiencies revealed a 
decrease of 8.9% in the difference for each 10.0% increase in the average (95% CI -
1.10% to -0.67%, p-value <0.001) (Figure 4-5). For clarification, a participant with 
actigraphy-measured sleep efficiency of 83.00% would report 80.1% sleep efficiency, 
whilst a participant with actigraphy-measured sleep efficiency of 73.00% would report 
61.20% sleep efficiency, and a participant with actigraphy-measured sleep efficiency of 
93.00% would report 99.00% sleep efficiency. 
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Figure 4-4 Bland-Altman plot of agreement between self-reported and actigraphy-
measured sleep efficiency  
 
 
 
Figure 4-5 Sleep efficiency bland-Altman plot with best fitting regression line 
between the average self-reported and actigraphy-measured sleep 
efficiencies and their differences 
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4.3.4.3 Agreement between self-reported and overall actigraphy-measured 
bedtime 
Actigraphy estimated a later bedtime of 37 minutes on average compared to self-
reported bedtime. Poor agreement was observed with a wide limit of agreement ranging 
from 01:10 (hours: minutes) earlier to 02:26 (hours: minutes) later bedtime (Figure 4-6). 
 
 
Figure 4-6 Bland-Altman plot of agreement between self-reported and actigraphy-
measured bedtime 
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4.3.4.4 Agreement between self-reported and overall actigraphy-measured 
getting-up time 
Actigraphy estimated a later getting-up from bedtime of 42 minutes on average 
compared to self-reported bedtime. The limit of agreement was wide ranging from 01:30 
(hours: minutes) earlier to 02:54 (hours: minutes) later getting-up time (Figure 4-7). 
 
 
Figure 4-7 Bland-Altman plot of agreement between self-reported and actigraphy-
measured getting-up time 
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4.3.4.5 Agreement between self-reported and actigraphy-measured SOL 
duration 
Poor agreement was also detected between self-reported and actigraphy measured SOL 
duration. The mean difference was -3.39 minutes, limit of agreement -67.17 minutes to 
60.40 minutes (Figure 4-8).  
 
 
Figure 4-8 Bland-Altman plot of agreement between self-reported and actigraphy-
measured sleep onset latency duration 
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4.3.5 Glycaemic characteristics 
169 participants had at least one full day of CGM data. Glycaemic characteristics were 
defined using CGM summary statistics and using CGM registered daily average-glucose 
curves.  
4.3.5.1 CGM summary statistics 
The overall mean (SD) of daily glucose-average was 5.88 (0.66) mmol/l, while the overall 
mean (SD) of daily glucose-SD was 1.09 (0.35) mmol/l . The mean IQR was from 5.13 
mmol/l to 6.53 mmol/l.  50% of participants had a glucose level within target for 93%- 
100% of the time (i.e. 22:23 (hours: minutes) to 24:00 (hours: minutes) per 24-hour day). 
Furthermore, 50% of the participants spent more than 64 minutes with a glucose level 
above recommended target. 50% of the participants spent 4 minutes or less with a 
glucose level in the hypoglycaemic zone and 25% of the participants spent more than 31 
minutes in the hypoglycaemic zone. The ratio of the hyperglycaemic glucose 
concentration (i.e. glucose-AUC above the target) to the total daily glucose concentration 
ranged between 0% and 11.12%, however it did not exceed 0.44% in half of the 
participants and did not exceed 1.13% in a three quarter of the participants. On the other 
hand, the ratio of the hypoglycaemic glucose concentration (i.e. glucose-AUC below the 
target) to the total daily glucose concentration ranged between 0% and 6.22%, though 
did not exceed 0.004% in fifty percent of participants (Table 4-6). 
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Table 4-6 CGM derived overall summary glycaemic characteristics of 169 
participants  
 
 
  
Mean-glucose (mmol/l); Mean(SD)  5.88 (0.66) 
SD-glucose (mmol/l); Mean(SD)  1.09 (0.35) 
Median-glucose (mmol/l); Mean(SD)  5.74 (0.66) 
25th percentile-glucose (mmol/l); Mean(SD)  5.13 (0.60) 
75th percentile-glucose (mmol/l); Mean(SD)  6.53 (0.80) 
Minimum-glucose (mmol/l); Mean(SD)  3.43 (0.79) 
Maximum-glucose (mmol/l); Mean(SD)  9.74 (1.64) 
Proportion-time  glucose-in target (%); 
Median(IQR); (range) 
 93.26 (87.04,97.22); (32.64, 
100) 
Proportion-time  glucose-above target (%); 
Median (IQR); (range) 
 4.51 (2.08, 10.42); (0.00, 
67.36) 
Proportion-time  glucose-below target (%); 
Median (IQR); (range) 
 0.28 (0.00, 2.20); (0.00, 32.55) 
Minutes  glucose-in target; Median(IQR); 
(range) 
 1342 (1253, 1399); (470, 1440) 
Minutes  glucose-above target; Median 
(IQR); (range) 
 64 (27,138); (0, 970) 
Minutes  glucose-below target; Median 
(IQR); (range) 
 4 (0, 31); (0, 468) 
Ratio glucose-AUC above recommended 
target (%); Median (IQR); (range) 
 0.44 (0.12, 1.13); (0.00, 11.12) 
Ratio glucose-AUC below recommended 
range(%); Median (IQR); (range)  
 0.004 (0.00, 0.14); (0.00, 6.22) 
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4.3.5.2 CGM registered daily average-glucose curves 
Mean and SD 
The mean and SD curves of the participants’ diurnal glucose concentrations are 
presented in Figure 4-9. The mean curve shows some prominent features in the diurnal 
glucose pattern: flattened glucose level overnight (from 02:00 am to 07:15 am), pre-
breakfast (dawn) ridge (from 07:15 am to 7:45 am), breakfast meal peak (from 07:45 am 
to 12:30 pm), lunch meal peak (from 12:30 pm to 06:00 pm) and dinner meal peak (from 
06:00 pm to 02:00 am). 
The mean (SD) at some of these prominent time-points were as follows: mid-way 
overnight (04:00 am) 5.39 (0.79) mmol/l; fasting (08:00 am) 5.46 (0.76) mmol/l; breakfast 
peak (10:00 am) 6.77 (1.08) mmol/l; nadir between breakfast and lunch peaks(12:30 pm) 
5.42 (0.70) mmol/l; lunch peak (03:00 pm) 6.66 (1.04); nadir between lunch and dinner 
peaks (06:00 pm) 5.86 (0.84) mmol/l; and dinner’s peak’s (10:00) 6.48 (0.85) mmol/l. 
Figure 4-9 shows that at the meals’ peak glucose, around 22% of participants’ glucose 
levels were higher than the upper recommended glucose target of 7.8 mmol/l.  
 
Figure 4-9 Registered average-curve curves; overall point-wise mean curve (red), 
±1SD curve (red), and ± 2SD (green curve). Dashed lines demarcate 
recommended ranges; 3.5 mmol/l hypoglycaemic threshold, 5.3 mmol/l 
recommended fasting level and 7.8 mmol/l hyperglycaemic threshold 
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Median and IQR 
A functional box plot of the glucose curves (Figure 4-10) also demonstrates that only 
75% of the curves rested within the recommended range (between 3.5 to 7.8 mmol/l) 
while the upper quarter of participants’ glucose curves stretched above that range. The 
functional box plot also shows that the median glucose curves at 08:00 am were just 
above the fasting recommended target of 5.3 mmol/l and half the participants’ curves 
were above that fasting target. 
 
Figure 4-10 Functional boxplot of registered average-curves. Middle curve is the 
median, pink-shaded area is the interquartile range, inner blue curves are the 
25th and the 75th percentile curves, outer blue curves are the lowest and 
upper range, dashed red curve is an outlier and black dotted lines demarcate 
recommended ranges 
 
Correlation matrix 
The glucose values across all participants, as well as within participants, were highly 
correlated at the period between midnight up to before breakfast with correlation 
coefficients above 0.6. These correlations are displayed as the ‘hot’ yellow and red 
shades on the correlation plots (Figure 4-11). During daytime, correlations were much 
lower and were the least around breakfast and the lunch peaks, displayed as the cold 
blue shades on the correlation plots (Figure 4-11). High correlation coefficients is noticed 
within around 30 minutes of the diagonal line in the correlation plot between 08:00 to 
24:00 HH:MM, indicating high auto-correlation (within-participants correlations) between 
glucose values within 30 minutes.  
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Figure 4-11 2D and 3D filled contour plot of glucose correlation matrix 
142 
 
 
Glucose curves velocity 
The rate of change of glucose values, as estimated by the glucose velocity curves, for all 
participants’ average-glucose curves and the mean glucose velocity curve ±SD curves 
are presented in Figure 4-12 and Figure 4-13, respectively. Positive sections of the 
velocity curves (above the horizontal zero line) represent the speed of uphill side of a 
glucose peak, while negative sections of the velocity curves (below horizontal zero line) 
represent the speed of the downhill side of a glucose peak (Figure 4-14). The mean 
glucose velocity at main meals was as follows: breakfast meal ranged between 0.8 
mmol/l/hour for the uphill side of the glucose peak and -0.8 mmol/l/hour downhill side of 
the glucose peak, lunch meal ranged between 0.7 mmol/l/hour for the uphill side of the 
glucose peak and 0.5 mmol/l/hour for the downhill side of the glucose peak, and dinner 
meal ranged between 0.3 mmol/l/hour for the uphill side of the glucose peak and 0.2 
mmol/l/hour for the downhill side of the glucose peak. 
 
 
 
Figure 4-12 Velocity curves of the 146 participants’ average-glucose curves 
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Figure 4-13 Glucose velocity mean curve (Blue), ±1SD curves (red) and ±2SD 
curves (green) 
 
 
 
Figure 4-14 Mean glucose curve (upper panel) and mean glucose velocity curve 
(lower panel) Green bars separate prominent mean glucose level curve’s 
features and correspondent inflections in the velocity curve, namely; 
overnight level, dawn ridge, breakfast peak, lunch peak and dinner peak. 
Overnight Daw Breakfast Lunch Dinner 
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4.4 Standard regression models results of the associations 
between self-reported and overall actigraphy measured 
sleep characteristics and overall glycaemic characteristics  
4.4.1 Self-reported   sleep characteristics and overall glycaemic 
characteristics  
This section present the results of multiple linear (Table 4-7) and multiple logistic (Table 
4-8) regression models of the association between self-reported  sleep characteristics 
(the predictors); PSQI total score, sleep duration, sleep efficiency, SOL duration, mid-
sleep time and subjective sleep quality rating, and overall summary glycaemic 
characteristics (the outcomes).  
PSQI total score 
Each unit increase in the PSQI total score was associated with a 0.027 mmol/l increase 
in the overall average glucose (Figure 4-15). The association was not statistically 
significant, but model diagnostics showed that participants 170 and 148 were extreme 
outliers and exerted very high residuals (Figure 4-16). Running the adjusted linear model 
after removing the data for these two participants improved the association coefficient 
and gave a statistically significant result (β 0.030; 95% CI 0.005 to 0.056; p-value 0.019). 
Furthermore, the PSQI total score was positively associated with the overall glucose SD 
(β 0.026; 95% CI 0.011 to 0.039; p-value <0.001) (Figure 4-17) 
Participants with a higher PSQI score had a lower odds of spending more than 93% of 
the day within glucose targets (OR 0.90; 95% CI 0.82 to 0.99; p-value 0.037) (Figure 
4-18), and a higher odds of spending more time in the hyperglycaemic zone (OR 1.15; 
95% CI 1.04 to 1.27; p-value 0.008). Moreover, a higher PSQI score was associated with 
a higher odds of having a higher ratio of glucose concentration in the hyperglycaemic 
zone (OR 1.16; 95% CI 1.05 to 1.28; p-value 0.003) 
 
Self-reported sleep duration 
A J-shaped relationship was observed between the self-reported sleep duration and the 
average glucose (Figure 4-19). In reference to 6-8 hours self-reported  sleep duration, 
sleeping less than 6 hours was associated with a 0.21 mmol/l increase in average 
glucose (95% CI -0.167 to 0.379), while sleeping more than 8 hours was associated with 
a 0.410 mmol/l increase in the average glucose (95% CI 0.129 to 0.691). On the other 
hand, a linear relationship was observed between self-reported sleep duration and SD 
glucose with 0.041 mmol/l lower SD glucose for each hour slept (95% CI -0.076 to -
0.005). 
145 
 
No association was observed between self-reported sleep duration and duration of time 
that glucose spent within or above the recommended range. However, each hour longer 
spent asleep lowered the odds of spending time in the hypoglycaemic zone (OR 0.74; 
95% CI 0.58 to 0.94; p-value 0.014). Shorter sleep duration compared to 6-8 hours of 
sleep duration were associated with higher odds of having a higher ratio of glucose 
concentration in hyperglycaemic zone, however the association was not statistically 
significant after adjusting for confounders (OR 2.54 ; 95% CI 0.96 to 6.68). On the other 
hand, each hour increase in the sleep duration was associated with a statistically 
significant lower odds of having a higher ratio of glucose concentration in the 
hypoglycaemic zone (OR 0.76; 95% CI 0.60 to 0.96). 
Self-reported sleep efficiency 
Self-reported sleep efficiency was not associated with average glucose or SD glucose. 
No statistically significant associations were observed with other summary glycaemic 
characteristics except for a lower odds of spending time in the hypoglycaemic zone with 
each 10% increase in self-reported  sleep efficiency (OR 0.78; 95% CI 0.63 to 0.98). 
Self-reported SOL duration 
Self-reported sleep onset latency of 30 minutes or more was associated with a higher 
average glucose (β 0.221; 95% CI 0.022 to 0.421; p-value 0.030) and a higher SD 
glucose (β 0.129; 95% CI 0.021 to 0.237; p-value 0.020). It was also associated with half 
the odds of spending time within the glucose target range (OR 0.48; 95% CI 0.24 to 
0.96) and double the odds of spending time in the hyperglycaemic zone (OR 2.01; 95% 
CI 1.004 to 4.04). Furthermore, it was also associated with a higher odds of having a 
higher ratio of glucose concentration in the hyperglycaemic zone (OR 2.51; 95% CI 1.27 
to 4.96). 
Mid-sleep time 
Later self-reported chronotype (higher mid-sleep time) was not associated with any of 
the overall summary glycaemic characteristics. 
Subjective sleep quality rating 
A deterioration in the participant’s subjective sleep quality rating had a linear association 
with average glucose, with a 0.145 mmol/l higher average glucose for each deterioration 
in rating of subjective sleep quality. However no associations were found with SD 
glucose or other summary glycaemic characteristics. 
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Figure 4-15 Predictive margins and 95% CI of the association between PSQI total 
score and overall average glucose 
 
 
Figure 4-16 Leverage versus normalised residual squared of PSQI total score and 
average glucose multiple linear regression model. The lines on the chart 
show the average values of leverage and the residuals squared. Points above 
the horizontal line have higher-than-average leverage; points to the right of 
the vertical line have larger-than-average residuals 
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Figure 4-17 Predictive margins and 95% CI of the association between PSQI total 
score and overall SD glucose 
 
 
 
 
Figure 4-18 Predictive margins and 95% CI of the association between PSQI total 
score and the probability of spending more time (>93%) within glucose target 
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Figure 4-19 Predictive margins and 95% CI of the association between self-
reported sleep duration and overall average glucose 
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Table 4-7 Linear regression models results of the association between self-reported sleep characteristics and overall average and 
SD glucose  
Glycaemic 
characteristics 
 n=168 Unadjusted models Adjusted models* 
Self-reported  sleep 
characteristics 
β 95% CI p-value β 95% CI p-value 
Average glucose 
(mmol/l) 
PSQI total score** 0.034 0.007 to 0.061 0.014 0.027 -0.001 to 0.054 0.056 
PSQI  sleep duration (hours)       
Short sleep vs. 6-8 hours 0.208 -0.065 to 0.481 0.012 0.106 -0.167 to 0.378 0.017 
Long sleep vs. 6-8 hours 0.414 0.127 to 0.700  0.410 0.129 to 0.690  
PSQI sleep efficiency (10%) -0.014 -0.081 to 0.052 0.670 -0.002 -0.063 to 0.067 0.949 
PSQI SOL duration ≥30 minutes 0.276 0.077 to 0.474 0.007 0.221 0.022 to 0.421 0.030 
PSQI mid-sleep time (hour) -0.066 -0.151 to 0.019 0.127 -0.061 -0.154 to 0.031 0.192 
PSQI subjective sleep quality 
(score) 
0.142 0.011 to 0.273 0.034 0.145 0.018 to 0.272 0.026 
SD glucose 
(mmol/l) 
PSQI total score 0.028 0.014 to 0.042 <0.001 0.026 0.011 to 0.039 <0.001 
PSQI  sleep duration (hours) -0.048 -0.083 to -0.013 0.007 -0.041 -0.076 to -0.005 0.026 
PSQI sleep efficiency (10%) -0.042 -0.076 to -0.001 0.018 -0.003 -0.007 to 0.0002 0.063 
PSQI SOL duration ≥30 minutes 0.148 0.042 to 0.254 0.006 0.129 0.021 to 0.237 0.020 
PSQI mid-sleep time (hour) -0.039 -0.084 to 0.007 0.095 -0.042 -0.092 to 0.008 0.104 
PSQI subjective sleep quality 
(score) 
0.07 -0.01 to 0.14 0.067 0.06 -0.01 to 0.13 0.102 
* Models were adjusted for; age, BMI at booking visit, ethnicity, treatment type, gestational age and recruitment centre 
** Model post estimation diagnostics showed some outliers, adjusted model results after excluding outliers presented in the text  
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Table 4-8 Logistic regression models results of the association between self-reported  sleep characteristics and overall duration 
within/above/ below recommended glucose range and ratio of AUC higher/ lower than the recommended glucose range  
Glycaemic 
characteristics 
 n=168 Unadjusted models  Adjusted models* 
Self-reported  sleep 
characteristics 
OR 95% CI p-value  OR 95% CI p-value 
Higher duration (>93%) 
within recommended 
range 
PSQI total score 0.88 0.80 to 0.96 0.003  0.89 0.81 to 0.99 0.028 
PSQI  sleep duration (hours)        
Short sleep vs. 6-8 hours 0.54 0.23 to 1.28 0.320  0.84 0.320 to 2.212 0.743 
Long  sleep vs. 6-8 hours 0.92 0.38 to 2.21   1.154 0.430 to 3.94  
PSQI sleep efficiency (10%) 1.15 0.94 to 1.41 0.181  1.07 0.85 to 1.33 0.580 
PSQI SOL ≥30 minutes 0.43 0.23 to 0.81 0.008  0.48 0.24 to 0.96 0.038 
PSQI mid-sleep time (hour) 1.21 0.93 to 1.57 0.163  1.27 0.92 to 1.77 0.150 
PSQI subjective sleep quality  0.75 0.50 to 1.12 0.154  0.82 0.53 to 1.28 0.383 
Higher duration (>4.0%) 
above recommended 
range 
PSQI total score 1.16 1.06 to 1.27 0.001  1.15 1.04 to 1.27 0.008 
PSQI  sleep duration        
Short sleep vs. 6-8 hours 2.59 1.07 to 6.24 0.067  1.98 0.74 to 5.27 0.248 
Long sleep vs. 6-8 hours 1.81 0.74 to 4.41   1.68 0.62 to 4.57  
PSQI sleep efficiency (10%) 0.86 0.70 to 1.05 0.140  0.89 0.72 to 1.12 0.346 
PSQI SOL ≥30 minutes 2.29 1.23 to 4.26 0.009  2.01 1.00 to 4.04 0.049 
PSQI mid-sleep time 0.83 0.64 to 1.08 0.172  0.82 0.59 to 1.13 0.226 
PSQI subjective sleep quality 1.39 0.93 to 2.01 0.110  1.39 0.87 to 2.18 0.133 
PSQI total score 1.06 0.97 to 1.14 0.185  1.09 0.99 to 1.19 0.062 
PSQI sleep duration (hours) 0.79 0.64 to 0.98 0.035  0.74 0.58 to 0.94 0.014 
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Higher duration (>0.0%) 
below recommended 
range 
PSQI sleep efficiency (10%) 0.83 0.67 to 1.02 0.081  0.78 0.62 to 0.98 0.033 
PSQI SOL ≥30 minutes 0.97 0.52 to 1.78 0.911  1.14 0.58 to 2.24 0.698 
PSQI mid-sleep time 0.85 0.65 to 1.11 0.243  0.81 0.59 to 1.11 0.184 
PSQI subjective sleep quality 1.09 0.73 to 1.63 0.669  1.18 0.76 to 1.81 0.462 
Higher ratio (>0.43%) of 
AUC above 
recommended range 
PSQI total score 1.17 1.07 to 1.28 0.001  1.16 1.05 to 1.28 0.003 
PSQI  sleep duration         
Short sleep vs. 6-8 hours 3.07 1.24 to 7.58 0.034  2.53 0.96 to 6.68 0.131 
Long sleep vs. 6-8 hours 1.81 0. 74 to  4.41   1.66 0.63 to 4.35  
PSQI sleep efficiency (10%) 0.81 0.66 to 1.01 0.057  0.85 0.68 to 1.06 0.153 
PSQI SOL ≥30 minutes 2.68 1.43 to 5.03 0.002  2.51 1.27 to 4.96 0.008 
PSQI mid-sleep time 0.88 0.68 to 1.14 0.323  0.90 0.66to 1.24 0.527 
PSQI subjective sleep quality 1.43 0.95 to 2.14 0.087  1.39 0.90 to 2.16 0.142 
Higher ratio (>0.0%) of 
AUC below 
recommended range 
PSQI total score 1.04 0.96 to 1.13 0.324  1.07 0.97 to 1.18 0.154 
PSQI sleep duration (hours) 0.81 0.65 to 0.99 0.048  0.76 0.60 to 0.96 0.023 
PSQI sleep efficiency (10%) 0.89 0.72 to 1.08 0.242  0.83 0.66 to 1.03 0.097 
PSQI SOL ≥30 minutes 0.86 0.47 to 1.58 0.628  1.04 0.53 to 2.06 0.910 
PSQI mid-sleep time 0.86 0.66 to 1.11 0.248  0.85 0.61 to 1.16 0.286 
PSQI subjective sleep quality 1.08 0.73 to 1.61 0.695  1.17 0.76 to 1.82 0.479 
*Models were adjusted for; age, BMI at booking visit, ethnicity, treatment type, gestational age and recruitment centre 
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4.4.2 Overall actigraphy measured sleep characteristics and overall 
glycaemic characteristics  
This section presents the results of multiple linear and multiple logistic regression models 
of the association between overall actigraphy measured sleep characteristics (the 
predictors): sleep duration, sleep efficiency, SOL duration, mid-sleep time and WASO 
duration, and overall summary glycaemic characteristics (the outcomes).  
A negative linear relationship was detected between the actigraphy measured sleep 
duration and the SD glucose (β -0.060; 95% CI -0.110 to -0.010; p-value 0.019). 
Furthermore, a higher actigraphy sleep efficiency was associated with a lower SD 
glucose (β -0.113; 95% CI -0.177 to -0.050; p-value 0.001), and an actigraphy SOL 
duration ≥ 30 minutes was associated with a higher SD glucose (β 0.178; 95% CI 0.058 
to 0.298; p-value 0.004). On the other hand, no association, neither linear nor U-shaped, 
between the actigraphy measured sleep duration and the overall average glucose was 
detected using multiple linear regression. Moreover, none of the actigraphy measured 
sleep characteristics was associated with the overall average glucose. 
Furthermore, an actigraphy SOL duration ≥ 30 minutes was associated with a lower odds 
of spending time within the recommended glucose targets (OR 0.43; 95% CI 0.19 to 
0.96). Each 10 minute increase in WASO duration was associated with a16% higher 
odds of having a glucose concentration above the recommended targets (Figure 4-20).  
Other associations were not statistically significant. The actigraphy mid-sleep time was 
not associated with the summary glycaemic measures. 
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Figure 4-20 Predictive margins and 95% CI of the association between WASO 
duration and the probability of having higher concentration of glucose above 
recommended target  
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Table 4-9 Linear regression models results of the association between actigraphy measured sleep characteristics and overall 
average and SD glucose  
* Models were adjusted for; age, BMI at booking visit, ethnicity, treatment type, gestational age and recruitment centre 
  
Glycaemic 
characteristics 
 
 n=153 Unadjusted models  Adjusted models* 
Actigraphy sleep 
characteristics 
β 95% CI p-value  β 95% CI p-value 
Overall average 
glucose (mmol/l) 
Actigraphy sleep duration 
(hours) 
0.027 -0.068 to 0.122 0.576  0.039 -0.055 to 0.132 0.415 
Actigraphy sleep efficiency 
(10%) 
-0.099 -0.217 to 0.019 0.101  -0.075 -0.196 to 0.046 0.208 
Actigraphy SOL ≥30 minutes 0.104 -0.126 to 0.333 0.372  0.123 -0.103 to 0.348 0.285 
Actigraphy mid-sleep time 
(hours) 
0.055 -0.028 to 0.137 0.193  0.040 -0.050 to 0.131 0.381 
Actigraphy WASO (10 
minutes) 
0.056 0.014 to 0.097 0.009  0.048 0.005 to 0.091 0.028 
Overall SD glucose 
(mmol/l) 
Actigraphy sleep duration 
(hours) 
-0.053 -0.102 to -0.003 0.036  -0.060 -0.110 to -0.010 0.019 
Actigraphy sleep efficiency 
(10%) 
-0.101 -0.169 to -0.048 0.001  -0.113 -0.177 to -0.050 0.001 
Actigraphy SOL ≥30 minutes 0.167 0.049 to 0.285 0.006  0.178 0.058 to 0.298 0.004 
Actigraphy mid-sleep time 
(hours) 
0.041 -0.002 to 0.088 0.061  0.044 -0.004to 0.092 0.070 
Actigraphy WASO (10 minutes) 0.024 0.001 to 0.046 0.037  0.021 -0.002 to 0.045 0.075 
155 
 
Table 4-10 Logistic regression models results of the association between actigraphy measured sleep characteristics and overall 
duration within/above/ below recommended glucose range and ratio of AUC higher/ lower than the recommended glucose 
range  
Glycaemic characteristics 
 
n=153 Unadjusted models  Adjusted models* 
 Actigraphy sleep characteristics OR 95% CI p-value  OR 95% CI p-value 
Higher duration (>93%) 
within recommended 
range 
Actigraphy sleep duration (hours) 1.06 0.80 to 1.41 0.670  1.06 0.77 to 1.47 0.713 
Actigraphy sleep efficiency (10%) 1.45 0.99 to 2.12 0.056  1.42 0.93 to 2.17 0.108 
Actigraphy SOL ≥30 minutes 0.48 0.24 to 0.96 0.038  0.43 0.19 to 0.96 0.038 
Actigraphy mid-sleep time (hours) 0.82 0.64 to 1.06 0.126  0.82 0.59 to 1.14 0.239 
Actigraphy WASO (10 minutes) 0.90 0.79 to 1.03 0.133  0.92 0.79 to 1.07 0.318 
Higher duration (>4.0%) 
above recommended 
range 
 
Actigraphy  sleep duration (hours) 1.06 0.80 to 1.40 0.700  1.09 0.79 to 1.51 0.595 
Actigraphy sleep efficiency (10%) 0.73 0.50 to 1.06 0.095  0.77 0.51 to 1.18 0.239 
Actigraphy SOL ≥30 minutes 1.49 0.75 to 2.97 0.248  1.52 0.69 to 3.34 0.293 
Actigraphy mid-sleep time (hours) 1.23 0.95 to 1.59 0.110  1.17 0.85 to 1.61 0.340 
Actigraphy WASO (10 minutes) 1.16 1.02 to 1.34 0.024  1.15 0.98 to 1.35 0.096 
Higher duration (0.28%) 
below recommended 
range 
Actigraphy sleep duration (hours) 1.03 0.78 to 1.37 0.814  1.00 0.74 to 1.36 0.975 
Actigraphy sleep efficiency (10%) 1.01 0.71 to 1.44 0.954  0.92 0.61 to 1.37 0.686 
Actigraphy SOL ≥30 minutes 1.03 0.52 to 2.04 0.928  1.01 0.48 to 2.12 0.975 
Actigraphy mid-sleep time (hours) 0.91 0.71 to 1.17 0.466  0.91 0.68 to 1.23 0.540 
Actigraphy WASO (10 minutes) 0.95 0.84 to 1.08 0.425  0.98 0.85 to 1.13 0.784 
Higher ratio (>0.43%) of 
AUC above recommended 
range 
Actigraphy  sleep duration (hours) 1.05 0.79 to 1.39 0.79  1.05 0.77 to 1.43 0.757 
Actigraphy sleep efficiency (10%) 0.76 0.53 to 1.10 0.152  0.78 0.52 to 1.17 0.222 
Actigraphy SOL ≥30 minutes 1.44 0.73 to 2.85 0.296  1.57 0.75 to 3.34 0.232 
Actigraphy mid-sleep time (hours) 1.17 0.91 to 1.51 0.211  1.18 0.87 to 1.61 0.285 
Actigraphy WASO (10 minutes) 1.17 1.02 to 1.34 0.026  1.16 1.00 to 1.36 0.049 
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Higher ratio (>0.00%) of 
AUC below recommended 
range 
Actigraphy sleep duration (hours) 0.91 0.69 to 1.21 0.531  0.89 0.65 to 1.21 0.445 
Actigraphy sleep efficiency (10%) 0.98 0.69 to 1.40 0.928  0.85 0.56 to 1.28 0.443 
Actigraphy SOL ≥30 minutes 0.96 0.49 to 1.89 0.906  0.92 0.43 to 1.97 0.837 
Actigraphy mid-sleep time (hours) 0.91 0.71 to 1.16 0.452  0.96 0.71 to 1.30 0.787 
Actigraphy WASO (10 minutes) 0.92 0.81 to 1.05 0.231  0.97 0.84 to 1.12 0.646 
* Models were adjusted for; age, BMI at booking visit, ethnicity, treatment type, gestational age and recruitment centre 
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4.5 Multilevel regression models results for the association 
between self-reported and daily actigraphy measured sleep 
characteristics and daily glycaemic characteristics  
4.5.1 Multilevel regression models results for the association 
between self-reported sleep characteristics and daily glycaemic 
characteristics  
This section presents the results of multilevel mixed effect linear (Table 4-11) and mixed 
effect logistic (Table 4-12) regression models of the association between self-reported  
sleep characteristics (the predictors); PSQI total score, sleep duration, sleep efficiency, 
SOL duration, mid-sleep time and subjective sleep quality rating, and daily summary 
glycaemic characteristics (the outcomes). Models were adjusted for weekend/weekday in 
addition to the set used in the overall study. Only complete dataset used in these 
analyses as CGM data intervals (days) were defined using daily actigraphy bedtime and 
getting-up time. The dataset consisted of 149 participants with 795 days, 1-6 days per 
participant. Multilevel mixed effect regression models for the analysis of this data had an 
improved fit over ordinary, only fixed term, regression models ( log likelihood p-value 
<0.001). The variance partition coefficient (VPC) ranged between 50% and 60% for the 
linear models and the intra-class correlation coefficient (ICC) ranged between 36% and 
40% for the logistic models. 
PSQI total score 
A higher PSQI total score was associated with: a higher SD glucose (β 0.022; 95% CI 
0.009 to 0.036; p-value 0.001); a lower odds of spending more than 93% of the daily time 
within the recommended glucose target (OR 0.89, 95% CI 0.81 to 0.97, p-value 0.010); a 
higher odds of spending more than 4% of the daily time above the recommended 
glucose target (OR 1.15; 95% CI 1.05 to 1.26; p-value 0.003); and a higher odds of 
having a higher ratio of glucose concentration (>0.43%) in the hyperglycaemic zone (OR 
1.18; 95% CI 1.08 to 1.30; p-value <0.001). Moreover, a higher PSQI was associated 
with a higher, but statistically non-significant, average glucose (β 0.018; 95% CI -0.011 to 
0.047; p-value 0.230). However, the model post estimation caterpillar residuals plot 
revealed participant 170 to be a potential outlier (Figure 4-21). Running the model while 
excluding participant 170 improved the model coefficients (β 0.029; 95% CI 0.002 to 
0.057; p-value 0.037). 
Self-reported sleep duration 
Compared to sleeping 6-8 hours, sleeping more than 8 hours was associated with 0.483 
mmol/l higher average glucose (95% CI 0.161 to 0.744). Sleeping less than 6 hours was 
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associated with, a non-statistically significant, 0.151 increase in average glucose (Figure 
4-22). Each hour increase in the sleep duration was associated with a 0.045 mmol/l 
decrease in the SD glucose (95% CI -0.064 to -0.002). Furthermore, both long and short 
sleep duration, compared to 6-8 hours, had lower odds of spending more than 93% of 
the time within glucose recommended targets, higher odds of spending more time above 
the recommended targets and higher odds of having higher concentration of glucose in 
hyperglycaemic zones. However none of these associations were statistically significant.  
Lastly, the longer the sleep duration the less likely the participants were to develop 
hypoglycaemia.  
Self-reported SOL duration  
Self-reported  sleep onset latency duration of 30 minutes or more was associated with: a 
0.301 mmol/l (95% CI 0.028 to 0.442) increase in daily average glucose; a 0.121 mmol/l 
(95% CI 0.007 to 0.199) increase in the daily SD glucose; a 62% (95% CI 0.20 to 0.73) 
lower odds of spending time within the glucose target range; more than twice the odds 
(95% CI 1.20 to 4.31) of spending more time in the hyperglycaemic zone; and three 
times the odds (95% CI 1.59 to 5.91) of having a higher ratio of glucose concentration 
above the recommended range. 
No statistically significant associations were observed between self-reported sleep 
efficiency, self-reported mid-sleep time and subjective sleep quality rating, with daily 
summary glycaemic measures. 
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Figure 4-21 Caterpillar plot of PSQI and average glucose model’s residuals with 
very high residuals for participant number 170 
 
 
Figure 4-22 Predictive margins and 95% CI of the association between self-
reported sleep duration and daily average glucose  
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Table 4-11 Multilevel linear regression models results of the association between self-reported sleep characteristics and daily 
average and SD glucose 
. participants=149 Unadjusted models fixed effects Adjusted models* fixed effects Adjusted models random effect 
Main exposure β 95% CI p-value β 95% CI p-value 
SD between 
participants 
(95% CI) 
SD within 
participants 
(95% CI) 
VPC** 
(95% CI) 
Daily average glucose (mmol/l) models 
PSQI total score 0.027 -0.00 to 0.057 0.070 0.018 -0.011 to 0.047 0.230 
0.58 
(0.51 to 0.66) 
0.47 
(0.45 to 0.51) 
0.60 
(0.53 to 0.66) 
PSQI  sleep duration***   
0.005 
  
0.009 
   
Short sleep  0.151 -0.131 to 0.433 0.031 -0.244 to 0.306 0.56 
(0.49 to 0.64) 
0.48 
(0.45 to 0.51) 
0.60 
(0.51 to 0.65) Long sleep  0.483 0.21 to 0.85 0.453 0.161 to 0.744 
PSQI sleep efficiency 
(10%) 
-0.001 -0.072 to 0.070 0.979 0.015 -0.053 to 0.083 0.664 
0.59 
(0.51 to 0.67) 
0.48 
(0.45 to 0.51) 
0.60 
(0.53 to 0.67) 
PSQI SOL ≥30 minutes 0.301 0.089 to 0.513 0.005 0.235 0.028 to 0.442 0.026 
0.57 
(0.50 to 0.65) 
0.48 
(0.45 to 0.51) 
0.59 
(0.51 to 0.65) 
PSQI mid-sleep time 
(hours) 
-0.047 -0.143 to 0.049 0.337 -0.056 -0.156 to 0.045 0.278 
0.58 
(0.51 to 0.66) 
0.48 
(0.45 to 0.51) 
0.60 
(0.53 to 0.66) 
PSQI subjective sleep 
quality score 
0.093 -0.048 to 0.234 0.198 0.103 -0.033 to 0.239 0.136 
0.58 
(0.51 to 0.66) 
0.48 
(0.45 to 0.51) 
0.60 
(052 to 0.66) 
Daily SD glucose (mmol/l) models 
PSQI total score 0.026 0.013 to 0.040 <0.001 0.022 0.009 to 0.036 0.001 
0.25 
(0.22 to 0.29) 
0.25 
(0.24 to 0.26) 
0.50 
(0.43 to 0.58) 
PSQI  sleep duration 
(hours) 
-0.045 -0.077 to -0.013 0.006 -.033 -0.064 to -0.002 0.038 
0.25 
(0.22 to 0.29) 
0.25 
(0.24 to 0.26) 
0.50 
(0.43 to 0.58) 
PSQI sleep efficiency 
(10%) 
-0.034 -0.066 to -0.002 0.040 -0.024 -0.056 to 0.007 0.126 
0.26 
(0.23 to 0.30) 
0.25 
(0.24 to 0.26) 
0.52 
(0.44 to 0.59) 
PSQI SOL ≥30 minutes 0.121 0.021 to 0.221 0.017 0.103 0.007 to 0.199 0.035 
0.26 
(0.22 to 0.29) 
0.25 
(0.24 to 0.26) 
0.51 
(0.44 to 0.59) 
PSQI mid-sleep time 
(hours) 
-0.028 -0.072 to 0.0170 0.225 -0.021 -0.067 to 0.025 0.365 
0.26 
(0.23 to 0.30) 
0.25 
(0.24 to 0.26) 
0.52 
(0.44 to 0.59) 
PSQI subjective sleep 
quality score 
0.051 -0.014 to 0.116 0.127 0.044 -0.019 to 0.107 0.172 
0.26 
(0.23 to 0.30) 
0.25 
(0.24 to 0.26) 
0.52 
(0.44 to 0.59) 
* Models were adjusted for; age, BMI at booking visit, ethnicity, treatment type, gestational age, weekend and recruitment centre. ** Variance partition 
coefficient.*** compared to 6-8 hours of sleep.  
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Table 4-12 Logistic regression models results of the association between self-reported  sleep characteristics and overall duration 
within/above/ below recommended glucose range and ratio of AUC higher/ lower than the recommended glucose range 
participants=149 Unadjusted models fixed 
effects 
Adjusted models* fixed effects Adjusted models random effects 
Main exposure OR 95% CI p-value OR 95% CI p-value Variance component 
(95% CI) 
ICC** 
(95% CI) 
Higher duration (>93%) within recommended range models 
 PSQI total score 0.84 0.77 to 0.94 0.001 0.89 0.81 to 0.97 0.010 2.15 (1.30 to 3.56) 0.40 (0.28 to 0.52) 
PSQI  sleep duration         
Short sleep vs. 6-8 hours 0.30 0.12 to 0.75 0.014 0.47 0.20 to 1.11 0.114 2.01 (1.34 to 3.64) 0.40 (0.29 to 0.53) 
Long sleep vs. 6-8 hours 0.39 0.14 to 1.05 0.50 0.20 to 1.24 
PSQI sleep efficiency (10%) 1.15 0.91 to 1.45 0.236 1.05 0.86 to 1.31 0.596 2.32 (1.41 to 3.79) 0.41 (0.30 to 0.54) 
PSQI SOL ≥30 minutes 0.31 0.15 to 0.62 0.001 0.38 0.20 to 0.73 0.003 2.12 (1.28 to 3.51) 0.39 (0.28 to 0.52) 
PSQI mid-sleep time (hours) 1.14 0.84 to 1.53 0.398 1.20 0.88 to 1.61 0.238 2.08 (1.28 to 3.39) 0.39 
(0.28 to 0.51) 
PSQI subjective sleep 
quality score 
0.71 0.46 to 1.10 0.131 0.73 0.49 to 1.10 0.135 2.01 (1.23 to 3.29) 0.38 (0.27 to 0.50) 
Higher duration (>4.0%) above recommended range models 
PSQI total score 1.18 1.07 to 1.30 0.001 1.15 1.05 to 1.26 0.003 2.07 (1.27 to 3.38) 0.39 (0.28 to 0.51) 
PSQI  sleep duration         
Short sleep vs. 6-8 hours 2.18 0.87 to 5.48 0.131 1.53 0.64 to 3.64 0.355 2.20 (1.36 to 3.55) 0.40 (0.29 to 0.52) 
Long sleep vs. 6-8 hours 2.09 0.76 to 5.70 1.78 0.71 to 4.46  
PSQI sleep efficiency (10%) 0.87 0.69 to 1.09 0.213 0.92 0.74 to 1.13 0.401 2.22 (1.31 to 3.46) 0.39 (0.29 to 0.51) 
PSQI SOL ≥30 minutes 2.67 1.34 to 5.34 0.005 2.27 1.20 to 4.31 0.012 2.23 (1.38 to 3.61) 0.40 (0.29 to 0.52) 
PSQI mid-sleep time (hours) 0.90 0.66 to 1.23 0.519 0.95 0.67 to 1.30 0.778 2.29 (1.42 to 3.70) 0.40 (0.30 to 0.53) 
PSQI subjective sleep 
quality score 
1.42 0.90 to 2.24 0.128 1.46 0.95 to 2.22 0.083 2.20 (1.38 to 3.56) 0.40 (0.29 to 0.52) 
Higher duration (>0.0%) below recommended range models 
PSQI total score 1.01 0.92 to 1.12 0.778 1.00 0.90 to 1.11 0.906 1.98 (1.00 to 3.95) 0.37 (0.23 to 0.55) 
PSQI  sleep duration          
Short sleep vs. 6-8 hours 1.78 0.72 to 4.40 0.035 1.70 0.69 to 4.21 0.021 1.60 (0.76 to 3.37) 0.32 (0.19 to 0.51) 
Long sleep vs. 6-8 hours 0.26 0.07 to 0.95  0.22 0.06 to 0.80  
PSQI sleep efficiency (10%) 0.94 0.74 to 1.20 0.629 0.96 0.75 to 1.21 0.707 1.98 (1.00 to 3.94) 0.38 (0.23 to 0.55) 
PSQI SOL ≥30 minutes 0.65 0.31 to 1.38 0.261 0.64 0.31 to 1.34 0.242 1.89 (0.96 to 3.85) 0.37 (0.23 to 0.54) 
PSQI mid-sleep time (hours) 0.79 0.56 to 1.11 0.173 0.77 0.54 to 1.11 0.161 1.84 (0.90 to 3.71) 0.36 (0.21 to 0.53) 
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PSQI subjective sleep 
quality score 
1.01 0.62 to 1.65 0.959 0.93 0.56 to 1.53 0.777 1.98 (1.00 to 3.94) 0.38 (0.23 to 0.54) 
Higher ratio (>0.43%) of AUC above recommended range models 
PSQI total score 1.15 1.06 to 1.25 0.001 1.18 1.08 to 1.30 <0.001 2.13 (1.27 to 3.58) 0.39 (0.27 to 0.52) 
PSQI  sleep duration         
Short sleep vs. 6-8 hours 2.78 1.05 to 7.40 0.069 1.94 0.79 to 4.80 0.248 2.38 (1.44 to 3.93) 0.42 (0.30 to 0.54) 
Long sleep vs. 6-8 hours 2.14 0.76 to 6.07  1.70 0.66 to 4.34    
PSQI sleep efficiency (10%) 0.78 0.61 to 0.99 0.046 0.83 0.66 to 1.03 0.092 2.38 (1.44 to 3.93) 0.42 (0.30 to 0.54) 
PSQI SOL ≥30 minutes 3.43 1.66 to 7.11 0.001 3.06 1.59 to 5.91 0.001 2.16 (1.30 to 3.61) 0.40 (0.28 to 0.52 
PSQI mid-sleep time (hours) 0.87 0.63 to 1.22 0.434 0.93 0.68 to 1.29 0.688 2.44 (1.48 to 4.03) 0.42 (0.30 to 0.54) 
PSQI subjective sleep 
quality score 
1.32 0.88 to 1.98 0.179 1.41 0.95 to 2.08 0.086 2.38 (1.44 to 3.93) 0.42 (0.31 to 0.55) 
Higher ratio (>0.0%) of AUC below recommended range models 
PSQI total score 1.01 0.92 to 1.12 0.778 1.00 0.90 to 1.11 0.906 1.98 (0.99 to 3.95) 0.37 (0.23 to 0.54) 
PSQI  sleep duration         
Short sleep vs. 6-8 hours 1.78 0.72 to 4.40 0.035 1.70 0.68 to 4.21 0.021 1.60 (0.76 to 3.38) 0.33 (0.19 to 0.51) 
Long sleep vs. 6-8 hours 0.26 0.07 to 0.94  0.22 0.06 to 0.80    
PSQI sleep efficiency (10%) 0.94 0.74 to 1.20 0.629 0.96 0.75 to 1.21 0.707 1.97 (0.99 to 3.93) 0.37 (0.23 to 0.54) 
PSQI SOL ≥30 minutes 0.65 0.31 to 1.38 0.261 0.64 0.31 to 1.41 0.242 1.89 (0.94 to 3.81) 0.37 (0.23 to 0.54) 
PSQI mid-sleep time (hours) 0.79 0.56 to 1.11 0.173 0.77 0.54 to 1.11 0.161 1.84 (0.90 to 3.71) 0.36 (0.21 to 0.53) 
PSQI subjective sleep 
quality score 
1.01 0.62 to 1.65 0.959 0.93 0.56 to 1.53 0.787 1.98 (0.99 to 3.94) 0.37 (0.23 to 0.54) 
* Models were adjusted for; age, BMI at booking visit, ethnicity, treatment type, gestational age, weekend and recruitment centre.  
** Residual intraclass correlation. 
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4.5.2 Multilevel regression models results for the association 
between daily actigraphy measured sleep characteristics and 
daily glycaemic characteristics 
This section presents the multilevel mixed effects models results; linear models (Table 
4-13) and logistic models (Table 4-14), of the association between actigraphy measured 
sleep indices during each night to the following days glycaemic characteristics (from 
getting up from bed to getting up the next day). The data consists of 795 nights and 795 
days for 149 participants with 1-6 nights/days per participant. Likelihood-ratio tests 
comparing the multilevel models to ordinary linear and logistic regression models were 
highly significant (p-value < 0.001). VPC for linear models ranged between 52% and 
60%, and residuals ICC for logistic models ranged between 37% and 42%. 
Short actigraphy measured sleep duration, compared to 6-8 hours of sleep, was 
associated with a higher average glucose the following day (β 0.119; 95% CI 0.004 to 
0.234) and a higher SD glucose the following day(β 0.064; 95% CI 0.004 to 0.124). 
However the Wald test p-values of the joint statistical significant of sleep categories 
(short, 6-8 hours, and long) as a whole was not conclusive, 0.089 and 0.091 
respectively. Furthermore, short sleep duration had a higher odds of hyperglycaemia and 
lower odds of being within the target range. None of these associations were statistically 
significant.  
Sleep onset latency of 30 minutes or more was associated with a 0.127 mmol/l higher 
average glucose the following day (95% CI 0.037 to 0.216; p-value 0.006). It was also 
associated with a slightly higher SD glucose and lower odds of being in the glucose 
target range and a higher odds of hyperglycaemia. None of these associations were 
statistically significant.  
Each 10% increase in sleep efficiency was associated with an 18% lower odds of having 
a high ratio of glucose above the recommended target (95% CI 0.67 to 1.00; p-value 
0.049).  Furthermore, later chronotype had: a lower odds of hypoglycaemia; a lower odds 
of spending time below the recommended glucose target (OR 0.72; 95% CI 0.55 to 0.95; 
p-value 0.014) and a lower odds of a high ratio of glucose concentration below the 
recommended target (OR 0.72; 95% CI 0.55 to 0.94; p-value 0.014). 
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Table 4-13 Multilevel linear regression models results of the association between actigraphy measured sleep characteristics and 
daily average and SD glucose 
n=795, cluster=149 Unadjusted models fixed effects  Adjusted models* fixed effects Adjusted models random effect 
Main exposure 
β 95% CI 
p-
value 
 
β 95% CI 
p-
value 
SD between 
cluster 
(95% CI) 
SD within 
cluster 
(95% CI) 
VPC** 
(95% CI) 
Daily average glucose (mmol/l) 
Actigraphy sleep duration           
Short sleep vs. 6-8 
hours 
0.129 0.013 to 0.244 
0.070 
 
0.119 0.004 to 0.234 
0.089 
0.58 
(0.51 to 0.66) 
0.48 
(0.45 to 0.51) 
0.60 
(0.53 to 0.66) Long sleep vs. 6-8 
hours 
0.060 -0.035 to 0.148 
 
0.059 -0.032 to 0.151 
Actigraphy sleep 
efficiency (10%) 
-0.016 -0.054 to 0.022 0.403 
 
-0.014 -0.052 to 0.024 0.471 
0.58 
(0.51 to 0.67) 
0.48 
(0.45 to 0.51) 
0.60 
(0.53 to 0.66) 
Actigraphy SOL ≥30 
minutes 
0.127 0.038 to 0.217 0.005 
 
0.127 0.037 to 0.216 0.006 
0.58 
(0.51 to 0.66) 
0.48 
(0.45 to 0.50) 
0.60 
(0.53 to 0.66) 
Actigraphy WASO (10 
minutes) 
-0.006 -0.020 to 0.007 0.378 
 
-0.006 -0.021 to 0.007 0.342 
0.59 
(0.51 to 0.67) 
0.48 
(0.45 to 0.51) 
0.60 
(0.53 to 0.66) 
Actigraphy mid-sleep 
time (hours) 
0.031 -0.010 to 0.072 0.142 
 
0.030 -0.015 to 0.075 0.198 
0.58 
(0.51 to 0.67) 
0.48 
(0.45 to 0.51) 
0.59 
(0.52 to 0.66) 
Daily SD glucose (mmol/l) 
Actigraphy sleep duration           
Short sleep vs. 6-8 
hours 
0.061 0.001 to 0.121 
0.045 
 
0.064 0.004 to 0.124 
0.091 
0.26 
(0.23 to 0.30) 
0.25 
(0.24 to 0.26) 
0.52 
(0.44 to 0.60) Long sleep vs. 6-8 
hours 
0.028 -0.020 to 0.075 
 
0.026 -0.021 to 0.074 
Actigraphy sleep 
efficiency (10%) 
0.001 -0.018 to 0.021 0.918 
 
0.000 -0.018 to 0.020 0.952 
0.26 
(0.23 to 0.30) 
0.25 
(0.24 to 0.26) 
0.53 
(0.44 to 0.60) 
Actigraphy SOL ≥30 
minutes 
0.032 -0.015 to 0.078 0.185 
 
0.032 -0.014 to 0.079 0.173 
0.26 
(0.23 to 0.30) 
0.25 
(0.24 to 0.26) 
0.52 
(0.44 to 0.60) 
Actigraphy WASO (10 
minutes) 
0.000 -0.007 to 0.007 0.988 
 
-0.000 -0.007 to 0.007 0.986 
0.26 
(0.23 to 0.30) 
0.25 
(0.24 to 0.26) 
0.52 
(0.44 to 0.60) 
Actigraphy mid-sleep 
time (hours) 
0.006 -0.015 to 0.027 0.593 
 
0.004 -0.019 to 0.027 0.774 
0.26 
(0.23 to 0.30) 
0.25 
(0.24 to 0.26) 
0.52 
(0.44 to 0.60) 
* Models were adjusted for; age, BMI at booking visit, ethnicity, treatment type, gestational age, recruitment centre and weekend.  
** Variance partition coefficient.  
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Table 4-14 Multilevel logistic regression models results of the association between actigraphy measured sleep characteristics 
and daily duration within/above/ below recommended glucose range and ratio of AUC higher/ lower than the recommended 
glucose range 
n=795, cluster=149 Unadjusted models fixed effects Adjusted models* fixed effects Adjusted models random effect 
Main exposure 
OR 95% CI p-value OR 95% CI p-value 
variance 
component (95% 
CI) 
ICC** 
(95% CI) 
Higher duration (>93%) within recommended range models 
Actigraphy sleep duration       
2.04 (1.25 to 3.32) 0.38 (0.27 to 0.50) Short sleep vs. 6-8 hours 0.84 0.48 to 1.48 0.831 0.91 0.511 to 1.59 0.923 
Long sleep vs. 6-8 hours 0.94 0.60 to 1.48  0.94 0.59 to 1.46  
Actigraphy sleep efficiency 
(10%) 
1.17 0.97 to 1.42 0.109 1.14 0.95 to 1.37 0.168 2.00 (1.22 to 3.27) 0.38 (0.27 to 0.50) 
Actigraphy SOL ≥30 minutes 0.66 0.42 to 1.03 0.067 0.66 0.42 to 1.03 0.067 2.01 (1.23 to 3.29) 0.38 (0.28 to 0.50) 
Actigraphy mid-sleep time 
(hours) 
0.89 0.74 to 1.06 0.178 0.91 0.75 to 1.10 0.326 2.00 (1.22 to 3.27) 0.38 (0.28 to 0.51) 
Actigraphy WASO (10 minutes) 0.96 0.90 to 1.03 0.262 0.97 0.90 to 1.04 0.390 2.01 (1.23 to 3.30) 0.39 (0.28 to 0.50) 
Higher duration (>4.0%) above recommended range models 
Actigraphy sleep duration       
2.23 (1.38 to 3.62) 0.40 (0.30 to 0.52) Short sleep vs. 6-8 hours 1.32 0.74 to 2.37 0.185 1.23 0.69 to 2.17 0.723 
Long sleep vs. 6-8 hours 1.11 0.70 to 1.76  1.14 0.72 to 1.79  
Actigraphy sleep efficiency 
(10%) 
0.86 0.70 to 1.04 0.119 0.86 0.71 to 1.04 0.135 2.20  (1.35 to 3.55) 0.40 (0.29 to 0.52) 
Actigraphy SOL ≥30 minutes 1.39 0.89 to 2.19 0.151 1.39 0.89 to 2.19 0.154 2.21 (1.37 to 3.57) 0.40 (0.29 to 0.52) 
Actigraphy mid-sleep time 
(hours) 
1.12 0.94 to 1.35 0.210 1.17 0.96 to 1.42 0.112 2.18 (1.34 to 3.53) 0.40 (0.29 to 0.52) 
Actigraphy WASO (10 minutes) 1.04 0.97 to 1.11 0.318 1.03 0.96 to 1.11 0.357 2.20  (1.36to 3.57) 0.40 (0.29 to 0.52) 
Higher duration (>0.0%) below recommended range models 
Actigraphy sleep duration       1.95 (0.97 to 3.90) 0.37 (0.23 to 0.54) 
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Short sleep vs 6-8 hours 0.73 0.34 to 1.55 0.414 0.76 0.35 to 1.62 0.593 
Long sleep vs. 6-8 hours 0.80 0.44 to 1.49  0.75 0.41 to 1.39  
Actigraphy sleep efficiency 
(10%) 
1.13 0.87 to 1.45 0.358 1.10 0.86 to 1.42 0.446 1.97 (0.99 to 3.93) 0.38 (0.23 to 0.54) 
Actigraphy SOL ≥30 minutes 1.00 0.54 to 1.84 0.999 1.04 0.56 to 1.92 0.896 1.99 (0.99 to 3.97) 0.38 (0.23 to 0.55) 
Actigraphy mid-sleep time 
(hours) 
0.83 0.66 to 1.04 0.108 0.72 0.55 to 0.95 0.014 2.18 (1.09 to 4.36) 0.40 (0.25 to 0.57) 
Actigraphy WASO (10 minutes) 0.97 0.89 to 1.07 0.551 0.98 0.90 to 1.08 0.710 1.97 (0.99 to 3.92) 0.37 (0.23 to 0.54) 
Higher ratio (>0.43%) of AUC above recommended range models 
Actigraphy sleep duration       
2.46 (1.49 to 4.06) 0.43 (0.31 to 0.55) Short sleep vs. 6-8 hours 1.69 0.92 to 3.10 0.192 1.59 0.88 to 2.90 0.249 
Long sleep vs. 6-8 hours 1.29 0.80 to 2.07  1.28 0.80 to 2.05  
Actigraphy sleep efficiency 
(10%) 
0.83 0.67 to 1.02 0.078 0.82 0.67 to 1.00 0.049 2.30 (1.38 to 3.81) 0.41 (0.30 to 0.54) 
Actigraphy SOL ≥30 minutes 1.13 0.71 to 1.79 0.615 1.16 0.73 to 1.83 0.531 2.40 (1.45 to 3.97) 0.42 (0.32 to 0.55) 
Actigraphy mid-sleep time 
(hours) 
1.05 0.87 to 1.27 0.629 1.10 0.90 to 1.35 0.325 2.37 (1.44 to 3.93) 0.42 (0.30 to 0.54) 
Actigraphy WASO (10 minutes) 1.05 0.97 to 1.13 0.189 1.05 0.98 to 1.13 0.149 2.36 (1.43 to 3.90) 0.42 (0.30 to 0.54) 
Higher ratio (>0.0%) of AUC below recommended range models 
Actigraphy sleep duration       
1.95 (0.97 to 3.90) 0.37 (0.23 to 0.54) Short sleep vs. 6-8 hours 0.72 0.34 to 1.55 0.634 0.76 0.35 to 1.62 0.593 
Long sleep vs. 6-8 hours 0.80 0.43 to 1.49  0.77 0.41 to 1.39  
Actigraphy sleep efficiency 
(10%) 
1.13 0.87 to 1.45 0.358 1.10 0.86 to 1.41 0.446 1.97 (0.99 to 3.93) 0.38 (0.23 to 0.54) 
Actigraphy SOL ≥30 minutes 1.00 0.54 to 1.84 0.999 1.04 0.56 to 1.92 0.896 1.98 (0.99 to 3.97) 0.38 (0.23 to 0.55) 
Actigraphy mid-sleep time 
(hours) 
0.83 0.66 to 1.04 0.108 0.72 0.55 to 0.94 0.014 2.18 (1.09 to 4.36) 0.40 (0.25 to 0.57 
Actigraphy WASO (10 minutes) 0.97 0.89 to 1.07 0.551 0.98 0.90 to 1.08 0.710 1.97 (0.99 to 3.91) 0.37 (0.23 to 0.54) 
* Models were adjusted for; age, BMI at booking visit, ethnicity, treatment type, gestational age, weekend and recruitment centre.  
** Residual intraclass correlation.  
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4.6 Function-on-scalar regression models results for the 
association between self-reported and overall actigraphy 
measured sleep characteristics and average-glucose curves 
This section presents the results from the functional regression models where self-
reported sleep characteristics from the PSQI questionnaire and the actigraphy-measured 
sleep characteristics were used to explain variation in the CGM glucose curves. The 
outcome in these models was the registered average-glucose curves.  All models were 
adjusted for the same set of confounders used in the ordinary regression models.146 
participants with at least two days of complete CGM recoding were included in this 
analysis. 
4.6.1 Functional regression models results for the association 
between self-reported sleep characteristics and the average-
glucose curves 
4.6.1.1 PSQI total score model 
Each single score increase in the PSQI total score was associated with a 0.06 mmol/l 
increase in the glucose level (95% CI 0.01 to 0.10) at the lunch peak (Figure 4-23). 
Higher than zero regression beta coefficient was also observed at other times of the day 
although the association was only statistically significant at the lunch peak time. 
 
Figure 4-23 Functional regression model coefficient curve; PSQI total score and 
glucose curves  
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4.6.1.2 Self-reported   sleep duration models 
Different relationships between self-reported sleep duration and the glucose level at 
different times of the day were observed. The functional regression model with self-
reported sleep duration linear term only (Figure 4-24) revealed a linear positive 
relationship between the self-reported sleep duration and the glucose level overnight (at 
05:00 am; β 0.08 mmol/l increase in glucose level for each hour slept; 95% CI 0.01 to 
0.15) and at the nadir between breakfast and lunch peaks (at 12:30 pm; β 0.12 mmol/l 
increase in glucose level for each hour slept; 95% CI 0.05 to 0.20).  
 
Figure 4-24 Functional regression model coefficient curve of linear term only self-
reported sleep duration and glucose curves  
 
On the other hand, the functional regression model with combined linear and quadratic 
(squared self-reported  sleep) terms of self-reported  sleep duration revealed a U-shaped 
relationship at other parts of the day (Figure 4-26); immediately after midnight (at 12:30 
am; linear term (β -0.61; 95% CI  -1.10 to -0.21); quadratic term ( β 0.05; 95% CI 0.02 to 
0.08)), at breakfast peak (at 08:30 am;  linear term (β -0.55; 95% CI  -0.92 to -0.20); 
quadratic term (β 0.04; 95% CI 0.02 to 0.08)),  and at the nadir between lunch and dinner 
peaks (at 06:00 pm; linear term (β -0.48; 95% CI  -0.88to -0.09); quadratic term (β 0.04; 
95% CI 0.01 to 0.07)). Figure 4-26 displays this U-shaped relationship at 08:30 am. Self-
reported sleep duration of around 5-8 hours predicted the lowest glucose level. 
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Figure 4-25 Functional regression model coefficient curves of the association 
between self-reported  sleep duration combined linear term (upper panel) and 
quadratic term (lower panel), and glucose curves  
 
 
 
Figure 4-26 U-shaped relationship of predicted glucose level at 08:30 am and self-
reported sleep duration (For participant with mean age, mean BMI, white 
ethnicity, 31 weeks of gestation, nulliparous, on diet management only and 
recruited from Leeds centre) 
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4.6.1.3 Self-reported  SOL duration model  
A Self-reported SOL duration of 30 minutes or more compared to shorter SOL duration 
was associated with having higher glucose levels overnight (at 02:00 am; β 0.37; 95% CI 
0.10 to 0.64), at the lunch peak (at 03:00 pm; β 0.45; 95% CI 0.12 to 0.77) and at the 
dinner peak (at 08:00 pm; β 0.50; 95% CI 0.20 to 0.80) (Figure 4-27). 
 
Figure 4-27 Functional regression model coefficient curve; self-reported SOL 
duration of 30 minutes or more and glucose curves 
 
4.6.1.4 Self-reported sleep efficiency model 
Each 10% increase in self-reported sleep efficiency was associated with a 0.1 mmol/l 
increase in glucose level at 12:30 pm (95% CI 0.04 to 0.12). 
 
Figure 4-28 Functional regression model coefficient curve; self-reported sleep 
efficiency (10%) and glucose curves  
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4.6.1.5 Self-reported mid-sleep time model 
Each one hour later mid-sleep time was associated with a 0.19 mmol/l higher glucose 
level overnight, but lower glucose at the breakfast and dinner peaks, 0.16mmol/l and 
0.21 mmol/l respectively (Figure 4-29). 
 
Figure 4-29 Functional regression model coefficient curve; Mid-sleep time (hours) 
and glucose curves 
 
4.6.1.6 Subjective sleep quality rating model 
Each deterioration in the subjective sleep quality rating was associated with a 0.22 
mmol/l increase in the glucose level at the lunch peak (Figure 4-30). 
 
 Figure 4-30 Functional regression model coefficient curve; Subjective sleep 
quality rating and glucose curves Subjective sleep quality rating 
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4.6.2 Functional regression models results for the association 
between actigraphy measured sleep characteristics and the 
average-glucose curves 
4.6.2.1 Actigraphy measured sleep duration models 
The functional regression model with actigraphy measured sleep duration (linear term 
only) revealed a negative association between the sleep duration and the glucose level 
just after midnight, as each hour slept longer was associated with a 0.11 mmol/l lower 
glucose level (95% CI -0.03 to -0.28) (Figure 4-31). In other parts of the day, the 
coefficient curve was above zero indicating a positive linear association, however the 
confidence range passed the zero no association line.  
 
 
Figure 4-31 Functional regression model coefficient curve of actigraphy measured 
sleep duration, linear term only, and glucose curves 
 
On the other hand, the regression model with combined linear and quadratic terms of 
actigraphy measured sleep duration revealed a  J-shaped association with the glucose 
curves observed at the nadir between the breakfast and lunch peaks (at 12:15 pm; linear 
term (β -1.10; 95% CI -0.35 to -1.85); quadratic term (β 0.085, 95% CI 0.035 to 0.135)) 
(Figure 4-32). This J-shaped relationship is displayed in Figure 4-33.   
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Figure 4-32 Functional regression model coefficient curves of association between 
actigraphy measured sleep duration combined linear term (upper panel) and 
quadratic term (lower panel), and glucose curves  
 
 
Figure 4-33 J-shaped relationship of predicted glucose level at 12:30 pm and 
actigraphy measured sleep duration (For participant with mean age, mean 
BMI, white ethnicity, 31 weeks of gestation, nulliparous, on diet management 
only and recruited from Leeds centre) 
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4.6.2.2 Actigraphy measured SOL duration model 
An actigraphy measured SOL duration of 30 minutes or more was not associated with 
higher glucose levels compared to a shorter SOL duration. 
 
Figure 4-34 Functional regression model coefficient curve; actigraphy measured 
SOL duration of 30 minutes or more and glucose curves 
 
4.6.2.3 Actigraphy measured sleep efficiency model 
Higher sleep efficiency was associated with having lower glucose levels in many parts of 
the day (Figure 4-35). However this association was statistically significant, for each 10 
% increase in the efficiency, at the time period between midnight and 04:00 am (at 12:30 
am; β -0.25, 95% CI -0.08 to -0.41), after the pre-breakfast ridge (at 07:45 am; β -0.15, 
95% CI -0.02 to -0.26), and after the lunch peak (at 03:30 pm; β -0.20, 95% CI -0.02 to -
0.38).  
 
Figure 4-35 Functional regression model coefficient curve; actigraphy measured 
sleep efficiency (10%) and glucose curves 
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4.6.2.4 Actigraphy mid-sleep time model 
The functional regression coefficient curve of the association between the mid-sleep time 
and the glucose curve showed a negative association after midnight and a positive 
association at the dinner peak (Figure 4-36). Each hour later mid-sleep time was 
associated with a 0.09 mmol/l lower glucose level at 12:30am (95% CI -0.05 to -0.14) 
and a 0.05 mmol/l higher glucose level at 08:00 pm (95% CI 0.00 to 0.09).  
 
Figure 4-36 Functional regression model coefficient curve; actigraphy measured 
sleep mid-sleep time (hours) and glucose curves 
 
4.6.2.5 WASO model 
Each 10 minutes longer WASO duration was associated with a 0.05 mmol/l (95% CI 0.02 
to 0.12) higher glucose level in most parts of the day except at the breakfast peak and 
around mid-night (Figure 4-37). 
 
Figure 4-37 Functional regression model coefficient curve; actigraphy measured 
WASO (10 minutes) and glucose curves 
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4.7 Function-on-scalar regression models results for the 
association between self-reported and actigraphy measured 
sleep characteristics and the glucose velocity curves 
This section presents results from the functional regression models where self-reported 
sleep characteristics from PSQI questionnaire and actigraphy measured sleep 
characteristics were used to explain variation in the CGM glucose velocity curves. The 
outcome in these models was the velocity curve of the registered average-glucose curve.  
All models were adjusted for the same set of confounders used in the ordinary 
regression models.146 participants with at least two days of complete CGM recordings 
were included in this analysis. As velocity curves have positive upturns and negative 
downturns, interpreting the regression coefficient is not as simple as interpreting the 
regression coefficient in section 0. A positive coefficient indicates an increase in value of 
positive speed (meaning a faster ascending side of the glucose peak) however it 
indicates a smaller value of the negative speed (meaning a slower descending side of 
the glucose peak) (Table 4-15). On the other hand, a negative coefficient indicates less 
positive speed value (meaning a slower ascent) and a more negative speed value 
(meaning a faster descent). Coefficient curves will be presented together with the 
intercept curve of the functional regression model to facilitate interpretation. The 
intercept curves represent the model’s adjusted mean velocity curve for participants of 
mean age, mean BMI, mean gestational age, nulliparous, white ethnicity, on diet 
management only and recruited from the Leeds centre 
   
 
 
Regression’s coefficient sign 
Positive Negative 
Glucose velocity 
sign 
Positive Faster ascend Slower ascend 
Negative Slower descend Faster descend 
Table 4-15 Key table of how to interpret the regression coefficients of glucose 
velocity functional regression models 
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4.7.1 Function-on-scalar regression models results for the 
association between self-reported sleep characteristics and the 
glucose velocity curves 
4.7.1.1 PSQI total score and velocity curves 
A higher PSQI total score (indicating poorer sleep quality) associated with a faster 
ascent and descent of the glucose peak at lunch time (Figure 4-38); each unit increase in 
PSQI total score is associated with a 0.041 mmol/l/hour (95% CI 0.022 to 0.061) and a 
0.025 mmol/l/hour (95% CI 0.005 to 0.045) increase in the speed of the ascent and 
descent of the glucose peak at lunch time, respectively. A higher PSQI total score was 
also associated with a slower ascent of the breakfast peak. 
 
Figure 4-38 Functional regression model’s coefficient (upper panel) and intercept 
(lower panel) curves of the association between PSQI total score and glucose 
velocity curves 
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4.7.1.2 Self-reported sleep duration and velocity curves 
Each hour increase in self-reported sleep duration is associated with a slower dawn 
ridge (β -0.04; 95% CI -0.05 to -0.01), faster ascent but slower descent of the breakfast 
peak (β -0.04; 95% CI -0.05 to -0.01) and (β 0.04; 95% CI 0.01 to 0.07) respectively, and 
a slower ascent of lunch peak (β -0.07; 95% CI -0.13 to -0.03).  
 
Figure 4-39 Functional regression model’s coefficient (upper panel) and intercept 
(lower panel) curves of the association between self-reported sleep duration 
(hours) and glucose velocity curves 
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4.7.1.3 Self-reported sleep efficiency (10%) 
Higher self-reported  sleep efficiency was associated with: increased velocity of the 
glucose curve overnight indicating a slower descent, increased velocity of the ascending 
side of the breakfast peak (at 09:30 am; β 0.05, 95% CI 0.01 to 0.09), while no 
association with the velocity of the descending side of the peak. Higher sleep efficiency 
was also associated with a slower ascent and descent of the lunch peak (at 02:00 pm; β 
-0.09, 95% CI -0.01 to -0.12) and (at 04:15 pm; β 0.06, 95% CI 0.02 to 0.10), 
respectively. Furthermore, a slower descent of the glucose level overnight (at 04:00 am; 
β 0.03, 95% CI 0.01 to 0.0.05) for each 10% increase in self-reported sleep efficiency 
was also visible (Figure 4-40).   
 
 
Figure 4-40 Functional regression model’s coefficient (upper panel) and intercept 
(lower panel) curves of the association between self-reported  sleep 
efficiency (10%) and glucose velocity curves 
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4.7.1.4 Self-reported SOL 
Self-reported  SOL of 30 minutes or more was associated with a slower ascent of the 
breakfast peak (at 08:15 am; β -0.17, 95% CI -0.04 to -0.24), a faster descent of the 
lunch peak (at 04:15 pm; β -0.21, 95% CI -0.11 to -0.31), but a slower ascent and 
descent of the dinner peak, (at 09:00 pm; β -0.27, 95% CI -0.12 to -0.40) and (at 12:15 
am; β 0.18, 95% CI 0.05 to 0.30), respectively (Figure 4-41). 
 
 
Figure 4-41 Functional regression model’s coefficient (upper panel) and intercept 
(lower panel) curves of the association between self-reported SOL (> 30 
minutes) and glucose velocity curves 
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4.7.1.5 Self-reported mid-sleep time 
A later self-reported mid-sleep time was associated with a faster descent in glucose level 
overnight (at 03:00 am; β -0.05, 95% CI -0.03 to -0.09), a slower ascent at dawn (at 
06:00 am; β -0.03, 95% CI -0.04 to -0.10) and a slower descent of the dinner peak (at 
11:00 pm; β 0.10, 95% CI 0.04 to 0.14) (Figure 4-42). Furthermore, a later self-reported 
mid-sleep time was associated with a slower descent of the glucose level at the nadir 
between the breakfast and lunch peaks (at 12:15pm), but a faster descent of the glucose 
levels at the nadir between the lunch and dinner (at 07:30pm). 
 
Figure 4-42 Functional regression model’s coefficient (upper panel) and intercept 
(lower panel) curves of the association between self-reported mid-sleep time 
(hours) and glucose velocity curves 
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4.7.1.6 Self-reported subjective sleep quality rating 
Subjective rating of sleep quality was not associated with the glucose level the following 
day (Figure 4-43). 
 
 
Figure 4-43 Functional regression model’s coefficient curve of the association 
between self-reported subjective sleep quality rating and glucose velocity 
curves 
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4.7.2 Function-on-scalar regression models results for the 
association between actigraphy measured sleep characteristics 
and the glucose velocity curves 
4.7.2.1 Actigraphy measured sleep duration 
The actigraphy sleep duration predictor and glucose curves velocity outcome linear 
functional regression model showed that longer sleep duration was associated with a 
lower rate of change of glucose level before the breakfast meal (at 07:30 am; β -0.08, 
95% CI -0.12 to -0.04), as well as a slower downhill descent of lunch and dinner peaks, 
(at 06:00 pm; β 0.07, 95% CI 0.01 to 0.12) and (at 01:00 am; β 0.10, 95% CI 0.05 to 
0.14), respectively (Figure 4-44). 
 
 
Figure 4-44 Functional regression model’s coefficient (upper panel) and intercept 
(lower panel) curves of the association between actigraphy measured sleep 
duration (hours) and glucose velocity curves 
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4.7.2.2 Actigraphy measured SOL duration 
Thirty minutes or more actigraphy measured SOL duration, compare to less than 30 
minutes, was associated with a 0.14 mmol/l/hour (95% CI 0.05 to 0.28) faster ascent of 
the glucose level at the dinner peak (Figure 4-45). 
 
Figure 4-45 Functional regression model’s coefficient (upper panel) and intercept 
(lower panel) curves of the association between actigraphy measured SOL 
duration, thirty minutes or more compared to less than thirty minutes, and 
glucose velocity curves 
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4.7.2.3 Actigraphy measured sleep efficiency (10%) 
Each 10% increase in actigraphy measured sleep efficiency was associated with a 0.12 
mmol/l (95% CI 0.04 to 0.19) increase in the ascending speed of the breakfast peak. 
Furthermore, better (higher) sleep efficiency was associated with a slower descent of the 
glucose level overnight (Figure 4-46). 
  
Figure 4-46 Functional regression model’s coefficient (upper panel) and intercept 
(lower panel) curves of the association between actigraphy measured sleep 
efficiency (10%) and glucose velocity curves 
 
  
186 
 
4.7.2.4 Actigraphy mid-sleep time 
Later mid-sleep time (hours) was associated with a 0.02 mmol/l/hour (95% CI 0.04 to 
0.01) slower rate of change of the glucose level at the nadir between the breakfast and 
lunch peaks but a 0.04 mmol/l/hour (95% CI 0.02 to 0.05) faster rate of change at the 
nadir between the lunch and dinner peaks (Figure 4-47). Moreover, it was associated 
with a 0.03 (95% CI 0.02 to 0.04) slower descent of the glucose level overnight. 
 
 
Figure 4-47 Functional regression model’s coefficient (upper panel) and intercept 
(lower panel) curves of the association between actigraphy measured sleep 
duration (hours) and glucose velocity curves 
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4.7.2.5 WASO 
Higher WASO duration (per 10 minutes) was associated with a slower ascent of the 
breakfast glucose peak (at 08:00 am; β -0.04; 95% CI -0.08 to -0.03) and a faster 
descent of the dinner glucose peak (at 10:00 pm; β -0.03; 95% CI -0.06 to -0.02) (Figure 
4-48). 
 
Figure 4-48 Functional regression model’s coefficient (upper panel) and intercept 
(lower panel) curves of the association between actigraphy measured WASO 
(10 minutes) and glucose velocity curves 
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4.8 Association between glucose level before and around 
bedtime and actigraphy measured sleep characteristics  
4.8.1 Actigraphy measured sleep duration 
All available daily glucose curves were aligned to bedtime to examine if the glucose level 
around bedtime, 2 hours before bedtime and the first 2 hours in bed, had any association 
with the subsequent actigraphy measured sleep duration. The dataset consisted of 792 
glucose curves from 146 participants with 2-6 glucose curves per participant. Figure 4-49 
displays the mean glucose curves of the daily glucose curves that preceded long 
(>8hours), short (<6 hours) and average (6-8hours) actigraphy measured sleep duration. 
The mean glucose curve of the daily glucose curves that preceded the long sleep 
duration had about 0.25 mmol/l on average higher glucose levels around bedtime 
compared to the mean glucose curve of the daily glucose curves that preceded average 
sleep duration. On the contrary, glucose levels, around bedtime, of the mean glucose 
curve of the daily glucose curves that preceded short sleep duration were almost 
identical to the glucose levels of the mean glucose curve of the daily glucose curves that 
that preceded the average sleep duration. However, a permutation t-test of the 
differences were not statistically significant. Figure 4-50 depict that around bedtime the 
observed t statistics (red curve) did not exceed the statistically significant maximum 0.05 
critical value (barred blue line). Values prior to 2-hours before bedtime glucose curves 
were not registered to meal peaks, and as such a difference in the glucose levels earlier 
in the day could not be explored. 
 
Figure 4-49 Mean glucose curves of daily glucose curves that preceded long, short 
and average actigraphy measured sleep duration Higher glucose levels 
around bedtime was followed by longer actigraphy measured sleep duration 
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Figure 4-50 Permutation t-test for the difference between: mean glucose curves of 
daily glucose curves that preceded short and average actigraphy measured 
sleep duration (upper panel), and mean glucose curves of daily glucose 
curves that preceded long and average actigraphy measured sleep duration 
(lower panel) 
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4.8.2  Other actigraphy measured sleep characteristics  
Scalar-on-function regression models, where glucose curves are the predictor of the 
regression models, of the associations between the glucose curves level around bedtime 
and actigraphy measured sleep efficiency, WASO or SOL durations showed no 
associations (Figure 4-51).  
 
Sleep efficiency
 
WASO 
 
Sleep onset latency
 
Figure 4-51 Functional on scalar regression models’ coefficients curves of the 
associations between glucose curves levels around bedtime and actigraphy 
measured sleep efficiency, WASO duration and SOL duration 
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Chapter 5 Discussion 
The research presented in this thesis is the first to examine the association between 
sleep and glucose control in GDM, with complete data records for 152 participants, 
assessing sleep characteristics using both subjective (PSQI) and objective (actigraphy) 
tools, using CGM to closely observe glucose control and applying FDA to analyse the 
CGM data. The key novel findings are that among pregnant women with GDM: 1) Poor 
sleep quality measured using PSQI total score was positively associated with higher 
glucose amplitude, more variability and faster rate-of-change; 2) Self-reported and 
actigraphy-derived sleep durations had a U-shaped association with glucose 
concentrations (though not sustained in all the statistical methods) and a positive 
association with glucose rate-of-change; and 3) Applying FDA methods to CGM data 
was practical and advantageous in extracting valuable detail and information . 
These main findings support the underlying stated hypothesis of this thesis, that:  
‘Sleep disturbances, such as short or long sleep duration, and lower sleep 
quality, increase the amplitude and variability of blood glucose in pregnant 
women with gestational diabetes (GDM).’ 
 
This current chapter summarises the research findings and compares them to other 
published studies, discusses the statistical methods used, sets out the study limitations, 
and expands on the study's clinical implications and future perspectives. 
5.1 Summary of the study findings 
This section outlines the main findings and discusses them in reference to other studies’. 
The order of discussing these findings is in the same order as the objectives enumerated 
in chapter one. For clarity the objectives were to:  
6- Evaluate sleep in pregnant women with gestational diabetes subjectively using 
the PSQI questionnaire and objectively using actigraphy gauging the agreement 
between the two tools derived sleep characteristics. 
7- Assess glycaemic control in pregnant women with gestational diabetes using 
CGM. 
8- Apply FDA methods to daily glucose curves derived from CGM data. 
9- Examine the association of subjective and objective sleep characteristics with 
glucose control using: a) the CGM derived summary indices and b) FDA of daily 
glucose curves. 
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10- Explore the causal direction of the relationship between sleep and glucose by 
also examining the association between glucose levels immediately prior to 
sleep, with the characteristics of that subsequent night’s sleep. 
5.2 Assessing sleep  
5.2.1 Actigraphy versus self-reported sleep 
This study assessed sleep in pregnant women with GDM by using the PSQI 
questionnaire (a subjective tool) and actigraphy (an objective tool) to measure various 
sleep characteristics. Although they are both supposedly measuring sleep, their 
comparative values with regards to sleep duration, SOL duration, sleep efficiency, 
bedtime, and getting-up from bed time had poor agreement between them. These results 
are broadly consistent with previous research on agreement between: PSQI and 
actigraphy (the SenseWear Pro Armband) sleep characteristics in women (Segura-
Jimenez et al., 2015); self-reported sleep duration and actigraphy (The Basic Mini 
Motionlogger Actigraph) in adolescents (Guedes et al., 2016); and PSQI and actigraphy 
(Actiwatch-16) in young adults (Lauderdale et al., 2008). Concurring with my results, 
Lauderdale et al. (2008) reported both systematic and proportional biases between self-
reported and actigraphy sleep duration in young adults. Studies during pregnancy have 
also revealed discordance between self-reported and actigraphy-measured sleep 
characteristics. Herring et al. (2013) found poor agreement between self-reported sleep 
duration from PSQI questionnaire and actigraphy-measured sleep duration (Actiwatch-
64) among pregnant women at 18 to 25 weeks of gestation. They reported a limit of 
agreement ranging from around -4 hours to +4 hours and a systematic bias of 25 
minutes. However, in contrast to the results of this study it was the self-reported sleep 
duration that overestimated the actigraphy-derived sleep duration. Furthermore, among 
pregnant women in their third trimester Tsai et al. (2012a) reported an average 22 
minutes longer self-reported sleep duration than actigraphy-derived sleep duration (using 
Actiwatch2 device). Bei et al. (2010) did not observe systematic bias but they reported 
no correlation between the two measures of sleep among pregnant women in their third 
trimester.  
The discrepancy between sleep characteristics assessed by either tool is expected. 
Each one of these tools is capturing different facets of sleep architecture and the validity 
of both tools are jeopardised by several limitations. Self-reported sleep characteristics 
are totally subjective and they suffer from recall bias. This bias could be a differential one 
(i.e. varies between individuals) as individuals with certain conditions or sleep disorders 
may recall their sleep experience (like sleep duration, SOL and frequency of disturbed 
night sleep) more vividly than individuals with a relatively better sleep experience. 
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Furthermore, individuals may round their sleep duration to the nearest 15 minutes 
(reporting 6.5, 6.45, 7.00 and so forth) and SOL to the nearest minutes (reporting 10, 15, 
20 and so forth). Individuals may also report a typical 'stand out' night rather than an 
average of more usual nights (Girschik et al., 2012). Nevertheless, during pregnancy the 
PSQI's psychometric properties (i.e. reliability and validity of the PSQI tool) showed good 
internal consistency (i.e. the PSQI component scores are closely related as a group) as 
evaluated by Cronbach's alpha reliability statistic >0.7, test-retest reliability (evaluated by 
intra class correlation coefficient) and construct validity (assessed by confirmatory factor 
analysis) (Skouteris et al., 2009; Jomeen and Martin, 2007; Qiu et al., 2016). The 
construct validity was improved further after excluding the use of sleep medication score 
(Jomeen and Martin, 2007). 
Actigraphy measures inactivity as an indicator of sleep, Whilst inactivity is a symptom of 
sleep some individuals with insomnia can keep still in bed while awake for prolonged 
period of time (de Souza et al., 2003; Stone and Ancoli-Israel, 2011). Actigraphy's ability 
to identify immobile wake status is frail and this impacts on its accuracy in assessing 
sleep in individuals with insomnia. On the other hand, pregnant women often experience 
restlessness while asleep as they feel uncomfortable staying in one position. The impact 
of pregnancy mobility while in bed on the accuracy of actigraphy in assessing sleep is 
unknown.  Actigraphy was found to underestimate total sleep time duration in a 
population of restless individuals with severe obstructive sleep apnoea, usually having 
frequent apnoea-related movement while asleep (Kim et al., 2013b). Validation studies 
on actigraphy against polysomnography during pregnancy are lacking and warrant future 
investigation.  
Polysomnography is still considered the ‘gold standard’ for measuring sleep and would 
have been the tool of choice to validate the actigraphy, as it can delineate sleep stages 
and the amount of time spent in deep sleep and it uses different techniques to define 
sleepiness and wakefulness. However, polysomnography is expensive, usually 
laboratory-based, and measures sleep for a limited period of time within an artificial 
environment. Moreover, it requires an expert technician to administer and attach its 
electrodes to the participants and then to read its output. It was not practical to use it in 
this study, which aimed to assess women in their usual home environment for a week at 
a time. It is also worth noting that neither polysomnography nor actigraphy can capture 
the individuals’ perception and satisfaction with the sleep experiences they had, which 
the PSQI does. This study's results and the results of the aforementioned studies among 
pregnant women do not imply any preference for self-reported or actigraphy sleep 
measurements tools, rather they support assessing sleep in pregnant women by using 
both tools. 
194 
 
5.2.2 Sleep characteristics  
The median self-reported and actigraphy-measured sleep duration in this study were 7 
hours and 7.4 hours, respectively. 25% of the participants reported sleeping less than 6 
hours of sleep per night, 25% reported sleeping more than 8 hours, and only 5% 
reported a sleep duration more than 9 hours. The median WASO duration was 46.1 
minutes and the other self-reported and actigraphy-derived sleep characteristics were as 
follows: median sleep efficiency 81.4% and 83.7%; median SOL duration 25 minutes and 
20.4 minutes; mean bedtime 22:35 HH:MM and 23.11 HH:MM, and mean get-up from 
bed time 07:30 HH:MM and 08:10 HH:MM, respectively. These results are in line with 
previously published results among pregnant women (Tsai et al., 2016c; Lee, 1998; 
Facco et al., 2010b; Twedt et al., 2015; Reid et al., 2017). 
Twedt et al. (2015) used actigraphy (Actiwatch Spectrum, Phillips Respironics) to 
objectively assess sleep in 37 pregnant women with gestational diabetes. Data were also 
analysed using the Actiware software and the algorithm set to medium threshold, similar 
to my study, and revealed a median sleep duration of 6.8 hours. Out of the 213 recorded 
nights; 46.3% of the nights showed sleep durations >5 and ≤7 hours, 37.8% of them 
showed sleep durations >7and ≤9 hours,  11% showed sleep durations < 5 hours and 
4.8% showed sleep durations > 9 hours sleep duration. However the proportions of 
participants with overall short or long sleep duration were not reported. Objective sleep 
duration in pregnant women without diabetes has also been assessed. Data were 
collected from a large US cohort (n=782) using actigraphy (Actiwatch Spectrum, Phillips 
Respironics) before the 23rd week of gestation and analysed using the same medium 
threshold (Reid et al., 2017).  86.8% had valid actigraphy records (of those invalid 
records; 40% were due to watch failure and 60% were due to participants 
noncompliance). They reported the following actigraphy-derived sleep characteristics: 
median sleep duration 7.4 hours, median sleep efficiency 85.2%, median WASO 42.2 
minutes, and median sleep-midpoint 03:38 am. 27.9% of the pregnant women in this 
study had a sleep duration of <7 hours and 2.9% had a sleep duration of > 9 hours.  
Whilst among 2427 pregnant women responding to an internet-based PSQI 
questionnaire in the USA, across all months of pregnancy the mean self-reported sleep 
duration was 6.75 hours and 37.9% reported sleeping 6 hours or less. Those 
respondents in their 7th month of pregnancy had a mean self-reported sleep duration of 
6.63 hours and 40.1% of them reported sleeping 6 hours or less (Mindell et al., 2015). 
Another cohort at 30 weeks of gestation had a mean self-reported sleep duration of 7.0 
hours and 39.9% of them had short sleep duration (<7 hours) (Facco et al., 2010b) 
Furthermore, studies of self-reported sleep duration and quality in the general population 
have also presented similar figures. A British cohort of 224 non-pregnant women aged 
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49-54 years reported a mean sleep duration of almost 7 hours,  and a median sleep 
efficiency of 85% (IQR 75% to 91%) (Leng et al., 2014). Among 103 993 adults aged 37–
63 years with no diabetes or cardiovascular diseases recruited from 2007 to 2010 into 
the UK Biobank cohort, 21.3% reported <7 hours sleep and 5.3% reported > 8 hours of 
sleep (Cassidy et al., 2016). Analysis of sleep data collected at wave 1 (2009-2011) of 
the UK Household Longitudinal Study Surveys (n=16427) revealed a mean sleep 
duration of 7.4 hours in adult participants aged 16-63 years. 56% of participants reported 
sleeping between seven and less than nine hours per night. 35% slept less than seven 
hours per night and 10% slept nine hours or more. Moreover, 22% of the participants 
rated their sleep quality as bad (Barnes et al., 2013). Among women aged between 16-
60 years participating in the survey (n=9215), 78.6 % slept 6-8 hours, 9.8% slept <6 
hours and 11.6% slept >9 hours. Around 10% of women participants aged between 16-
44 years reported sleeping less than 6 hours and 25% of them rated their sleep quality 
as bad  (Meadows and Arber, 2011).  
Comparing sleep duration in aged-matched pregnant and non-pregnant women using 
the UK Household Longitudinal Study Surveys, Alafif et al. (2016) demonstrated that 
pregnant women had higher risk of reporting both short sleep <7hours (RRR 1.22) and 
long sleep >9 (RRR 1.45) compared to non-pregnant women. Pregnant women were 
also more likely to report bad sleep quality (RRR 1.6) and to report more difficulty staying 
awake during the day (RRR 1.28) compared to non-pregnant women. 
In summary, sleep duration and sleep quality in pregnant women with GDM obtained in 
this study seem to be very similar to that obtained from other studies involving pregnant 
women with and without GDM. Pregnant women are more likely to have shorter and 
longer sleep durations, and poorer sleep quality than non-pregnant women. However, to 
my knowledge there is no published study comparing sleep in pregnant women with 
established GDM and pregnant women without diabetes. 
5.2.3 Sleep quality as assessed by PSQI total score 
More than 67% of the study participants had poor sleep quality as indicated by a PSQI 
total score of more than five, and they had a median PSQI total score of seven. Similar 
results were reported in a recent systematic review and meta-analysis of sleep quality as 
assessed by PSQI during pregnancy (Sedov et al., 2017).  They reviewed 24 articles 
from 12 different countries and included pregnant women in different trimesters of 
pregnancy. They concluded that the PSQI total score is high during pregnancy with an 
average value of 6.1 and ranged from a mean of only 3.96 among at 14 weeks gestation 
to as high as 8.55 among women at weeks gestation. The mean PSQI total score was 
8.1 for all studies that included women in their third trimester. The percentage of women 
with poor sleep (PSQI>5) ranged between 20.8 % and 76.3%.  
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Among the studies included in this review Mindell et al. (2015) reported 75.1% of women 
having poor sleeper and a mean PSQI score of 8.55 in a multi-ethnic American pregnant 
women at seven months gestation. Blair et al. (2015) reported a mean PSQI score of 6.9 
at 19-30 weeks gestation with no statistically significant difference between African 
American and European American pregnant women. In another study among multi-
ethnic American pregnant women at around 22nd weeks of gestation Qiu et al. (2016) 
reported a mean PSQI total score of 5.23 and  37% of participant had poor sleep quality. 
At 30-32 weeks of gestation, Okun et al. (2011) reported a higher mean PSQI score of 
7.79 for American pregnant women who had eventually delivered their new-borns 
prematurely, and a PSQI score of  5.26 for pregnant women who had eventually 
delivered their new-borns at term. Whilst Facco et al. (2010b) surveyed a cohort of 189 
pregnant American women at early pregnancy (mean gestation 13.8 weeks) and later in 
pregnancy (mean gestation 30.0 weeks). They reported mean PSQI total scores of 5.4 
and 6.3, and 39.0% and 53.5% reported poor sleep quality (PSQI>5), respectively. The 
only published article from the UK (to my knowledge) was among pregnant women in 
early pregnancy (around 14 weeks of gestation). They reported a PSQI total score of 
6.21 among depressed women and 3.23 among non-depressed women (classification of 
depression was based on the Edinburgh Postnatal Depression Scale) and 26% of the 
women had a PSQI>5 (Jomeen and Martin, 2007).  
The results of this thesis and the findings from these multiple previous research studies 
suggests that poor sleep quality is very common during pregnancy and worsens with the 
advance of pregnancy. Identifying pregnant women with poor sleep quality might require 
the use of a higher cut-off point than the 5 PSQI threshold used in the general 
population. A cut-off point of around 6-7 might be more appropriate for instance during 
the third trimester, when so many women experience sleep disturbance, however this 
will require further investigation. 
5.3 Assessing glucose control 
5.3.1 CGM derived summary metrics 
The overall mean-glucose and SD-glucose mean (SD) in this study were 5.88 (0.66) 
mmol/l and 1.09 (0.35) mmol/l, respectively. Half of the participants in this study 
experienced glucose concentrations above the 7.8 mmol/l upper recommended 
threshold for more than 60 minutes per day and a quarter of the participants spent more 
than 2 hours and thirty minutes per day above this threshold. To understand the meaning 
of these values, some references are needed. However, as mentioned in the introduction 
chapter, there are no established references or normative thresholds for CGM derived 
summary metrics in women with GDM. There are several published studies on CGM 
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summary metrics from healthy individuals and one from pregnant women without 
diabetes. In a study collecting 4 days of masked CGM data from 22 normal weight and 
16 obese pregnant women without diabetes around 28 weeks gestation from the USA, 
the overall mean-glucose mean (SEM) was 5.22 (0.16) mmol/l for normal weight 
participants and 5.72 (0.16) mmol/l for obese participants (Harmon et al., 2011). A study 
based in the UK, obtained 3 days of masked CGM data from 78 healthy multi-ethnic 
individuals without diabetes, and found an overall mean-glucose and SD-glucose mean 
(SD) of 5.1 (0.5) and 1.5 (0.7), respectively (Hill et al., 2011).  In 434 healthy Chinese 
using Medtronic CGM system (masked/real-time specification is not available) the mean-
glucose was 5.77 (0.57) mmol/l and the SD-glucose was 0.79 (0.32) (Zhou et al., 2009). 
Whereas in 29 healthy Japanese using the MiniMed Medtronic real-time CGM system, 
the mean-glucose and the SD-glucose were 6.4 (0.8) and 1.2(0.4) (Nomura et al., 2011) 
and in 32 healthy Americans using Abbott FreeStyle Navigator real-time CGM system, 
the mean-glucose and the SD-glucose were 5.67 (0.39) and 1.00 (0.22), respectively 
(Mazze et al., 2008). In summary, the results obtained in my study, of treated GDM, 
showed mean-glucose results that were slightly higher than those reported in healthy 
individuals (except for the result from the Japanese study). Whilst the SD-glucose was 
either similar, smaller or higher than that reported in healthy individuals. 
Half of the participants in my study experienced glucose concentrations above the 7.8 
mmol/l upper recommended threshold for more than 60 minutes per day and a quarter of 
the participants spent more than 2 hours and thirty minutes per day above this threshold. 
These results are higher than those reported in healthy individuals. Among healthy 
individuals Borg et al. (2010) found that glucose concentrations did not exceed the 7.8 
mmol/l threshold in only 7% of the participants. Half the participants spent more than 26 
minutes per day above this limit and a quarter of the participants experienced glucose 
levels above this limit for at least 75 minutes per day. Another study reported glucose 
concentrations within the range of healthy participants 70 mg/dl to 125 mg/dl (3.89 
mmol/l to 6.94 mmol/l) for 91% only of the total duration of CGM (Derosa et al., 2009). 
This may suggest room for improving the treatment of women with GDM, to achieve 
more 'normal' time within glucose targets than were achieved in my current study. 
5.3.2 FDA of CGM data 
By fitting the CGM data into daily glucose curves, FDA has revealed the diurnal glucose 
pattern and the rate-of-change of glucose across the day, and it has enabled the 
calculation of the mean and SD of glucose concentrations across the 24-hour day. FDA 
has shown that the mean fasting/ pre-breakfast glucose concentrations for around half of 
the participants exceeded the 5.3 mmol/l recommended upper threshold, and that the 
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mean postprandial glucose concentrations for around a quarter of the participants 
exceeded the 7.8 mmol/l recommended upper threshold. 
These glucose curves have also shed some light on the behaviour of glucose in 
pregnant women with GDM. The time to postprandial peak was around two hours in this 
study. Longer than one hour time to peak was reported during pregnancy with and 
without diabetes, mean (SD) 82 (18) minutes and 74 (23) minutes, respectively (Buhling 
et al., 2005). In my study the breakfast peak had a higher amplitude and a faster rate-of-
change than the lunch and dinner peaks. The breakfast peak has previously been 
reported to be higher than the lunch and dinner peaks in healthy individuals, albeit 
consuming the same standardised meals (Freckmann et al., 2007).  This could be 
related to the circadian rhythms of insulin; the high and fast up-hill side of the breakfast’s 
peak could be explained by the lower concentrations of circulating insulin in the morning 
compared to later times in the day, and the fast down-hill side of the breakfast’s peak 
could be explained by the higher post-meal insulin response observed in the morning 
compared to later times in the day (Sensi and Capani, 1976; Van Cauter et al., 1992; 
Boden et al., 1996). 
5.4 Sleep and glucose control 
This section summarises the main findings pertaining to the association of; PSQI total 
score sleep quality, reported and actigraphy-measured sleep durations, reported and 
actigraphy-measured SOL duration, reported and actigraphy-measured mid-sleep time, 
WASO duration, and glucose control as assessed by summary metrics and smooth 
glucose curves. 
5.4.1  PSQI total score sleep quality and glucose control 
I found that a higher PSQI total score implying poorer sleep quality was associated with 
a higher amplitude and more variability of glucose concentrations. This was revealed 
from the adjusted standard regression models as well as the multilevel regression 
models incorporating within participants’ variation in the modelling strategy. Each one 
score increase in PSQI total score was related to: 0.027 mmol/l increase in mean-
glucose, 0.026 mmol/l increase in SD-glucose (denoting higher variability), 11% lower 
odds of having glucose concentrations within the recommended range, and 15% higher 
odds of having glucose concentrations above the upper threshold limit. 
Further FDA regression models on the association between PSQI total score and 
smooth glucose curves and glucose velocity curves has yielded stronger associations 
giving more details about the relationship. The FDA models revealed that at lunch time, 
each one score increase in PSQI total score was associated with a 0.06 mmol/l increase 
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in glucose concentration and a 0.025 mmol/l/hour increase in the rate-of-change of 
glucose concentrations.  
5.4.2 Self-reported and actigraphy-derived sleep durations and 
glucose control 
The relationship between sleep duration as measured by actigraphy and as self-reported 
in the PSQI questionnaire with mean-glucose were not identical. Whereas, compared to 
6-8 hours sleep duration, the short actigraphy-derived sleep duration but not the long 
was associated with higher mean-glucose, it was the long self-reported sleep but not the 
short which was associated with higher mean-glucose (Figure 5-1). On the other hand, 
their relationship to SD-glucose were more similar, as both short actigraphy-derived and 
self-reported sleep durations, but not long sleep duration were associated with higher 
SD-glucose (Figure 5-2). There were no associations between sleep duration, neither 
actigraphy-derived nor self-reported, with glucose concentrations being within or above 
the recommended glucose concentration range. 
 
   
Figure 5-1 Coefficients plot of the results of multilevel regression models of self-
reported and actigraphy-derived sleep durations with mean-glucose (the dot 
represent the coefficient and the line depict the 95% CI, short and long sleep 
compared to 6-8 hours sleep duration) 
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Figure 5-2 Coefficients plot of the results of multilevel regression models of self-
reported and actigraphy-derived sleep durations with SD-glucose (the dot 
represent the coefficient and the line depict the 95% CI, short and long sleep 
compared to 6-8 hours sleep duration) 
 
Using FDA, self-reported sleep duration showed a complex relationship with smooth 
glucose curves and glucose velocity curves. Each one hour increase in self-reported 
sleep duration was associated with a 0.08 mmol/l increase in glucose concentration at 
dawn time (04:00 to 08.00 am) and a 0.12 mmol/l increase in glucose concentration at 
the time between the breakfast and the lunch meals. Whereas there was a U-shaped 
association between self-reported sleep duration and glucose concentrations just after 
midnight, at breakfast, and at the time between lunch and dinner.  
On the other hand, actigraphy-derived sleep duration had a negative association with 
glucose concentration after midnight (i.e. the shorter the actigraphy-derived sleep 
duration the higher the glucose concentration) and a J-shaped association (higher 
association estimated for longer sleep duration than for shorter sleep duration) with 
glucose concentrations at lunch.  
Moreover, longer self-reported sleep duration was associated with: a slower rise of 
glucose at the dawn ridge, associated with glucose concentrations that were already 
higher than those with shorter sleep duration; a faster ascent but slower descent of the 
breakfast peak which could be related to insulin depletion overnight and higher insulin 
resistance; and a slower ascent of lunch peak associated with glucose concentrations 
that were already high before lunch.  
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5.4.3 Self-reported and actigraphy-derived SOL duration and glucose 
control 
A self-report of taking thirty minutes or longer to fall asleep at night after going to bed 
(indicative of initial insomnia), was associated with glucose dysregulation as revealed by 
assorted methods used in this study. SOL≥ 30 minutes was associated with a 0.235 
mmol/l increase in mean glucose, a 0.103 mmol/l increase in SD-glucose, a 62% lower 
odds of having glucose concentrations within the target range, and more than twofold the 
odds of having glucose concentrations above the upper threshold limit. FDA revealed 
that SOL≥ 30 minutes was associated with higher glucose concentrations between 
midnight and breakfast, at lunch time and at dinner time. The maximum association was 
at dinner time were it was associated with a 0.50 mmol/l increase in glucose 
concentration. SOL≥ 30 minutes was also associated with a slower ascent and descent 
of breakfast peak and faster descent of lunch peak. 
Actigraphy-derived SOL duration was associated with CGM summary metrics: mean-
glucose (not statistically significant), SD-glucose, proportion time within target >93%, 
proportion time above target >4%. However, most of these associations did not remain 
significant in the multilevel regression models except for a positive association with 
mean-glucose. Actigraphy-derived SOL duration did not show a significant association 
with glucose curves. 
5.4.4 Other self-reported and actigraphy-derived sleep characteristics 
and glucose control 
Other self-reported and actigraphy-derived sleep characteristics including sleep 
efficiency, mid-sleep time, subjective sleep quality and WASO duration were not 
associated with higher glucose amplitude or variability using the CGM summary metrics. 
Unexpectedly, the functional regression coefficient curve of self-reported sleep efficiency 
and glucose curves depicted a positive association, with each 10% increase in sleep 
efficiency associated with a 0.10 mmol/l increase in glucose concentrations around noon. 
Later reported mid-sleep time was associated with higher glucose concentrations after 
midnight but lower glucose concentrations at breakfast and dinner times. Though not 
statistically significant, a poorer subjective rating of sleep quality was associated with 
higher glucose concentrations in the period from lunch peak till midnight. Actigraphy-
derived longer WASO duration (an indicative of sleep disturbance and maintenance 
insomnia or simply biphasic sleep) was associated with higher glucose concentrations. 
For each 10 minutes increase in WASO duration there was around 0.05 mmol/l increase 
in glucose concentrations after midnight till breakfast time, at lunch peak and at dinner 
peak. That is a 1 hour WASO duration would result in a 0.3 mmol/l increase in glucose 
concentrations at these time intervals. 
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5.4.5 Reverse causality 
Using FDA this study did not find any association between higher glucose concentrations 
at the time of going to sleep and the following sleep duration, efficiency, WASO duration 
or SOL duration. Nights that were followed by a longer sleep duration had a 0.25 mmol/l 
glucose higher at bedtime and at 2 hours after bedtime than nights that were followed by 
6-8 hours of sleep, however the differences were not statistically significant. 
5.4.6 This study findings compared to findings from other studies 
Among pregnant women with established GDM 
Twedt et al. (2015) reported a negative linear association between actigraphy-derived 
sleep duration and fasting and one-hour postprandial capillary blood glucose, however a 
curvilinear relation more than a linear one was more likely to explain their results. After 
categorising sleep duration into groups, they elicited a U-shaped trend, albeit the 
association was only statistically significant for the very short sleep duration group (< 
5hours) compared to the (≥7 to <9 hours) reference sleep duration group. The study 
suffered low power issues with a sample size of only 37 participants and just 10 nights of 
the 213 nights they recorded were in the long sleep duration group (> 9 hours). In the 
present study only short actigraph-derived sleep duration (<6 hours) was associated with 
higher mean-glucose and SD-glucose (compared to 6-8 hours sleep duration), while a U-
shaped relationship was revealed at the time interval between breakfast and lunch using 
FDA. In contrast to the present study, Twedt et al. (2015) had also reported a negative 
association between chronotype and fasting blood glucose. Unlike the present study, 
they did not find any association between WASO duration and fasting or postprandial 
blood glucose concentrations. 
The findings from my study on the relationship between sleep and glucose control, is 
also supported by other observational studies that looked at the risk of developing GDM 
in pregnant women with <7 hours compared to ≥ 7 hours self-reported sleep duration 
(Facco et al., 2010a; Reutrakul et al., 2011) and with ≤4 hours compared to ≥ 9 hours 
self-reported sleep duration(Qiu et al., 2010). 
Individuals with T2DM or T1DM 
Previous studies of individuals with T2DM or T1DM, were mainly cross-sectional 
observational studies, used various tools to assess sleep (polysomnography, actigraphy 
or questionnaire) and they evaluated glycaemic control chiefly via a single HbA1c 
reading or a fasting blood glucose level (Lee et al., 2017; Reutrakul et al., 2016). In an 
extensive systematic review and meta-analysis among adult participants with T2DM, Lee 
et al. (2017) included fifteen observational studies evaluating the association between 
subjective (mainly using PSQI questionnaire) sleep duration and quality with glycaemic 
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control. They found a U-shaped association between sleep duration and HbA1c and 
fasting blood glucose, as well as, higher HbA1c with poorer sleep quality.  However, 
different studies used different sleep duration categories, and different PSQI-poor quality 
sleep cut-off points. In one study using actigraphy only, sleep efficiency weakly 
negatively correlated with HbA1c (r = −0.29; p-value = 0.047) with no measure estimate 
of the association reported by the authors (Trento et al., 2008). On the other hand, a 
systematic review and meta-analysis among adult participants with T1DM, Reutrakul et 
al. (2016) found that: in questionnaire based studies those with longer sleep duration and 
good sleep quality (as specified by the questionnaire used in the study) had lower 
HbA1c, while in polysomnography and actigraphy based studies there were no 
associations between HbA1c and stages of sleep, sleep efficiency (>85%) or sleep 
duration.   
Healthy individuals 
In a laboratory-based study, 14 healthy young men were monitored at baseline (2 days) 
and during 5 days/nights of restricted sleep duration (5 hours in bed). The experimental 
period was tightly controlled with standardised meals and only light physical activity 
allowed within the lab premises. At day 1 of the baseline and after five nights of restricted 
sleep, glucose concentrations together with other hormones were assayed using blood 
sampled from an indwelling intravenous catheter at fasting and then every 2 hours. 
Glucose was also monitored using a CGM system (The Medtronic Guardian® REAL-
Time) with 2 hourly capillary blood calibration. Participants had higher glucose 
concentrations after five nights of restricted sleep (5 hours in bed) compared to baseline 
values (Reynolds et al., 2012). Mean glucose concentrations was higher by 0.6 mmol/l 
after 5 nights of sleep restriction compared to baseline, mean (SD) were 5.5 (0.1) mmol/l 
and 4.9 (0.1), respectively. Glucose concentrations were higher at breakfast than at 
lunch and dinner similar to the results of the study presented in this thesis. They showed 
an exaggerated post prandial glucose response after sleep restriction, particularly after 
breakfast Figure 5-3 and Figure 5-4 depict the study results. The study also found higher 
insulin secretion in the first half of the day and higher cortisol and adrenocorticotropic 
hormone (ACTH) in the second half of the day, after five days of restricted sleep 
compared to baseline (Figure 5-3).  
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Figure 5-3 Glucose and hormonal assays results from 2 hours apart intravenous 
blood samplings on baseline day 1 (grey dotted line) and after five nights of 
sleep restriction (black solid line) (Reynolds et al., 2012) ; reused under the 
Creative Commons Attribution License. 
 
 
 
Figure 5-4 Glucose curves from CGM system on baseline day 1 (B1 grey curve) 
and after five nights of sleep restriction (SR5 black curve); adapted from 
(Reynolds et al., 2012) ; reused under the Creative Commons Attribution 
License. 
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In another experimental study involving 11 young men, glycaemic response to a high 
carbohydrate breakfast meal was much higher after six nights of induced partial sleep 
deprivation (4 hours in bed only) compared to the glycaemic response of the same 
content breakfast meal after six nights of recovery sleep (12 hours in bed), albeit similar 
insulin concentrations measured in both situations. In the same study, glycaemic 
responses and insulin concentrations after lunch and dinner did not differ. However, an 
intravenous glucose tolerance test (IGTT) done after five nights of sleep deprivation 
showed a pattern similar to that seen in individuals with impaired glucose tolerance, The 
IGTT normalised after 6 nights of recovery sleep. (Spiegel et al., 1999). In another study 
with a lesser degree of sleep restriction, 15 young healthy adults were evaluated after 3 
nights of sleep deprivation (restricted time in bed by 1-3 hours less than their usual) and 
after 3 nights of their usual sleep duration. Glucose concentrations after the OGTT test 
were similar after the nights of sleep deprivation to those after usual sleep duration, 
however the fasting insulin concentration and insulin excreted during the OGTT after the 
sleep deprivation nights were much higher than those after the regular sleep duration 
nights (Wang et al., 2016b). Taken together, these experimental sleep restriction studies 
and a few others (Donga et al., 2010) are very suggestive of an insulin resistant state 
induced by sleep deprivation with possible underlying hormonal imbalance (more details 
in next section). 
5.4.7 Clinical relevance 
This study has shown a statistically significant association between PSQI total score as 
estimated poor sleep quality and glucose concentration with 0.06 mmol/l increase in 
glucose concentration for each score increase in PSQI total score. Although the 
association was statistically significant, a worsening/improvement of 10 scores in the 
PSQI total score is required to produce a clinically significant results of 0.6 mmol/l in 
glucose concentration (as discussed previously in Methods chapter, section 3.2). With 
PSQI total scores ranging from “0” (best sleep quality) to “21” (worst sleep quality) and a 
median PSQI score observed in this study of “7”, a difference of 10 scores in PSQI total 
score is potentially attainable. Furthermore, as depicted in Figure 4-26, compared to 
sleeping 6-8 hours, sleeping just 2- 4 hours per night was associated with 0.8-0.3 mmol/l 
higher glucose concentration, whilst sleeping 10 hours per night was associated with 0.5 
mmol/l higher glucose concentration. These associations are both statistically and 
clinically significant. Nevertheless, further research and a clinical trial aiming to improve 
sleep quality and duration is needed to ascertain if these associations are causal. 
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5.5 Proposed pathophysiological mechanisms 
There are many postulated pathophysiological mechanisms of the relationship between 
sleep disturbance and glucose metabolism, mainly through the stimulation of insulin 
resistance and the effect of sleep on hormonal balance. In experimental studies among 
healthy young individuals sleep disturbances were linked to alteration in the secretion of 
important hormones involved in the metabolism of glucose - cortisol, growth hormone, 
glucagon, the appetite regulating hormones (leptin and ghrelin) and thyroid hormone.  
Sleep disturbances, such as sleep deprivation and poor sleep quality, are perceived by 
the body as stressors that trigger the activation of the hypothalamic-pituitary-adrenal 
axis, as well as, inhibit the recovery the hypothalamic-pituitary-adrenal axis activation 
caused by other stressors leading to higher circulating levels of stress hormones 
(Leproult et al., 1997; Palagini et al., 2014).  
Stress hormones, like cortisol, activate the production of glucose through glycogenolysis 
(degradation of stored glycogen) and gluconeogenesis (synthesis of new glucose 
molecules mainly in the liver). They also trigger the release of hunger hormones (such as 
ghrelin) and the suppression of satiety hormones (such as leptin) leading to more food 
intake. Stress hormones suppress the production of insulin as well. All these hormonal 
mechanisms lead to a surge in the circulating blood glucose. Under a normal sleep/wake 
pattern cortisol exhibits a circadian rhythm characterised by a rise of cortisol 
concentration in the second half of sleep till it reaches a peak at dawn and in the early 
morning, then the cortisol concentration declines again to reach its lowest levels at the 
first two hours of sleep (Davidson et al., 1991). Studies investigating the relationship 
between sleep deprivation and cortisol secretion have not found a statistically significant 
difference between the mean 24-hour cortisol levels following a sleep deprived night 
compared to a non-sleep deprived night. They did find a statistically significant higher, 
around 37% to 45% , nocturnal cortisol level following a sleep deprivation night 
(Davidson et al., 1991; Leproult et al., 1997; Redwine et al., 2000; Spiegel et al., 1999; 
Reynolds et al., 2012). Furthermore, better sleep quality as indicated by a higher 
proportion of slow wave sleep (deepest sleep) was negatively correlated with cortisol 
levels measured the next day. Whilst, a poorer sleep quality and disturbed sleep as 
indicated by a higher proportion of stage 1 NREM sleep (lightest sleep) and WASO were 
positively correlated with cortisol levels measured the next day (Vgontzas et al., 1999). 
Moreover, poor sleep quality (PSQI>5) was also associated with higher levels of 
inflammatory markers (interleukin-8) among African American pregnant women (Blair et 
al., 2015) 
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Growth hormone (GH) is another important hormone that is released mainly during 
sleep, especially during slow wave sleep in the first half of the night's sleep (Van Cauter 
and Plat, 1996). GH is a hormone that is responsible for the regeneration of body cells 
and tissues and plays a role in the restorative action of sleep. It also plays a major role in 
glucose metabolism (Gunawardane et al., 2015). GH counteracts the effects of insulin on 
glucose metabolism, suppresses muscle uptake of glucose, stimulates gluconeogenesis 
and thus raises blood glucose levels. The absent or reduced levels of GH seen in those 
with insomnia, sleep deprivation and those with a low proportion of deep sleep (Redwine 
et al., 2000; Lieb et al.) causes a marked insulin hypersensitivity and hypoglycaemia 
overnight and this could explain the positive linear association between sleep duration 
and glucose concentration at the second half of the night observed in section 1.6.1.2 of 
the current study. Hypoglycaemia triggers a counter regulatory response by the body to 
return to the euglycaemic state. These counter regulatory responses include the 
inhibition of insulin secretion and the stimulation of glucagon and cortisol secretion. 
Fasting glucagon concentration was significantly higher (p=0.003) following restricted 
sleep than ad libitum sleep (Wang et al., 2016b). These hormones cause endogenous 
production of glucose leading to higher levels of circulating blood glucose and resulting 
in the dawn phenomenon in the early morning. They also causes the fast and the 
exaggerated response to the breakfast meal (Sprague and Arbeláez, 2011). Moreover, 
chronic GH deficiency is counterbalanced by insulin resistance (Gunawardane et al., 
2015). In addition, following a depletion of growth hormone after a sleep deprived night, 
a recovery night will be accompanied by higher than baseline production of GH during 
sleep (Redwine et al., 2000). Individuals with intact pancreatic beta-cell function 
counteract higher levels of GH by hyperinsulinemia, however if long term, it may cause 
insulin resistance in the liver, adipose tissue and skeletal muscle (Moller et al., 1991). 
Placental growth hormones which have a major role in glucose metabolism during 
pregnancy (Frankenne et al., 1988) may add to the complexity of the hormonal 
turbulence that accompanies sleep disturbance. To the best of my knowledge there is no 
study examining the relationship between sleep disturbances and placental growth 
hormone. 
Sleep disturbance, mainly sleep curtailment has also been linked to an increased 
appetite and craving for carbohydrate rich snacks (Shlisky et al., 2012). In a clinical trial 
involving 12 healthy men, plasma leptin and ghrelin concentrations and subjective 
ratings of hunger and appetite were monitored after 2 days of restricted sleep duration 
and after 2 days of extended sleep duration. Leptin was 8% lower, ghrelin was 28% 
higher and participants rated higher hunger and appetite especially for high carbohydrate 
contents foods after sleep curtailment compared to sleep extension (Spiegel et al., 
2004). In another study nine healthy men were subjected to; one night of 7 hours sleep 
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duration, one night of 4.5 hours restricted sleep duration and one night of total sleep 
deprivation, separated by 2-week washing periods. Mean (SD) plasma ghrelin 
concentration had a negative relationship with sleep duration as follows:  0.85 (0.06) 
ng/ml after total sleep deprivation, 0.77 (0.04) ng/ml after sleep restriction, and 0.72 
(0.04) ng/ml after 7 hours sleep duration. Moreover, Hunger ratings indicated stronger 
feelings of hunger in relation to the extent of sleep deprivation. However, mean plasma 
leptin levels were not affected by sleep duration (Schmid et al., 2008). A further clinical 
study among twelve healthy young men also reported increased energy consumption 
and higher pre-breakfast and pre-diner perceived hunger after one night of 4 hours 
restricted sleep duration compared to energy consumption and perceived hunger after 
one night of 8 hours sleep duration (Brondel et al., 2010). On the other hand, 
Nedeltcheva et al. (2009b) did not find any difference in leptin and ghrelin levels after 5.5 
hours in bed restricted sleep duration compared to 8.5 hours in bed sleep duration, albeit 
they reported increased consumption of calories from high carbohydrate contents snacks 
after the restricted sleep duration night. Another study did not find any association 
between sleep curtailment and perceived hunger, appetite hormones level or total 
energy intake (St-Onge, 2013). 
Lastly, the effect of sleep on thyroid and thyroid stimulating hormones (TSH). In normal 
conditions TSH levels surge in the night (around 4-5 hours before usual sleep time) and 
lower after sleep onset (Allan and Czeisler, 1994). However, with total sleep deprivation, 
TSH levels stay elevated and increase further overnight (Knutson et al., 2007; Allan and 
Czeisler, 1994). Elevated TSH stimulates the secretion of excess thyroid hormone in the 
circulation. Thyroid hormone leads to a higher circulating blood glucose via multiple 
mechanisms including suppression of insulin secretion, enhancing renal excretion of 
insulin, alteration of glucose metabolism and glycogenolysis (Potenza et al., 2009). 
Nevertheless, after two days of total sleep deprivation the amplitude of the TSH surge 
diminishes due to the exerted negative-feedback by higher thyroid hormone levels (Van 
Cauter et al., 1994). In the Spiegel et al. (1999) sleep curtailment study, described in 
details in section 5.4.6, thyroid hormone concentrations were higher after six nights of 
partial sleep deprivation compared to its level after six nights of sleep recovery, mean 
(SD) 9·1 (0·3) ng/dl and 8·5 (0·3) ng/dl, respectively, p<0·01. Furthermore, Baumgartner 
et al. (1993) studied the effect of partial sleep deprivation on TSH among 10 healthy 
young women under strict laboratory conditions. After spending 3 hours asleep (from 
10:30 pm to 01:30 am) the women were woken and they stayed awake till the next sleep 
time. TSH was markedly elevated following the sleep interruption and remained so 
during the course of the following day. TSH decreased again in the next sleep period. 
Though these changes in thyroid and TSH recovered fast after recovery sleep, multiple 
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episodes of sleep curtailment and sleep recovery may lead to the development of insulin 
resistance (Spiegel et al., 2005). 
In summary, the hormonal turmoil caused by sleep curtailment and poor sleep quality are 
all likely to contribute to the hyperglycaemic state and insulin resistance (Figure 5-6). 
Nonetheless, while there are many postulated mechanistic pathways between short 
sleep duration and glycaemic dysregulation, the link between long sleep duration and 
such glycaemic dysregulation is still obscure. 
Excess sleep and spending a prolonged time in bed are associated with many 
disadvantageous health impacts and even with higher mortality (Patel et al., 2006), as 
too much of a good thing is not necessarily good! Sleep can be looked upon similarly to 
food, where food intake is necessary for wellbeing, yet both starvation and overeating 
are detrimental for health. Indeed, long sleep was associated with a higher mortality risk 
in older adults than short sleep (Youngstedt and Jean-Louis, 2011). Postulated 
mechanisms of oversleeping include a lack of motive (nothing to do after waking-up), 
depression, daytime lethargy, lower physical activity and sedentary life style (Grandner 
and Drummond, 2007). Furthermore, longer sleep may not be accompanied by a good 
proportion of deep refreshing slow wave sleep (Youngstedt and Kripke, 2004). 
Individuals with sleep-disordered sleeping may compensate for low sleep quality by 
oversleeping. Long sleep  has been linked to impairment in health status, daily activities 
and work productivity even in a group of individuals without underlying diseases such as 
sleep-disordered breathing and depression (Dean et al., 2010). In experimental studies, 
extending sleep duration for young adults with habitual sleep duration of 7-8 hours 
resulted in an impairment of mood and lower cognitive abilities (Taub and Berger, 1973; 
Reynold et al., 2014). In another sleep extension randomised clinical study, increasing 
the habitual sleep duration by more than 2 hours per day for one week was associated 
with a 2-fold increase in the levels of inflammatory markers (Interleukin-6) (Figure 5-5) 
and even increased the level of daytime sleepiness compared to the habitual sleep 
baseline week (Reynold et al., 2014). However, in this particular study although the 
allocation of the study participants to the study groups was randomised it is clear in 
Figure 5-5 that the control group had higher baseline Interleukin-6 concentrations. A 
possible inflammatory process linked to long sleep duration may be implicated in the 
impairment of glucose regulation possibly through pancreatic beta cell destruction and 
insulin resistance (Kristiansen and Mandrup-Poulsen, 2005). 
Taken together these effects manifested by a longer sleep duration may lead to lower 
uptake of glucose by body tissue and less utilization of glucose due to lower demand, 
ultimately resulting in a higher circulating blood glucose (Figure 5-6).  
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Figure 5-5 Interleukin-6 mean (SE bars) levels at the end of baseline weeks and 
experiment week for the control and time-in-bed (TIB) extension groups 
(Reynold et al., 2014); reused under the Creative Commons Attribution 
License. 
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Figure 5-6 Schematic diagrams depicting the pathophysiological mechanism of the causal pathway between sleep duration and 
glycaemia 
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5.6 Study limitations  
Epidemiological studies, as in my present study, can show strength of associations but 
they cannot prove causality. Furthermore, they are subjected to multiple issues that can 
distort the validity of the observed associations. Confounding bias, volunteer bias, 
measurement bias, recall bias, loss to follow-up, and reverse causation are some of 
these issues (Stuckless and Parfrey, 2009). As such, the findings of this study are 
inherently susceptible to a number of substantive biases. My results therefore need to be 
interpreted in the context of several limitations.   
5.6.1 Confounding bias 
The results of this study might be susceptible to confounding bias due to insufficient 
adjustments in the regression models for some potential confounder variables, namely 
diet, physical activity and sleep-disordered breathing (Skelly et al., 2012).  
Diet and physical activity 
Dietary intake data was not collected as a part of this study. The Actiwatches measured 
activity counts, however they were not supplemented by heart rate data and thus energy 
expenditure could not be estimated from them. Furthermore, heart rate was also required 
to confirm if the accelerations detected by the Actiwatches during the day were caused 
by the participants’ body movement due to them being active or rather the accelerations 
were an artefact from simply being in an accelerating transportation vehicle. 
Nevertheless, the putative causal links between sleep, diet, physical activity and glucose 
control are fraught with complexity (Dolezal et al., 2017; Frank et al., 2017). It can be 
argued that diet and physical activity are not acting as confounders rather they are 
mediators in the causal path between sleep and glucose control (Figure 5-7). Sleep 
impact on glucose control could be interceded by its effect on the dietary amounts and 
choices and on the perceived exhaustions and enthusiasm to perform physical activity 
(VanHelder and Radomski, 1989; Hogenkamp et al., 2013). In the case of being 
mediators, adjusting for diet and physical activity in the regression model is not 
recommended (Richiardi et al., 2013; Gilthorpe, 2011b; Schisterman et al., 2009). Thus 
confounding bias is unlikely to have affected this study as a result of not adjusting for diet 
and physical activity. However, residual confounding bias from other 
unknown/unmeasured confounders could still affect the results of this study (Fewell et 
al., 2007; Jager et al., 2008). 
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Sleep-disordered breathing  
There is a ream of articles on the association between snoring, sleep apnoea and other 
sleep-disordered breathing with the risk of developing diabetes and other metabolic 
syndrome diseases in general population (Seetho and Wilding, 2014; Shaw et al., 2008; 
Punjabi et al., 2004; Sabanayagam et al., 2012) and with the risk of GDM in pregnant 
women (Luque-Fernandez et al., 2013; Qiu et al., 2017; Ge et al., 2016; Bisson et al., 
2014; Bourjeily et al., 2010). However, the results have been inconsistent and moderated 
by obesity. Sleep-disordered breathing is a potential confounder in the association 
between sleep and glucose control, as it can be associated with glucose control through 
hypoxia, as well as causing sleep disturbances (short sleep duration, poor sleep quality 
and sleepiness during the day) (Figure 5-8). I was not able to adjust for sleep-disordered 
breathing and this could potentially expose the study findings to confounding bias.   
 
 
 
Figure 5-7 Causal diagrams of the association between sleep and glucose control 
showing diet and physical activity as; a mediators (right and left upper panel) 
and a confounders (right and left lower panel) 
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Figure 5-8 Causal diagrams of the association between sleep and glucose control 
showing sleep-disordered breathing as a confounder 
5.6.2 Monophasic versus biphasic sleep 
Sleep in newborns and in the early years of a human beings life is described as 
polyphasic (i.e. having multiple sleep/wake cycles within the 24-hour day) (Crabtree and 
Williams, 2009). This sleep pattern changes rapidly to become one of a more solid sleep 
interval during the night, with wakefulness during the day (i.e. monophasic sleep). 
However, biphasic sleep (i.e. having a core sleep interval during the night and a 
nap/multiple naps or a short sleep interval during the day) is common in some cultures 
and can take different forms. One form is represented by the midday siesta seen in some 
European and Latino cultures (Nieto, 2015), midday napping in China (Brunt and Steger, 
2004) and midday Qailulah in some Islamic cultures (Tumiran et al., 2015; BaHammam, 
2011). This form is common in countries where the temperatures are usually high at 
noon. To avoid direct sun heat and avoid dehydration, residents of hot climates have 
adapted to take midday rest and nap around noontime and then resume work in the 
afternoon, however this practice is less common among residents of cold climates 
(Bursztyn, 2013).  Another form of biphasic sleep is when the individual wakes up in the 
morning after sleeping for several hours during the night to do some rituals or duties for a 
couple of hours or less and then resumes sleeping for a couple more hours (Matuzaki et 
al., 2014). For instance a woman may wakeup in the morning to prepare breakfast for 
her children, walk them to school and then return home to enjoy a few more hours of 
sleep. A third form of biphasic sleep is when individuals doze and take naps as a form of 
rectification for a short night sleep. 
Some researchers endorse napping of 10- 30 minutes in the midday, but not later in the 
day, as a healthy sleep behaviour (Tumiran et al., 2015; Milner and Cote, 2009; Dhand 
and Sohal, 2006). However, other research has linked napping, especially when 
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combined with short sleep duration, to the development of T2DM (Leng et al., 2016), 
however this association was not evident in another study (Kowall et al., 2016). A 
systematic review and meta-analysis of studies investigating the association between 
napping and the risk of cardiovascular disease and T2DM concluded that long naps of 
more than 40 minutes per day, but not shorter naps, were associated with  a higher risk 
of T2DM, and naps longer than 60 minutes were associated with a higher risk of 
cardiovascular diseases (Yamada et al., 2016; Yamada et al., 2015). 
Napping frequency and duration could modify the main sleep duration (Rawal et al., 
2017). However, my study has only assessed the core/main night sleep interval and did 
not investigate napping or midday sleep intervals. This may have subjected the study 
results to a misclassification bias. 
5.6.3 Non-random sampling, volunteer bias and generalisability of the 
study results 
The study population were consecutive recruits from pregnant women with GDM 
attending the DIP clinic. Although the consecutive sampling method is a non-probability 
sampling method, it was the most practical and suitable sampling method for this study 
and it was unlikely to have caused any systematic bias (Henry, 1990). However, 
volunteers may not share the same characteristics as non-responders, such as their age, 
ethnicity, the level of glucose control or the extent of sleep disturbance. This volunteer 
bias may endanger the validity of the study findings (Salkind, 2010). So, a high non-
response (decline) rate may have biased the results of this study, as the responders 
might not be representative of the sampled (source) population (i.e. population of 
pregnant women with GDM attending Leeds and York DIP clinics) (Stuckless and 
Parfrey, 2009). This may affect the internal validity of the study results, i.e. the degree to 
which the study findings yield a correct inference about the association between the 
exposure and the outcome in the source population (Rothman and Greenland, 2005; 
Gail and Benichou, 2000). Likewise, it can affect the external validity of the study results, 
i.e. the generalisability of the study inference to the target population (i.e. pregnant 
women with GDM in general) (Gail and Benichou, 2000). 
However, it is unlikely that validity of this study has been substantially affected. The 
mean age distribution of the study participants was around 32 years old and it ranged 
between 18-45 years. This is the same age distribution expected for women of child 
bearing age. Comparing the ethnicity distribution of the study participants to the ethnicity 
distribution of the England and Wales 2011 general population published census results 
showed some differences (Office for National Statistics, 2012). White ethnicity accounted 
for the majority in the census (86.0% of the population), however they only compromised 
60.9% of this study's participants. The proportion of other ethnic groups were much 
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higher in this study compared to the census results, as follows: Asian 21.4% vs. 7.5%, 
Black 10.9% vs. 3.3%, and other ethnic groups 6.8% vs.1.0%. However, this could 
reflect the difference in the prevalence of GDM among various ethnic groups, as well as 
the selective risk factor based screening for GDM advised by NICE and followed in 
Leeds and York NHS Trusts. Adjusting for the participants’ characteristics, in a similar 
manner to adjusting for confounders, can also control some of the potential bias and 
improve the validity of the study findings (Rothman et al., 2008). However, the inference 
from this study cannot be extrapolated to T1DM and T2DM. The association between 
sleep and glucose control in T1DM and T2DM needs investigating.  
5.6.4 Limited resources 
The iPro CGM systems and the Actiwatches were relatively expensive. The price of the 
Medtronic iPro system was £1377, the price of the Enlite sensor was £53 for each 
sensor, £275 for a pack of five sensors, £525 for a pack of ten sensors. The Actiwatch 
was £613 each (£740 including VAT). With the limited funds I had, only a limited number 
of these devices were available at a time. Adding to this I had some degree of Actiwatch 
failure which led to the loss of 5% of actigraphy records in this study. This was similar to 
the proportion reported by other research among pregnant women (Reid et al., 2017). 
The limited number of these two systems, meant that I could not recruit more women in 
the time frame I had. 
With the surge of cheap and widely commercially available generic accelerometers wrist-
bands gadget and smart phones applications, it is tempting to use them instead of the 
expensive professional actigraphs. However, they are usually of low resolution, more 
prone to measuring artefact, have no clear specifications and have been found to have 
low sleep measuring accuracy (Ancoli-Israel et al., 2015; Meltzer et al., 2015; Evenson et 
al., 2015; Toon et al., 2016). Moreover, smart phone applications consume a phones 
battery and may require connecting them to an electrical source during the night and 
placing them under the pillow or mattress while asleep. This could expose the individual 
to a burning risk from the phone battery overheating and exploding.  
5.6.5 Measurement errors 
Glucose measurements  
Though CGM systems have the advantage of close monitoring of glucose levels in a 
continuous fashion enabling the recognition of glucose daily patterns and enhancing the 
detection of hyperglycaemic and hypoglycaemic episodes over an extended period of 
days, it is not without a caveat. In addition to the expensive cost and the relatively low 
uptake by the potential participants, measurements errors could affect the accuracy of 
the results. At a time of rapid blood glucose rate-of-change interstitial glucose may 
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experience a time lag of 5 to 15 minutes behind the blood glucose (Boyne et al., 2003; 
Rossetti et al., 2010). The lag happens as glucose takes time to diffuse from the 
capillaries to the interstitial compartment. At times of rapid glucose change there is a 
discrepancy of interstitial and blood glucose concentrations. Nonetheless, in the latest 
advanced CGM systems’ algorithms lags are considered and slightly controlled for using 
some statistical filters (Pleus et al., 2015; Schmelzeisen-Redeker et al., 2015; Hayter et 
al., 2009). Rapid rate-of-change and the associated lag also affect the accuracy of the 
CGM readings (Kumareswaran et al., 2013; Scuffi et al., 2012). Furthermore, the 
accuracy of the CGM system depends on the accuracy of the glucometer used to 
measure the capillary blood glucose. In the current study various glucometers from 
different manufacturers were used by the participants, as per supply by the DIP clinics. 
Accuracy of these glucometers may vary leading to lower accuracy of CGM calibrations 
(Rossetti et al., 2010). However, any measurement bias resulting from glucometer 
inaccuracy is less likely to be differential and any measurement bias would be towards 
the null.  
Sleep measurements 
As discussed earlier both PSQI and actigraphy sleep assessments have not been 
validated against polysomnography during pregnancy. Measurement error and 
misclassification of sleep characteristics could result from these two measurement tools 
inaccuracy. Furthermore, actigraphy objectively measures movement and lack of 
movement as crude estimates of being awake or asleep. However, it requires manual 
and subjective manipulation to determine bedtime and getting out of bed time, which 
renders it not totally objective. It also erroneously identifies being unsettled and frequent 
change of sleeping position while asleep, which is common during late trimester 
pregnancy, as being awake. 
Measurement errors due to categorisation of variables 
Measurement errors could have been introduced by categorising continuous variables 
into groups in the current study (Tu and Greenwood, 2012; Royston et al., 2006). Sleep 
duration was categorised into three groups to explore the postulated U-shaped 
relationship in some of the regression models, SOL duration was categorised in two 
groups to mimic the clinical diagnosis of initial insomnia, other proportion and ratio 
variables were categorised to enhance the validity of the regression models. To be 
consistent in the approach applied for categorisation, cut-points used were either: a 
clinical reference value such as in the case of SOL duration; the 25th and the 75th 
percentiles for categories of three groups such in the case of sleep duration; and the 
median for categories of two groups such in proportion of time within target range 
variable. 
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5.7 Discussion of the FDA methods 
Application of FDA methods to the CGM data enabled appreciation of the temporal 
sequences and the correlations between glucose data-points. It enabled the display of 
the CGM data as visual, easily comprehensible, and logically explicable glucose curves. 
Descriptive data extracted by the FDA methods (including the mean, the SD, the median 
and the interquartile range of glucose curves) had more physiological meaning and 
known reference values compared to overall summary metrics such as mean-glucose 
and SD-glucose. Using the smoothing methods enabled the presentation of the daily 
glucose curves as one unit instead of multiple adjacent points. It also provided a novel 
insight on the relationship between glucose curves at different times of the day with 
multiple covariates. The timing and the amplitude of the association were easily 
interpretable in a similar manner to the interpretation of standard regression models. 
In this study I developed a registration loop to align and then extract a single daily curve 
for each participant to elude the need to use multilevel mixed effect FDA due to its 
computational complexity. Further work is needed to improve and simplify the application 
of the multilevel mixed effect FDA to CGM data needs.  
Registration aligned the glucose curves and separated the amplitude variation from 
phase variation, however it was not perfect. Some curves’ peaks and troughs were 
located far from most of the other curves’ peaks and could not be aligned even after 
multiple iterations. This residual phase variation may disrupt the findings of this study. 
Further registration needs sufficient computer memory space and takes a relatively long 
time for each iteration. The time and the computer memory capacity required for 
registration increases with denser data and larger number of records. Adequate 
computer memory capacity is also required for extracting the regression model 
coefficients’ standard errors in order to construct the 95% confidence band. 
Whilst registration was essential in this research to identify the variation in glucose 
curves’ amplitudes and how much of the variation could be explained by various sleep 
characteristics, other research may be more concerned with the variation in timing of 
glucose curves’ peaks and nadirs, i.e. phase variation. In the later condition registration 
would not be advisable. Moreover, CGM data from GDM patients may be expected to be 
more homogeneous and less variable than CGM data from pregnant women with T1DM 
and T2DM, especially those on insulin treatment. FDA methods have been applied to 
data from these populations but without using full registration (Law et al., 2015). 
Other statistical methods that have been used to analyse longitudinal data such as 
multilevel growth models can technically be applied to CGM data, however they lack 
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some of the beautiful features of FDA methods such as registration. To my knowledge 
there are no published studies applying these methods to CGM data.  
FDA tools are relatively new and they are developing with fast momentum. However, 
they have not been widely adopted among researchers and statisticians at the same 
speed functional data are produced by the advance in devices and technologies. 
Furthermore, FDA tools are available only in some much specialised, R and MATLAB, 
statistical software, which need professional training and good experience in such 
software. 
5.8  Planned publications 
1- Relationship of sleep to glucose control in gestational diabetes: a study using 
continuous glucose monitoring and functional data analysis; in preparation for 
Diabetes Care 
2- Analysis of continuous glucose monitoring data; from summary metrics to 
functional data analysis In preparation for  Diabetes Technology & Therapeutics  
3- CGM-FDA R software package; the study CGM-FDA code syntax formulated into 
a package to be deposited in The Comprehensive R Archive Network - R Project 
(CRAN R-project). 
4- Poor agreement between subjective and objective sleep measures among 
pregnant women with gestational diabetes; in preparation for Sleep. 
 
5.9 Future research 
1- Extending the findings from my research, I am planning to investigate the direct 
association of sleep characteristics measured during the last trimester of GDM 
pregnancy to pregnancy outcome.  
2- Analysis of the relationship between CGM summary metrics and glucose smooth 
curves with infant birthweight is ongoing with cooperation with other members of 
the research team. 
3- Another rather technical research study is to do with actigraphy data. Manual 
editing of bedtime and getting-up from bed time is time consuming and tedious. 
Building an algorithm to automatically integrate the bedtimes and getting-up times 
from the sleep diary together with other indicators such as activity levels and light 
levels would improve the feasibility and potentially the results of the actigraphy.   
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4- Validating the application of the FDA smoothing methods and the registration-
loop developed in this thesis to secondary CGM data from T1DM and T2DM 
patients.  
5.10  Implications and future recommendations 
This study has shown the clear advantage of analysing CGM data using FDA methods. 
Future studies involving the use of CGM should ensure the use of FDA analysis methods 
as described in this thesis. The R software codes syntax written as part of this study and 
a planned CGM-FDA R software package will facilitate the use of these methods by 
many researchers.  
This study has also demonstrated the repercussions of sleep disturbances on glucose 
control. Therefore this study calls upon both clinicians and policy makers to attend more 
closely to sleep disturbance as a potentially modifiable risk factor for glucose 
dysregulation in pregnant women with GDM. Intervention strategies for sleep 
improvement and enhancement were find to be feasible and effective during pregnancy 
(Lee et al., 2016; Tsai et al., 2016a).  
A randomised clinical trial studying the effect of sleep enhancement (using several 
methods such as sleep hygiene techniques instructions and cognitive therapy) on 
improving glycaemic control would strengthen the evidence extracted from this study. 
Sleep hygiene techniques include avoiding caffeine at night, practicing mindfulness and 
yoga, performing mild physical exercise, having more exposure to natural light during the 
day and avoiding blue light and electronic gadgets during nighttime and especially before 
going to bed. 
Further investigation of the role of sleep disturbances on glycaemic control in pregnant 
women with T1DM and T2DM warrant investigation. Evidence to date from T1DM and 
T2DM people in the general population has been based on cross-sectional single value 
glycaemic evaluations. Studies using CGM systems have the potential to shed more light 
on the potential associations.  
Despite the extensive work done in this research to the application of FDA methods to 
CGM data, there is abundant room for further progress. Particularly in regards to 
multilevel functional regression modelling. 
Lastly, future research should be undertaken to validate PSQI questionnaire and 
actigraphy-derived sleep characteristics against polysomnography at different trimesters 
during pregnancy. Emphasis should be put on developing and validating actigraphy-
algorithms during pregnancy.  
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5.11  Conclusion 
Gestational Diabetes (GDM) is extremely prevalent and is associated with a higher risk 
of complications to the mothers and the newborns. Sleep disturbances have been 
associated with lower glycaemic control among non-pregnant population with T1DM and 
T2DM. There is a paucity of such studies among pregnant women with diabetes with 
only one small sample size study among pregnant women with GDM. This gap in 
literature leads to the main study aim which was to evaluate the association between 
sleep of pregnant women with GDM and their glycaemic control. 
Over the course of two years and ten months, this study was able to recruit 192 pregnant 
women with GDM at their third trimester from a main recruitment centre (the diabetes in 
pregnancy clinics at Leeds hospital trust) and a secondary recruitment centre (the 
diabetes in pregnancy clinics at York hospital trust). Recruitment was challenging 
particularly at the beginning, however with some modulation in the study protocol the 
take-up by potential participants had improved remarkably.   
To cover multiple facets of sleep structure of the pregnant women, sleep was assessed 
subjectively using the Pittsburgh Sleep Quality Index (PSQI) self-reported questionnaire 
and objectively using actigraphy device (Actiwatch2 Respironics). To assess the 
glycaemic control, close monitoring of glucose concentrations was accomplished using 
masked CGM system (iPro2 Medtronic). 152 participants had sufficient data retrieved 
from them, i.e. the PSQI questionnaire data and at least one night actigraphy-derived 
sleep data and one 24-hour day CGM data. 
Data from CGM systems are dense and highly auto-correlated, summarising these 
extensive data into one-value summary metrics, which is the usual approach, risk the 
loss of the inherent information within them. Functional data analysis (FDA) is an 
advance statistical method that can accommodate dense auto-correlated data and it was 
first used to analyse CGM data in 2015. This study has further developed and improved 
the application of FDA methods to CGM data. 
Though they had poor agreement between their values, both self-reported and 
actigraphy-derived sleep characteristics of pregnant women with GDM reflected the 
degree of sleep disturbances. This was particularly in form of poor sleep quality and 
higher proportion of both shorter and longer sleep durations than average (6-8 hours).  
FDA methods presented consecutive discrete CGM data-points as smooth glucose 
curves with a functional form, i.e. function of time. Penalised B-spline basis expansion 
was used to achieve this functional form. Phase variation, i.e. the variation of the timing 
of glucose curves peaks and nadirs, was separated from amplitude variation, i.e. the 
variation of the height of glucose curves peaks and nadirs, by aligning the curves using 
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continuous registration method. Registered smooth glucose curved revealed the 
physiological diurnal glucose pattern of the participants, and the identification the 
average and the variability of this diurnal pattern was feasible by calculating the mean, 
the SD, the median and the IQR curves.  
Standard regression models using various CGM summary metrics as the outcome, and 
functional regression models using the registered smooth curves as the outcome was 
applied to study the associations of different sleep characteristics on the glycaemic 
control. These models demonstrated a positive association between sleep disturbances, 
mainly poor sleep quality, short and long sleep duration, sleep onset latency and wake 
after sleep onset duration, with higher glycaemic amplitude, variability and rate-of-
change. With FDA showing the time of the day where these associations are mainly 
located. 
To conclude, the analyses presented in this thesis, confirm that sleep disturbances are 
associated with suboptimal glucose control in women with GDM. 
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Appendix B PSQI Form Administration Instructions 
and Scoring 
 
 
Form Administration Instructions 
 
The range of values for questions 5 through 10 are all 0 to 3. 
 
Questions 1 through 9 are not allowed to be missing except as noted below.  If these questions 
are missing then any scores calculated using missing questions are also missing.  Thus it is 
important to make sure that all questions 1 through 9 have been answered.   
 
In the event that a range is given for an answer (for example, ‘30 to 60’ is written as the answer to 
Q2, minutes to fall asleep), split the difference and enter 45. 
 
Reference 
 
Buysse DJ, Reynolds CF, Monk TH, Berman SR, Kupfer DJ:  The Pittsburgh Sleep Quality Index:  
A new instrument for psychiatric practice and research.  Psychiatry Research 28:193-213, 1989. 
 
Scores – reportable in publications 
 
On May 20, 2005, on the instruction of Dr. Daniel J. Buysse, the scoring of the PSQI was 
changed to set the score for Q5J to 0 if either the comment or the value was missing.  This may 
reduce the DISTB score by 1 point and the PSQI Total Score by 1 point. 
 
PSQIDURAT   DURATION OF SLEEP 
   IF Q4 > 7, THEN set value to 0 
   IF Q4 < 7 and > 6, THEN set value to 1 
   IF Q4 < 6 and > 5, THEN set value to 2 
   IF Q4 < 5, THEN set value to 3 
Minimum Score = 0 (better); Maximum Score = 3 (worse) 
 
PSQIDISTB SLEEP DISTURBANCE 
 IF Q5b + Q5c + Q5d + Q5e + Q5f + Q5g + Q5h + Q5i + Q5j (IF Q5JCOM 
is null or Q5j is null, set the value of Q5j to 0) = 0, THEN set value to 0 
 
IF Q5b + Q5c + Q5d + Q5e + Q5f + Q5g + Q5h + Q5i + Q5j (IF Q5JCOM 
is null or Q5j is null, set the value of Q5j to 0) > 1 and < 9, THEN set 
value to 1 
 
IF Q5b + Q5c + Q5d + Q5e + Q5f + Q5g + Q5h + Q5i + Q5j (IF Q5JCOM 
is null or Q5j is null, set the value of Q5j to 0) > 9 and < 18, THEN set 
value to 2 
 
IF Q5b + Q5c + Q5d + Q5e + Q5f + Q5g + Q5h + Q5i + Q5j (IF Q5JCOM 
is null or Q5j is null, set the value of Q5j to 0) > 18, THEN set value to 3 
 
Minimum Score = 0 (better); Maximum Score = 3 (worse) 
 
PSQILATEN   SLEEP LATENCY 
   First, recode Q2 into Q2new thusly: 
IF Q2 > 0 and < 15, THEN set value of Q2new to 0 
IF Q2 > 15 and < 30, THEN set value of Q2new to 1 
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IF Q2 > 30 and < 60, THEN set value of Q2new to 2 
IF Q2 > 60, THEN set value of Q2new to 3 
Next 
   IF Q5a + Q2new = 0, THEN set value to 0 
IF Q5a + Q2new > 1 and < 2, THEN set value to 1 
IF Q5a + Q2new > 3 and < 4, THEN set value to 2 
IF Q5a + Q2new > 5 and < 6, THEN set value to 3 
 
Minimum Score = 0 (better); Maximum Score = 3 (worse) 
 
PSQIDAYDYS   DAY DYSFUNCTION DUE TO SLEEPINESS 
   IF Q8 + Q9 = 0, THEN set value to 0 
   IF Q8 + Q9 > 1 and < 2, THEN set value to 1 
   IF Q8 + Q9 > 3 and < 4, THEN set value to 2 
   IF Q8 + Q9 > 5 and < 6, THEN set value to 3 
Minimum Score = 0 (better); Maximum Score = 3 (worse) 
 
PSQIHSE   SLEEP EFFICIENCY 
  Diffsec = Difference in seconds between day and time of day Q1 and day 
Q3 
  Diffhour = Absolute value of diffsec / 3600 
              newtib =IF diffhour > 24, then newtib = diffhour – 24 
            IF diffhour < 24, THEN newtib = diffhour 
(NOTE, THE ABOVE JUST CALCULATES THE HOURS BETWEEN 
GNT (Q1) AND GMT (Q3)) 
  tmphse = (Q4 / newtib) * 100 
 
  IF tmphse > 85, THEN set value to 0 
  IF tmphse < 85 and > 75, THEN set value to 1 
  IF tmphse < 75 and > 65, THEN set value to 2 
  IF tmphse < 65, THEN set value to 3 
Minimum Score = 0 (better); Maximum Score = 3 (worse) 
 
PSQISLPQUAL  OVERALL SLEEP QUALITY 
   Q6 
Minimum Score = 0 (better); Maximum Score = 3 (worse) 
 
PSQIMEDS   NEED MEDS TO SLEEP 
   Q7 
Minimum Score = 0 (better); Maximum Score = 3 (worse) 
 
PSQI    TOTAL 
   DURAT + DISTB + LATEN + DAYDYS + HSE + SLPQUAL + MEDS 
Minimum Score = 0 (better); Maximum Score = 21 (worse) 
Interpretation:   TOTAL < 5 associated with good sleep quality 
     TOTAL > 5 associated with poor sleep quality 
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Appendix C Sleep diary 
 
231 
 
Appendix D Actigraphy clinicians’ report 
 
 
Subject ID: CGDM081 
DOB:                              Age:                          Gender: Female 
Recording Period: from 19/08/2015 15:14:00 to 27/08/2015 05:08:45 
 
Indications for Use: 
 
 
 
 
 
 
Summary Statistics:          
          Bed Time Get Up Time Time in Bed 
(hours) 
Total Sleep 
Time (hours) 
Onset 
Latency 
(minutes) 
Sleep 
Efficiency 
(percent) 
WASO 
(minutes) 
#Awak. 
        Min 21:59:30 06:24:30 7:54:30 6:06:45 3.25 67.98 47.75 67 
        Max 23:57:00 08:32:15 9:40:45 6:49:15 57.00 79.14 92.50 84 
        Avg 22:44:38 07:30:36 8:45:57 6:30:36 22.86 74.45 67.61 73.86 
 
Interpretation: 
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1  Subject ID:         CGDM081 
  DOB:                    
Actogram: 
 
 
                Activity Scale: 500/0, White Light Scale: 84989.7/0.1   
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1  Subject ID:         CGDM081 
  DOB:                                              
Actogram: 
 
 
                Activity Scale: 500/0, White Light Scale: 84989.7/0.1  
 
 
 
 
 
 
 
Daily Statistics: 
        Date Bed Time Get Up Time Time in Bed 
(hours) 
Total Sleep 
Time (hours) 
Onset 
Latency 
(minutes) 
Sleep 
Efficiency 
(percent) 
WASO 
(minutes) 
#Awak. 
        Wednesday 
19/08/2015 
22:53:15 07:33:00 8:39:45 6:06:45 28.75 70.56 67.25 78 
        Thursday 
20/08/2015 
22:30:00 06:24:30 7:54:30 6:15:15 17.75 79.08 81.25 81 
        Friday 
21/08/2015 
23:28:00 08:07:45 8:39:45 6:31:30 16.00 75.32 68.75 67 
        Saturday 
22/08/2015 
23:57:00 08:32:15 8:35:15 6:47:45 6.50 79.14 92.50 73 
        Sunday 
23/08/2015 
22:21:15 07:01:00 8:39:45 6:49:15 30.75 78.74 58.50 84 
        Monday 
24/08/2015 
22:03:30 07:15:30 9:12:00 6:15:15 57.00 67.98 47.75 67 
        Tuesday 
25/08/2015 
21:59:30 07:40:15 9:40:45 6:48:30 3.25 70.34 57.25 67 
        Wednesday 
26/08/2015 
NaN NaN NaN NaN NaN NaN NaN NaN 
Each day represented above is from 12:00:00 to 12:00:00 on the next day. 
 
Summary Statistics: 
          Bed Time Get Up Time Time in Bed 
(hours) 
Total Sleep 
Time (hours) 
Onset 
Latency 
(minutes) 
Sleep 
Efficiency 
(percent) 
WASO 
(minutes) 
#Awak. 
        Min 21:59:30 06:24:30 7:54:30 6:06:45 3.25 67.98 47.75 67 
        Max 23:57:00 08:32:15 9:40:45 6:49:15 57.00 79.14 92.50 84 
        Avg 22:44:38 07:30:36 8:45:57 6:30:36 22.86 74.45 67.61 73.86 
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Appendix E Actiware derived sleep intervals and 
summary statistics 
 
 © 2014 Koninklijke Philips N. V. All rights reserved. 
Interval Definitions 
Rest intervals- These are periods of time when the subject activity is low and the subject is 
likely to be at rest. When set, they are indicated on the Actogram by aqua shading. Typically 
this will be used to indicate the in-bed period. Actiware will automatically apply the sleep 
interval detection algorithm once a rest interval is defined. 
The first data point in the rest interval is used for the bed time and the last data point as the 
get-up time. 
Sleep Intervals- These are periods of time when the subject is likely to be asleep. These 
intervals are created automatically by the software once a rest interval is defined. They 
represent the periods of time between sleep onset and sleep end and are indicated by blue 
shading. 
Active Intervals- These are periods of time when the subject activity indicates that they are 
alert and moving. Active Intervals are created automatically when rest intervals are set and 
include all periods not included in a rest or excluded interval. No shading is used to indicate 
these intervals. 
Excluded Intervals- These are periods of time that are excluded from all analytical 
calculations. These intervals are intended to indicate when subjects remove the Actiwatch or 
for periods of invalid data. These are generally set manually and are indicated by dark blue 
shading.  
Interval Information 
Start Date - The date for the first epoch of any given interval. 
Start Day - The day of the week for the first epoch of any interval. 
Start Time - The time for the first epoch at the start of any given interval. 
Duration - The time elapsed between the start time and the end time of any given interval, in 
minutes. 
End Date - The date for the last epoch of any given interval. 
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End Day - The day of the week for the last epoch of any given interval. 
End Time - The time for the last epoch at the end of any given interval. 
Activity Statistics 
Total AC - The sum of all valid physical activity counts for all epochs for the given interval. 
Avg AC/min - The average of all valid physical activity counts for all epochs for the given 
interval divided by the epoch length in minutes. 
Avg AC/epoch - The average of all valid physical activity counts for all epochs for the given 
interval. 
Std AC - The standard deviation of all valid physical activity counts for all epochs for the 
given interval. 
Max AC - The largest valid physical activity value recorded during the given interval. 
Total Invalid Time (activity) - The epoch length in minutes multiplied by the total number of 
epochs for a given interval for which the physical activity count value is invalid. This may 
occur under multiple circumstances including excluded intervals, device error, 
communication error, data corruption, time the logger is in the docking station, or time 
between data collection sessions. 
%Invalid AC - The total invalid time (activity) divided by interval duration multiplied by 100. 
Sleep/Wake Statistics 
Note: In order for an epoch to be score-able as sleep or wake, it must have a valid physical 
activity count, and in addition there must be a sufficient number of epochs before and after 
the epoch being scored that also have valid physical activity counts. 
Sleep Time - The total number of epochs for the given interval scored as sleep by Actiware 
(or manually set as sleep by you) multiplied by the epoch length in minutes. 
% Sleep - The percentage of epochs in an interval that are scored as sleep. Scored total 
sleep time divided by (interval duration minus total invalid time (sleep/wake)) multiplied by 
100. 
# Sleep Bouts - The total number of continuous blocks of epochs where each epoch is scored 
as sleep for the given interval. 
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Avg Sleep Bout - The scored total sleep time divided by the number of sleep bouts for the 
given interval. 
Onset Latency - The time required for sleep to start after initiating the intent to sleep. The 
time between the start of a given rest interval and the sleep interval start time, in minutes, 
and is controlled by the sleep interval detection algorithm. 
Snooze Time - The time required to become active after sleep end. The time between the 
end of a given sleep interval and the end of the rest interval, and is controlled by the sleep 
interval detection algorithm. 
Sleep Efficiency - The percentage of time spent in bed sleeping. Scored total sleep time 
divided by (interval duration minus total invalid time (sleep/wake)) of the given rest interval 
multiplied by 100. 
WASO (Wake After Sleep Onset) - This is the total number of epochs between the start time 
and the end time of the given sleep interval scored as wake by Actiware software (or 
manually set as wake by you using Actiware software) multiplied by the epoch length in 
minutes.    
Note: WASO is identical to scored total wake time when the given interval is a sleep interval. 
Wake Time - The total number of epochs between the start time and the end time of the 
given interval scored as wake by Actiware software (or manually set as wake by you) 
multiplied by the epoch length in minutes. 
% Wake - The percentage of epochs in an interval that are scored as wake. Scored total 
wake time divided by (interval duration minus total invalid time (sleep/wake)) multiplied by 
100. 
# Wake Bouts - The total number of continuous blocks of epochs where each epoch is 
scored as wake for the given interval. 
Avg Wake Bout - The scored total wake time divided by the number of wake bouts for the 
given interval. 
Invalid Time SW - The total number of epochs for the given interval for which the sleep/wake 
scoring algorithm did not have enough data to determine a sleep or wake score multiplied by 
the epoch length in minutes. 
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Note: The insufficient data condition can be caused by invalid or manually excluded epochs. 
%Invalid SW - The percentage of epochs for a given interval for which the sleep/wake 
scores are invalid. Total invalid time (sleep/wake) divided by interval duration multiplied by 
100.  
Mobility Statistics 
Note: In order to be score-able as IMMOBILE or MOBILE, an epoch must have a valid 
physical activity count. 
Immobile Time - The total number of epochs for the given interval scored as IMMOBILE by 
Actiware software multiplied by the epoch length in minutes. 
% Immobile - The percentage of epochs in the given interval scored as immobile. Scored 
total immobile time divided by (interval duration minus total invalid time (activity)) multiplied 
by 100. 
# Immobile Bouts - The total number of continuous blocks of epochs where each epoch is 
scored as immobile for the given interval. 
Avg Imm Bout - The scored total immobile time divided by the number of immobile bouts for 
the given interval. 
#1min Imm Bouts - The number of immobile bouts that are one minute in length for the given 
interval. 
%1min Imm Bouts - The percentage of immobile bouts that are one minute in length for the 
given interval. 
Mobile Time - The total number of epochs for the given interval scored as MOBILE by 
Actiware software multiplied by the epoch length in minutes. 
% Mobile - The percentage of epochs in the given interval scored as mobile. Mobile time divided by 
(interval duration minus total invalid time (activity)) multiplied by 100. 
# Mobile Bouts - The total number of continuous blocks of epochs where each epoch is scored as 
mobile for the given interval. 
Avg Mob Bout - The scored total mobile time divided by the number of mobile bouts for the 
given interval. 
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Fragmentation Index - This is an index value that includes mobility and short sleep bouts. The sum 
of percent mobile and percent one minute immobile bouts divided by the number of immobile 
bouts for the given interval. 
Light Statistics 
Illuminance is used for white or photopic light measurements and is expressed in lux. 
Coloured (RGB or red-green-blue) light is measured in irradiance or flux. Irradiance has units 
of uW/cm^2 (microwatts per square centimetre). Flux has units of photons/cm^2/s (photons 
per square centimetre per second). 
Note: Irradiance/flux (red-green-blue light) statistics apply to the Actiwatch Spectrum,  
Spectrum PRO and Spectrum Plus. 
Total Exposure - The sum of all valid light data in minutes. 
Avg Light - The average light value for the given interval. 
Std Light - The standard deviation of the light values for the given interval. 
Max Light - The largest light value for the given interval. 
TALT - The total accumulation of time, in minutes, during which the Actiwatch was exposed 
to an intensity of illumination above the given illuminance or irradiance/flux threshold. 
Invalid Time L - The total number of epochs for the given interval for which the light value is 
invalid. This may occur under multiple circumstances including excluded intervals, device error, 
communication error, data corruption, time the logger is in the docking station, or time between data 
collection sessions. 
% Invalid Time L - Total invalid time (illuminance or irradiance/flux) divided by interval 
duration multiplied by 100. 
Advanced - Press this button to adjust the Enhanced Sleep Statistics setting described in the 
Sleep/Wake Statistics section of this help topic. 
Note: For all above standard deviation statistics, standard deviation is computed with (n – 1) 
rather than (n) in the denominator of the variance. 
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